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Abstract
Hypoxia followed by rapid reoxygenation within the body can lead to cell and tissue dam-
age through the production of reactive oxygen species (ROS) and the resulting oxidative
stress. This ischemia and reperfusion is associated with a number of common human
diseases such as cancer, stroke and cardiovascular conditions. The cellular response to
oxidative stress is characterised by post-translational modification and changes in gene
expression. This project focusses on how oxidative stress induced by hypoxia and rapid
reoxygenation affects the activation of NF-κB; a rapidly-acting transcription factor that
plays a key role in the eukaryotic cell response to infection, radiation and oxidative stress.
NF-κB is perpetually activated in a variety of common human diseases such as heart dis-
ease, chronic inflammation and cancer; conditions that are also associated with oxidative
stress.
Investigations presented in this thesis demonstrate the profound effects that hypoxia and
reoxygenation have on cell biology, as well as highlighting how these opposite stimuli are
so closely connected. The effects of hypoxia and reoxygenation on the cell cycle, DNA
damage, cell proliferation and cell survival are all explored in this project, giving great
insight into the possible mechanisms at work in response to these stresses.
It has been demonstrated previously that certain members of the phosphatidylinositol
3-kinase-related kinase (PIKK) family such as Ataxia Telangiectasia-Mutated (ATM) are
able to coordinate the activation of NF-κB pathways in response to specific stimuli such
as following DNA damage or oxidative stress. This project has identified a novel role of
another member of this family, Ataxia Telangiectasia and Rad-3-related protein (ATR)
in the NF-κB response to reoxygenation-induced oxidative stress.
xxi

Introduction
Hypoxia and reoxygenation, or ischemia and reperfusion, describe a drop in oxygen levels
in cells or tissues to a level lower than normal followed by a return of oxygen. Fluctuations
in oxygen levels are a common occurrence in the body and can occur in healthy tissues,
even coordinating physiological processes such as stem cell differentiation and digestion.
As such, the control of oxygen gradient and reactive oxygen species (ROS) is critical
for the health of a cell, a loss of ROS homeostasis can lead to protein, lipid and DNA
damage; a state known as oxidative stress. Oxidative stress as a result of hypoxia and
reoxygenation occurs in many disease states, such as chronic inflammation, stroke, heart
disease and cancer. Understanding the effects of this stress on cells and tissues, and the
mechanisms involved in the cellular response to these stimuli, is therefore critical in the
treatment of these conditions.
Previous work on hypoxia and reoxygenation has implicated the NF-κB family of rapidly-
acting transcription factors in the response to these stresses. The NF-κB transcription
factors are activated in response to a wide range of stresses such as infection, inflammation
and DNA damage, in addition they regulate the expression of many target genes either
directly or through cross-talk with other signalling pathways. Coordinated activation of
upstream signalling pathways to control NF-κB activity is therefore critical so that the cell
responds to a stress appropriately; each stimulus activates a unique pathway encompassing
different proteins, post-translational modifications and timings. Aberrant activation of
the NF-κB pathway is associated with many diseases, including all of those mentioned
above, therefore understanding the mechanism involved in the response to individual
stresses is critical in understanding disease pathogenesis and developing potential novel
therapies.
Some progress has been made on elucidating the molecular mechanisms responsible for
the activation of this pathway in hypoxia, however literature describing the kinetics of
this activation in response to reoxygenation is scarce. In addition due to the variations in
oxygen level, cell line, timings and gas exchange protocols used in previous work, many
publications present conflicting findings. Here an improved method of gas exchange was
used to determine the effects of hypoxia and reoxygenation on NF-κB pathway activation.
This thesis describes how hypoxia and reoxygenation induces canonical NF-κB signalling,
with particular focus on the key proteins and post-translational modifications involved in
this activation. In addition investigations into cell proliferation, gene transcription and
cell cycle dynamics were performed to determine the cellular effects of this activation.
Together data presented in this thesis as uncovered some of the mechanisms of NF-κB
activation in response to hypoxia and reoxygenation, as well as determining the effects that
these stresses have on the health of the cell. More work needs to be done to characterise
these mechanisms further, however this project provides a good starting point to develop
from and highlights some key areas of future work.
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1.1 Cell Biology Background
1.1.1 The Central Dogma
Virtually every cell in the human body contains the human genome; around 6 billion
bases of nucleic acid sequence in most somatic (diploid) cells. This deoxyribonucleic acid
(DNA) code comprises just 4 different nitrogen-containing nuclear bases; cytosine (C),
guanine (G), adenine (A) and thymine (T). The specific order, position and combination
of these 4 seemingly simple bases within the genome encodes all of the information required
to build a whole organism, in this case a human. Each human has its own unique, yet
predominantly similar code, which in an individual can dictate eye colour or predisposition
to disease. The human genome encodes an estimated 20,000 different protein coding genes
as well as non-coding DNA such as pseudogenes, introns and untranslated areas of DNA
as well as regulatory sequences. The organisation and regulation of these is critical to
build a living organism.
Figure 1. The Structure and Organisation of DNA within a Chromosome. The chemical
structure of a DNA nucleotide comprises a phosphate group, a sugar group and a base
group. The sugar and phosphate groups form phosphodiester bonds to create a sugar-
phosphate backbone, while the bases; cytosine (C), guanine (G), adenine (A) and thymine
(T) protrude inwards, pairing to complementary bases on the other strand by hydrogen
bonding. This structure forms a double strand DNA helix, which is compacted into
the nucleus through wrapping around proteins called histones to form nucleosomes on a
’thread’. Protein interactions between the nucleosomes allows further complex coiling to
occur, culminating in the formation of a compacted chromosome structure. Adapted from
Nielson, Kumar and Jansen’s papers [1][2][3].
In spite of being so large, the human genome is organised in such a specific and controlled
manner that it fits into the nucleus of the cell, with the exception of a small circle of
mitochondrial DNA that is located within the mitochondria. DNA is commonly present
in a double stranded helix, with sequences running in opposite 5’ to 3’ direction (Fig. 1).
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Hydrogen bonds between A and T, and C and G hold the helix in place, ensuring that
the strands are complimentary to one another. These complementary double stranded
DNA helices fit into tiny spaces such as the nucleus in structures known as chromosomes.
The human genome contains 23 pairs of chromosomes, that exist in the cell as the highly
structurally regulated form of chromatin. Chromatin is comprised of DNA and histone
proteins, which allows DNA to become tightly packed and folded in a specific, highly
conserved and tightly regulated manner. This chromatin must be loosened by epigenetic
and histone modifications to allow transcription to occur as specific genes need to be
accessed by the the transcription machinery [4]. Chromatin therefore plays an important
role in many aspects of cell biology including DNA repair, replication and transcription.
The central dogma describes how this DNA code is transcribed to produce ribonucleic acid
(RNA), which is then translated into proteins (Fig. 2). This process requires regulation
every step of the way, from control of gene expression by transcription factors and other
regulatory proteins, to correct processing of the pre-mRNA (messenger RNA) to mRNA,
then the transport and localisation of this mRNA to the cytoplasm where it is either
degraded or translated into proteins by the ribosome. The cell contains a plethora of
proteins that control and coordinate each step of this process, to allow cells to carry out
normal functions involving metabolism and development, as well as responding to a given
stimuli.
Figure 2. The Central Dogma of Molecular Genetics. This figure summarises the central
dogma of molecular genetics, showing the transfer of information from DNA to protein.
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1.1.2 Transcription by RNA Polymerase II
RNA polymerase II is one of 3 eukaryotic DNA-dependent RNA polymerases and is re-
sponsible for the synthesis of pre-messenger RNA (mRNA), the RNA required for protein
production [5]. The initiation of transcription by RNA polymerase II at the promoters
of genes requires the coordinated recruitment of a series of general transcription factors
alongside an RNA polymerase enzyme, which is responsible for RNA transcription (Fig.
3) [6].
The transcription machinery is systematically recruited to the promoter region of the
gene beginning with the TFIID transcription factor (Fig. 3). This contains the TATA-
binding protein (TBP) and TBP-associated factors (TAF)s that facilitate this binding
[7]. TFIIB then locates the start of the gene, and together with TFIID undergoes a large
conformational change, bending the DNA helix and initiating the melting or breaking
of the hydrogen bonds by the general transcription factors [8]. This forms an 18 base
unwound section of DNA helix is known as an RNA-polymerase-promoter open complex.
Following this, TFIIF is recruited alongside RNA polymerase II to form the pre-initiation
complex (PIC) [5][9][10]. Finally TFIIE and TF11H are recruited to complete formation
of the transcription initiation complex [11].
Transcription is initiated when the C-terminal domain (CTD) of RNA polymerase II is
phosphorylated, the majority of the general transcription factors then dissociate from
the complex and RNA pol II moves along the the length of the gene producing RNA
(Fig. 4). This occurs in a 3’ to 5’ direction along the template strand of the DNA
[12][13][14]. During transcription complementary RNA nucleotides are hydrogen bonded
to the exposed template strand of the DNA, with the sugar-phosphate backbone being
constructed in parallel by the RNA polymerase II subunit RPB1 to form an mRNA strand
[15].
As transcription continues beyond the promoter region, elongation factors and chromatin
remodelling complexes are recruited to regulate the elongation stage of transcription [16].
When RNA pol II reaches the end of the gene, termination of transcription commences
(Fig. 4). Adenines are added to the new 3’ end in a process called polyadenylation and
a 5’ cap is added to the start of the mRNA to prevent degradation when the pre-mRNA
is released. The newly synthesised mRNA, the RNA polymerase and associated factors
dissociate from the DNA strand, allowing the helix to close back up into its normal double
stranded form [17][18].
1.1.3 Transcription Factors and Co-regulators
The general transcription factors are sufficient for basal transcription, however they work
alongside other more specialised transcription factors and co-regulators in order to control
responses to certain stimuli or in a cell-specific manner [19]. Recruitment of the PIC and
transcription machinery to a gene’s promotor was initally thought to be controlled by
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Figure 3. RNA Polymerase II Recruitment and Transcription Initiation. RNA polymerase
II is recruited to the TATA site of a gene systematically by a series of general transcription
factors. The first of these, TFIID, senses the promoter of the gene, binds to the DNA and
leads to a conformational change in the DNA. This leads to the recruitment of TFIIB,
then TFIIF, which mediates the recruitment of RNA polymerase II to the DNA. This
complex is referred to as the pre-initiation complex. Recruitment of further general tran-
scription factors, TFIIE and TFIIH follows to form the transcription complex. Elongation
is initiated by phosphorylation of the C-terminal domain (CTD) of RNA polymerase II,
general transcription factors are released and transcription commences.
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Figure 4. RNA Polymerase II Transcription Elongation and Termination. Once RNA
polymerase II is recruited to the site of the gene and is phosphorylated it begins tran-
scription. Double stranded DNA is ’melted’ and hydrogen bonds are broken to form an
’open bubble complex’, which moves in a 3’ to 5’ direction down the gene with the RNA
polymerase. In this site the RNA polymerase recruits RNA NTPs and pairs them to
complementary bases on the DNA forming a DNA-RNA hybrid. The sugar-phosphate
backbone is built and the RNA is slowly released as the DNA-RNA bonds are broken.
The open complex closes up as the RNA polymerase continues down the gene until it
reaches the termination sequence. Here the open complex is closed up, the RNA poly-
merase dissociates from the DNA and the new RNA is cleaved and released for further
processing.
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transcription factors alone [20][21], however this is now believed to be regulated by a
wide range of general transcription factors as well as other co-regulators [6][22]. These
specialised transcription factors control the rate of gene transcription through promoting
or repressing RNA polymerase activity directly, through binding to nearby promoters
or through more distal elements on the DNA [23]. This allows specific and controlled
coordination of this critical first step in the initiation of transcription [6].
Transcription factors contain sequence specific DNA-binding domains and bind DNA
through helix-loop-helix, helix-turn-helix, leucine zipper or zinc finger domains. Many of
these proteins contain a transcriptional activation domain as well as this DNA binding
domain, suggesting that they have roles as transcription factors independently of the gen-
eral transcription machinery [24][25]. When specialised transcription factors do not bind
directly with the general transcription machinery co-factors are required to control acti-
vation; these do not bind to the DNA. Transcription factors can either activate or repress
transcription of specific genes through their interaction with co-factors; co-activators or
co-repressors [5][23][26][27].
1.1.4 Post-translational Regulation of Proteins
Following biosynthesis of the protein by the ribosome post-translational modifications
are carried out (Fig. 5). These modifications ensure that the protein is present in the
cell in its mature form, as well as controlling many aspects of molecular biology and cell
signalling through promoting or inhibiting activity, targeting the protein for degradation
or promoting stability. These encompass both reversible and irreversible events to regulate
levels of active protein in the cell. As there are so many varieties of post-translational
modifications in mammalian cells, only a select few will be covered in this thesis [28].
Post-translational modifications can occur anywhere along the length of a protein at spe-
cific sites that usually act as the nucleophile in the chemical reaction that occurs during
the modification process. These reactions often involve the modification of an existing
functional group or the addition of a new functional group to the existing protein by
a specific enzyme. An example of modification of an existing functional group includes
deamidation where glutamine or asparagine residues are converted to glutamic acid or
aspartic acid residues respectively. Whereas addition of a functional group to the protein
includes a plethora of reactions including phosphorylation, hydroxylation and methyla-
tion.
In other cases post-translational modifications can include structural modifications through
proteolytic cleavage of the protein at specific peptide bonds and/or the formation of new
disulphide bonds by covalent linkage between two cysteine amino acids. These modifi-
cations can also control localisation of the protein within the cell, for example covalent
addition of a C14 saturated acid to a glycine residue in a process called myristolation
leads to lipid membrane localisation of the targeted protein. In other instances proteins
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Figure 5. Post-Translational Modifications. Overview of some of the reversible post-
translational modifications that occur in eukaryotic cells. These control many aspects of
molecular cell biology including, protein stability, protein activation, protein inhibition
and signalling pathway activation.
are modified in a manner that targets them for degradation by the proteosome, such as
addition of the protein ubiquitin in a process called ubiquitination. Many of these post-
translational modifications can have different effects on a protein, for example although
ubiquitination can lead to degradation, it can also control nuclear-cytoplasmic location
of the protein as well as promoting and repressing interactions with other proteins in a
signalling pathway.
The most common post-translational modification is phosphorylation (Fig. 6), with 58383
different phosphorylation events reported experimentally [29]. Phosphorylation describes
the process by which a phosphate group is covalently bound to an amino acid residue;
usually serine, threonine or tyrosine in eukaryotes. This can lead to a change in the struc-
tural conformation of the protein leading to its activation, deactivation or modifying its
function. Phosphorylation is carried out by kinase enzyme proteins, while the reverse re-
action, dephosphorylation, is carried out by phosphatase enzymes. This process is readily
reversible, rapid and energy efficient, making it an excellent mechanism in rapidly-acting
signalling pathway responses. The conformational change incurred due to phosphoryla-
tion is due to the charged, hydrophilic group that is added during this reaction. This
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Figure 6. Phosphorylation of Target Proteins. Phosphorylation is one of the most com-
monly occurring post-translational modifications in eukaryotic cells and controls many
aspects of protein function including signal transduction. Phosphorylation occurs through
transfer of a phosphoryl group to serine, threonine or tyrosine residues from an ATP to
produce ADP. The reverse reaction, dephosphorylation, is carried out by the phosphatase
enzyme and requires H2O.
alters how this amino acid interacts with amino acids physically close due to the primary,
secondary, tertiary and quarternary structure of the protein. The function of the pro-
tein is therefore altered as these modifications affect how the modified protein interacts
with other proteins, blocking and creating binding sites. As a result phosphorylation may
lead to a variety of responses depending on the context and location of the modification.
As well as activating or inhibiting protein activation, phosphorylation has been linked
to protein degradation and protein-protein interactions. In a laboratory setting, specific
phosphorylation events can be detected using primary antibodies raised against them.
This can be used to monitor activation of key signalling pathways and responses to stress
and is an important tool used in this thesis.
Another post-translational modification of note is ubiquitination (Fig. 7). Unlike phos-
phorylation this process involves the covalent bonding of a 76 amino acid polypeptide
[30][31][32]. Ubiquitination can modify substrate proteins in a variety of different ways,
making them one of the most versatile mechanisms of post-translational modification.
The most simple form of this, monoubiquitination, involves the binding of one ubiquitin
protein to the target, this occurs in three steps; activation, conjugation and ligation by
the E1, E2 and E3 ubiquitin ligases respectively in a cascade. Further conjugation of
ubiquitin to this first ubiquitin can occur through successive isopeptide bonds at the start
methionine or at specific lysines at positions 6, 11, 27, 29, 33, 48 and 63. Polyubiqui-
tination usually occurs at lysines 48 or 63, generally resulting in targeting proteins for
degradation by the proteosome or functioning in the control of signal transduction, DNA
damage response and DNA repair respectively [33][34][35][36].
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Figure 7. Ubiquitination of Target Proteins. Ubiquitination describes the addition of
one or several ubiquitin proteins to lysine residues. This requires a two-stage activation
process involving the E1 ubiquitin-activating enzyme that produces a ubiquitin-adenylate
intermediate then binding of an E1 cysteine to ubiquitin by a thioester bond, causing the
release of AMP. The E2 ubiquitin-conjugating enzyme then transfers the ubiquitin from
the E1 enzyme to a cysteine on the E2 enzyme. The E3 ubiquitin ligases then recognise
and bind a target protein and transfer the active ubiquitin to a lysine residue. Further
additions of ubiquitin can occur in linear or branched forms, these can occur on the
same lysine residues of ubiquitin up the chain or on a mixure of different lysine residues.
Multiple mono-ubiquitination can also occur along the protein. In this activation cascade,
E1 proteins can bind many E2s that can in turn bind many E3s to precisely coordinate
the appropriate form of activation.
As a result of this diverse polyubiquitination, ubiquitination is one of the most versatile
post-translational modifications that occurs in the cell. Ubiquitination therefore creates
a range of changes in protein conformation to control activation, repression, degradation
and stability of the protein [37][38][39]. Reversal of ubiquitination occurs readily by a
group of deubiquitination enzymes, or DUBs, allowing rapid removal of ubiquitination
events on proteins.
One final post-translational modification of note for this thesis is hydroxylation. This
chemical reaction involves the covalent binding of a hydroxyl group an amino acid; mostly
commonly proline, lysine or asparagine. The latter is critical in the response of cells to
hypoxia, this will be covered in more detail in a later section, but generally the loss of
oxygen prevents hydroxylation from occurring leading to changes in signalling pathway
activation and protein stability.
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1.2 The NF-κB Family of Transcription Factors
This project focusses predominantly on the activation of the NF-κB family of transcription
factors and the mechanism behind this activation (Fig. 8). Originally identified in B
lymphocytes in 1986, NF-κB was discovered to bind to the κ light chain enhancer sequence
of immunoglobulins and the SV40 enhancers to control gene expression in response to a
given stimulus [40][41].
There are 5 members of the NF-κB family; RelA, RelB, c-Rel, NF-κB1 and NF-κB2
that are characterised by a 300 amino acid long rel homology domain (RHD) present
towards the N-terminal of the proteins (Fig. 8). This region shares homology with
the v-Rel oncogene and has 3 main functions; DNA binding through the DNA binding
domain (DBD), dimerisation or inhibitor binding and a domain that promotes nuclear
translocation through a nuclear localisation sequence (NLS) [42]. Despite being highly
conserved, variations in the RHD enables different NF-κB subunits to form different
combinations of hetero- and homo-dimers to respond to different stimuli. These different
combinations of hetero- and homo-dimers to recognise distinct κB sites of 9-10 base pairs
of an almost palindromic DNA sequence; 5’-GGGRNWYYCC-3’ (N, any base; R, purine;
W, adenine or thymine; Y, pyrimidine). This κB sequence is located in the promoters or
enhancers of hundreds of genes [42][43].
There are 2 main classes of NF-κB proteins, characterised by the protein sequence to the
C-terminus of the RHD, which determines the method by which the protein is sequestered
in the cytoplasm and the resulting method of activation. Class I describes subunits NF-
κB1 and NF-κB2 [42], which are present in the cytoplasm as the inactive precursors
p105 and p100. These inactive precursors contain multiple inhibitory ankyrin repeats at
the C-terminal end of the protein. Ankyrin repeats are 33-residue motifs that mediate
protein-protein interactions and protein folding, however in the context of precursor class
I NF-κB subunits they act as transrepressors; negative regulators of activation. Following
activation from upstream signalling pathways, these ankyrin repeats are proteolytically
cleaved and processed from their inactive precursor forms to their mature forms; p50 and
p52 respectively. These cleaved forms of NF-κB1 and NF-κB2 are no longer sequestered
in the cytoplasm and are free to move in the the nucleus as directed by their nuclear
localisation signal. Class 1 NF-κB subunits also contain a glycine rich region directly to
the C-terminus of the RHD that acts as a processing signal to aid this activation.
Although class I NF-κB subunits play a key role in transcriptional control, to directly
activate gene expression rather than repressing transcription they must dimerise with the
second class of subunits; RelA(p65), RelB and c-Rel [42]. In addition to their DBDs
these class II subunits contain transactivation domain (TAD)s on their C-terminus and
are therefore potent activators of gene expression. Sequestration of class II subunits in
the cytoplasm requires blocking of a nuclear localisation signal on the NF-κB subunit by a
family of inhibitors known as the inhibitor of κB (IκB)s. The IκB protein holds NF-κB in
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Figure 8. The NF-κB Family and Inhibitors. The NF-κB family of rapidly acting tran-
scription factors comprises 5 different subunits that form a range of homo- and het-
erodimers that recognise distinct 9-10 base pair sequences on DNA to moderate tran-
scription. They are activated through post-translational modification either through the
cleavage of ankyrin repeat transrepressors (p105/p50 and p100/p52) or through the phos-
phorylation, ubiquitination and degradation of ankyrin-containing inhibitors (RelA, c-Rel
and RelB).
the cytoplasm in an inactive form until upstream signalling leads to IκB phosphorylation
and inactivation. IκB then releases its class II NF-κB subunit, which is able to translocate
into the nucleus to control gene expression.
The inhibitors of class II NF-κB subunits (IκBα, IκBβ, IκB, BCL-3, IκBζ and IκBNS)
and the precursors to p50 and p52 (p105/IκBγ and p100/IκBδ) contain ankyrin repeat
sequences (Fig. 8). The former subset work by binding to NF-κB and covering the NLS,
the latter must be proteolytically cleaved to allow activation. Cleavage of p105 to p50
occurs in relatively constant amounts regardless of external stimulus, however cleavage of
p100 to p52 requires external stimuli and signalling from upstream kinases to be initiated.
The function of these IκB proteins and motifs allows control of NF-κB activation and
allows for almost instant activation of these rapidly-acting transcription factors [44].
12
1.2.1 The NF-κB Family in Health and Disease
NF-κB has been implicated in a wide range of diseases and conditions that comprise
both general diseases as well as multiple forms of cancer [45][46][47] (Fig. 9). The large
number of diseases that NF-κB is linked to is most likely due to the large number of
inducers of NF-κB activation as well as the sheer number of NF-κB target genes. The
cross-talk between other critical cell signalling pathways again highlights the complexity
of NF-κB signalling and the need for precise control of its activation through elaborate
pathways and mechanisms. Loss of control of signalling could occur in many stages of
NF-κB activation and could have a knock-on effect in many aspects of cell biology. It is
for these reasons that aberrant NF-κB activation is linked with so many diseases.
Figure 9. General Diseases and Cancers Linked with NF-κB Activation. A wide-range of
general diseases (black) and cancers (red) have been previously linked with NF-κB [43].
The range of general diseases that NF-κB has been linked to is broad and affects many
organs and biological mechanisms across the body (Fig. 9). Ageing related diseases such
as Alzheimers disease, Parkinsons disease, cataracts, hearing loss and arthritis have all
been linked to NF-κB and its role in inflammation and response to stress [48][49][50][51][52]
[53]. Diseases affecting other organs such as the lung are also commonly linked to NF-
κBs role in inflammation either following injury [54][55] or as secondary effect of another
condition such as asthma through inflammatory reactions, chronic obstructive pulmonary
disease through the onset of oxidative stress [56][57], or cystic fibrosis, the latter of which
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has been shown to affect the NF-κBs crosstalk with the apoptotic response to stress [58].
Diseases affecting the cardiovascular system have also been linked with aberrant NF-κB
activation. Transcription of genes associated with the development of pulmonary hyper-
tension is controlled by NF-κB activation, the temporal and spatial expression of these
can lead to tissue-remodelling involved in the development of this often fatal condition
[59][60]. NF-κB has also been implicated in chronic heart failure through its role in
immune and inflammatory responses [61] as well as in the development of hypercholes-
terolemia and atheroschlerosis. These closely linked conditions of the vascular wall have
been linked to aberrant NF-κB activation through its role in the response to oxidative
stress as well as inflammation [62][63]. This role of NF-κB in the response to cycling
oxygen levels and ischemia and reperfusion stresses will be discussed in more detail in a
later section, however it is important to note this critical link between NF-κB, oxidative
stress and the inflammatory response.
Conditions affecting the liver, pancreas, kidneys and digestive tract have also been demon-
strated as having a strong link to NF-κB activation [64][65][66][67][68][69][70]. In the case
of alcoholic liver disease, regularly increased levels of ethanol exacerbates oxidative stress
in tissues and the mechanisms that control for this stress for example through the activa-
tion of NF-κB [65]. Liver disease is closely linked to pancreatic disease; the activation of
NF-κB in a diseased liver due to inflammatory responses leads to increased production of
chemokines and cytokines by NF-κB. Aside from promoting hepatic necrosis, this has been
linked to an increased risk of pancreatitis through increased production of inflammatory
cytokines and chemokines [66]. Inflammatory bowel disease and other autoimmune con-
ditions have also been associated with aberrant regulation of NF-κB activation. NF-κB
is an essential responder in the intestinal immune system, however unsolicited activation
and the resulting production of inflammatory and immune factors occurring against the
self can lead to the development of Crohns disease or colitis symptoms [68][69][70].
In many of these conditions, disease pathogenesis occurs due to complex responses of the
cell to oxidative stress and inflammation (Fig. 10) [71]. Within the body each tissue
has its own physiological niche, each with its own ’normal’ level of oxygen and its own
immunological activity. Indeed many of these tissues commonly undergo hypoxic stress
due to high levels of cell proliferation and increased metabolic demand, here the hypoxic
gradient is controlled, regulating pathways associated with physiological processes such
as haematopoietic stem cell differentiation and homeostasis. Within pathological sites,
such as in inflamed tissues, loss of control of the oxygen gradient may occur [71]. Erratic
blood supply within a tumour enviroment or uncontrolled metabolic processes associated
with inflammation can lead to changes in oxygen levels. This onset of hypoxia contributes
to the loss of control of processes such as immune cell differentiation and cell signalling,
promoting inflammation and disease further (Fig. 10). Cross-talk between hypoxic and
non-hypoxic signalling pathways can lead to the production of pro-inflammatory cytokines
14
Figure 10. Oxidative Stress and Inflammation. The link between oxidative stress, the
immune response and inflammation is a tightly regulated process. Loss of regulatory
control across this dynamic pathway can lead to increased inflammation, immune response
and oxidative stress. As these are all so closely linked, aberrant activation of one part of
this mechanism can have knock-on effects elsewhere in a cycle of inflammation, immune
response and oxidative stress. Figure adapted from Taylor et al., 2017 [71].
such as tumour necrosis factor (TNF), which further amplify inflammatory responses
[72][73]. As such hypoxia inducible factor (HIF) plays a key role in the control of oxidative
stress-induced inflammation. HIF controls gene expression in immune cells exposed to
hypoxia, coordinating their downstream effects and controlling their metabolism, thereby
controlling inflammation and the immune response [71][72].
In addition to its role in the development of these inflammatory, immune and stress disor-
ders, aberrant NF-κB activation can lead to the promotion of cancer development. This
constitutive activation of NF-κB can occur following mutations in NF-κB subunits and
upstream pathway components such as IKK subunits that could affect the regulation of
NF-κB activation, affecting key cellular responses and processes such as through promo-
tion of proliferation and survival, angiogenesis, metastasis and inflammation [74][75][76].
The promotion of these processes occurs mostly through aberrant regulation of NF-κB
activation, for example upregulation in the expression of cyclin D1 leads to increase move-
ment through the cell cycle and results in increased proliferation; causing the cell to bypass
essential cell cycle checkpoints [77].
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A second example of tumour promotion directed by NF-κB is through aberrant expression
of genes involved in apoptosis. Up-regulation in the expression of inhibitor of apoptosis
(IAP)s such as cIAP-2 and other proteins involved in regulation of apoptosis can lead to
an increased survival of cancer cells and can lead to cancer progression. Both of these
processes can contribute to the progression of cancer as cells containing DNA damage will
not be repaired and will avoid apoptosis, allowing mutations to be passed to daughter cells
[78][79]. NF-κB also plays an important role in the development of cancer in new sites in
the body. Its role as a transcriptional regulator of pro-angiogenesis genes such as VEGF
and the transcription factor HIF, promotes the growth of new vasculature, allowing cancer
cells to move into the blood stream to other sites in the body [80]. NF-κB’s role in cancer
development and progression also promotes metastasis through the increased production
of cell adhesion molecules, allowing cancer cells to adhere to a new secondary site in the
body through matrix metalloproteinases [81]. These factors combined highlight NF-κB as
an important promoter in the progression of cancer. Studies have also implicated NF-κB
as a negative regulator of cancer development, this is particularly important in the early
stages of the disease due to NF-κB’s role in the immune and inflammatory response where
it assists in the targeting and controlled destruction of tumour cells [82].
1.2.2 Activation of The NF-κB Pathway
The NF-κB response was originally thought of as a fairly simple activation process that
responded to inflammation following stimulation from TNF or lipopolysaccharides, how-
ever over the years the diversity of NF-κB stimulating factors has become apparent (Fig.
11) [42][83][44]. Studies carried out in the late 1980s mostly identified viral products
such as Tax1 (HIV-1), E1A (Adenovirus 5) and iel (CMV) [84] [85][86], as well as the
inflammatory cytokine TNF and the eukaryotic parasite Theileria parva [87][88][89].
Throughout the 1990s a whole range of other inducers were identified, including bacteria
(Staphyllococcus aureus) [90], bacterial products such as membrane lipoproteins [91], ther-
apeutic drugs such as camptothecin, cisplatin and etoposide [92][93][94], receptor ligands
such as CD-40[95], growth factors (TNFα) [96] and chemical agents such as thapsigargin
that causes ER stress [56]. Around this time it was discovered that physical and environ-
mental stresses could also initiate NF-κB activation. These include but are not limited to;
shear stress [97], UV irradiation [98], cigarette smoke [99] and heavy metals such as lead
and nickel [100][101]. Oxidative stress also induces NF-κB activation through chemical
induction after treatment with hydrogen peroxide [102], while more physical methods of
oxidative stress induction such as hyperoxia [103], ischemia/hypoxia [104] and reoxygena-
tion [105] can also activate NF-κB. Further investigations have since identified hundreds
of other inducers of NF-κB pathway activation (Fig. 11) [43]. Based on these findings it
is likely that other inducers of NF-κB pathway activation will be discovered in the years
to come.
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Figure 11. NF-κB is Activated by a Variety of Inducers. NF-κB pathway activation is
induced by a plethora of diverse stimuli. This schematic does not show all inducers, rather
giving an idea of the sheer number of inducers of the NF-κB pathways. Inducers of the
NF-κB pathways include responses to inflammation and infection via cytokines, viruses,
bacteria and proteins, through exposure to stresses from the environment, through phys-
ical and physiological stresses and following oxidative stress. It can also be activated
following exposure to chemicals and after treatment with certain drugs. Apoptotic me-
diators, modified and over-expressed proteins, receptor ligands, mitogens, hormones and
growth factors can also activate NF-κB. This broad range of inducers highlights both the
importance of the NF-κB proteins and the need to control activation and downstream
effects through elaborate activation pathways [43].
17
Each inducer of NF-κB leads to the activation of its own specific version of the pathway, in-
volving different protein interactions and different post-translational modification events.
Regardless of the upstream or downstream signalling pathway specificities, the majority of
signals converge on the IKK complex. Chemokines and cytokines for example can activate
the NF-κB pathway through interactions with cell surface receptors, which in turn inter-
act with proteins in the cytosol to transduce the signal downstream to the IKK complex
[87][88]. The pattern recognition receptors (PRR)s such as Toll-like receptor (TLR)s and
NOD-like receptor (NLR)s are expressed in cells involved in the innate immune response.
Damage-associated molecular patterns (DAMP)s and pathogen-associated molecular pat-
terns (PAMP)s initiate noninfectious and infectious inflammatory responses respectively
through interaction with these PRRs, which can lead to the activation of the NF-κB
pathway after upstream signals converge on the IKK complex [106].
In addition to these responses to inflammation and infection, other stresses such as geno-
toxic and oxidative stress activate the NF-κB pathway, again through the convergence of
upstream signalling to the IKK complex. An example of genotoxic stress leading to the
activation of the NF-κB pathway is that of camptothecin treatment. Camptothecin [92]
is a DNA damaging agent that causes doubles strand breaks. Following detection of this
damage, ATM is activated and in turn activates the NF-κB pathway. In this instance ac-
tivation of NF-κB occurs as a result of independent sensing of damage rather than simple
upstream interaction of a receptor ligand with a cytokine such as TNFα [87][88]. Reports
on the effects of oxidative stress on NF-κB activation have been conflicting [107]; studies
suggest that reactive oxygen species (ROS) can affect signalling across many aspects of
the pathway including direct interactions with the IKK complex itself [108][109][110][111].
The cellular responses to genotoxic stress and oxidative stress will be covered in more de-
tail in a later section.
1.2.3 NF-κB Signalling
NF-κB pathways requires a wide range of post-translational modifications such as phos-
phorylation and ubiquitination. Different post-translational modifications occur on differ-
ent proteins and residues depending on the specific inducer and the strength of the stim-
ulus. These proteins act as intermediates between the stress or sensor of stress and the
activation of the IKK complex, and subsequently NF-κB subunits. Often two upstream
pathways will act in parallel upstream of the IKK complex following exposure to different
inducers. In some cases there will be overlaps in the proteins and post-translational mod-
ifications involved but each pathway will have distinct inducers and downstream effects
[42][112].
NF-κB signalling comprises two main pathways; the canonical (classical) and non-canonical
(alternative) pathways (Fig. 12). RelA, c-Rel and p105/p50 dimers are associated with
canoncial pathway activation, while RelB and p100/p52 dimers are present as part of the
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non-canonial pathway[113]. There are several key differences between these two signalling
pathways, one of which is the mechanism behind activation. The former is dependent on
the phosphorylation and degradation of the IκB protein that inhibits activation, while
the latter is activated following phosphorylation and subsequent ubiquitin-mediated pro-
teasomal cleavage to process p100 to p52. This activation of either pathway cannot take
place without the post-translational modification of the IκB protein. The protein complex
responsible for this, the IKK complex, is therefore pivotal in the activation of NF-κB.
The sub-units of the IKK complex differ between the canonical and non-canonical NF-
κB pathways. A trimeric form of the IKK complex is present in the canonical pathway,
comprising of 1 regulatory subunit, the NF-κB essential modulator (NEMO)/IKKγ, and
2 kinase subunits IKKα and IKKβ [113][114]. In the canonical pathway IKKβ is widely
considered to be kinase responsible for downstream signal transduction and NF-κB acti-
vation. In the non-canonical pathway the IKK complex comprises an IKKα homodimer,
therefore IKKα is responsible for signal transduction as opposed to IKKβ [42]. In both
the canonical and non-canonical pathways, regardless of stimulus or the upstream pro-
teins and post-translational modifications involved, signalling mostly converges on the
IKK complex. This again highlights the importance of the IKK complex and its role as a
central regulator of the activation of NF-κB.
The upstream mechanism of canonical IKK complex activation varies greatly from stimu-
lus to stimulus, but usually requires the activation and coordination of upstream targets
such as TAK1-binding protein 2/3 (TAB2/3), TAK1, receptor interacting protein (RIP)
and TNF receptor associated factor (TRAF) (canonical pathway) or NIK (non-canonical
pathway). It has been reported that TRAF is involved in activation of both canonical
and non-canonical NF-κB activation, while RIP is only involved in canonical pathway
signalling through interactions with NEMO[42]. Ubiquitination is essential for the trans-
duction of signal to the IKK complex. Here TRAF6 acts as an E3 ubiquitin ligase to
induce activation of the IKK complex alongside an E2 conjugating enzyme complex com-
prising Ubc13 and Uev1A. This activation occurs through K63-linked polyubiquitination
of NEMO to activate the IKK complex. This leads to the activation of the IKKβ subunit,
through phosphorylation events on serine residues [115][42].
As part of the canonical pathway, activation of IKKβ then leads to the phosphorylation
of IκBα at serines 32 and 36, leading to dissociation of IκBα from RelA [116]. RelA is no
longer being sequestered in the nucleus by the ankyrin repeats of IκBα and its nuclear
localisation signal is no longer blocked, RelA is therefore able to form dimers with other
NF-κB family members, translocate into the nucleus and control gene expression [117].
This process was characterised by Hunag et al in 2000 [117]. The phosphorylation and
subsequent release of IκBα leads to its polyubiquitination and degradation by the 26S
proteasome. This degradation and removal of IκBα is observed following induction of the
NF-κB pathway by inducers such as TNFα, however following exposure to other stimuli
such as hypoxia degradation is not observed [118].
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Figure 12. Canonical and Non-Canonical NF-κB Signalling. NF-κB is activated in re-
sponse to a wide range of stimuli. Non-Canonical signalling typically occurs through
NF-κB-inducing kinase (NIK) and involves transduction through a IKKα homodimer
to activate RelB and p100 dimers. Ubiquitination of p100 leads to its processing and
subsequent release of RelB and p52 heterodimers into the nucleus to coordinate gene ex-
pression. In the canonical signalling pathway, upstream signals converge on a trimeric
form of the IKK complex from upstream kinases such as transforming growth factor-β
activated kinase-1 (TAK1). Phosphorylation of the beta subunit of the IKK complex
allows signal transduction to IκBα. The subsequent phosphorylation of IκBα causes its
dissociation from RelA, p50 and c-Rel dimers and degradation. Since IκBα can no longer
sequester NF-κB in the cytoplasm, NF-κB is free to move into the nucleus and coordinate
transcription.
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The activation of the NF-κB pathway described above is broadly considered to be the
‘typical’ route of canonical signalling. The activation through the IKK complex that
leads to the the serine 32/36 phosphorylation, ubiquitination and degradation of IκBα
and the subsequent release of RelA, has been extensively studied. This rapid, almost
immediate, activation of the canonical NF-κB pathway is associated with the ‘traditional’
activators such as inflammatory cytokines and bacterial products. Due to the vast range
of different stimuli and downstream targets NF-κB signalling is extremely complex, as
such this ‘typical’ mechanism of activation is not always upheld [42][119].
As discussed earlier, other activators of the canonical NF-κB pathway include DNA dam-
age inducers such as chemotherapeutic drugs and UV-C radiation. As one would imagine
the cellular response to DNA damage is very different to the response to inflammation and
infection, as such the response of the canonical NF-κB to this stress is different [42][117].
Earlier studies have described a mechanism for NF-κB that occurs independently of the
IKK complex following UV stress, and involves alternative post-translational modifica-
tions of IκBα to control its degradation [120][121][122]. In this slower actvation of NF-κB,
downstream transduction of signal to IκBα occurs in a p38 and casein kinase 2 (CK2)-
dependent manner rather than through the IKK complex, although other reports indicate
that NEMO is still required for this signalling [123].
In the late 1990s and early 2000s it was reported that IκBα degradation can occur in
the absence of serine 32/36 phosphorylation in the response to DNA damage induced
by chemotherapeutic agents [120][122]. Other studies have implicated tyrosine 42 phos-
phorylation of IκBα as an alternative means of releasing and activating NF-κB, and
contributing to the subsequent ubiquitin-mediated degradation of IκBα [124][125]. In ad-
dition, activation of NF-κB in the absence of IκBα has been reported alongside tyrosine 42
phosphorylation [118]. Until more recently, phosphorylation of IκBα at serines 32/36 has
been linked to its degradation, following K-48-linked ubiquitination [78][126][127][128].
However these studies have highlighted some of the alternative means of inducing NF-κB
activation through regulation of IκBα, as well as indicating that serine 32/36 phospho-
rylation was not as critical for IκBα degradation as previously believed. Indeed, more
recent reports suggest that IκBα can be sumoylated at this ubiquitination site, which
prevents ubiquitination and degradation, stabilising IκBα, yet allowing for the release
and activation of NF-κB [129][130].
As described above, this activation of NF-κB subunits is complex both in terms of up-
stream signalling, and the transduction of signal through the IKK complex to either the
IκB proteins or the class I NF-κB subunits. Following the activation and release of NF-
κB subunits and the formation of homo- and hetero-dimers, further modifications can
occur on the NF-κB subunits themselves to allow them coordinate gene expression ap-
propriately in the nucleus. The best characterised subunit, RelA, contains many residues
that are known to be phosphorylated in response to different stimuli to elicit the correct
transcriptional response.
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Inactivation of the NF-κB pathways occurs once the activation signal has stopped; at this
stage the level of nuclear export of NF-κB subunits is greater than import [131][132]. In
addition to this the inhibitory IκB proteins are direct transcriptional targets of NF-κB
leading to the inhibition of NF-κB through a negative feedback loop [133].
1.2.4 Regulation of Transcription by The NF-κB Family of Transcription
Factors
As discussed earlier, the NF-κB pathways are activated by a plethora of different inducers,
in response to inflammation, infection and other stresses. It therefore makes sense that
NF-κB equally regulates the transcription of a large number of different genes, with
perhaps as large a range of diversity as the inducers have.
In addition to coordinating the transcription of the gene encoding IκBα in a negative
feedback loop [126], NF-κB controls the transcription of class 1 NF-κB family members.
Full length inactive p105 and p100 precursors are transcribed to replace the activated
cleaved forms of these proteins so that the pathway is able to be activated again in future
rounds of signal pathway activation [134][135]. Studies have highlighted the complexity
of this process as expression of the p50 precursor p105 is controlled by both RelA and
p50 itself [134]. p100 expression is also promoted by RelA interactions but suppressed
following p52 binding in a negative feedback loop [135]. In addition to this, the expression
of NF-κB subunits c-Rel and RelB are controlled by NF-κB pathway activation. The for-
mer, c-Rel is autoregulated through a negative feedback loop [136], while RelB expression
is controlled by both RelA and RelB [137].
Several studies have demonstrated that NF-κB itself is able to coordinate the expression
of activators of the NF-κB pathways [138][139][140][141]. Transcription of genes encoding
Interleukin-8 (IL-8) and TNF chemokines can lead to prolongation of NF-κB activation or
the activation of other NF-κB dimers to coordinate the expression of different genes. Both
IL-8 and TNF activate NF-κB through interaction with cell surface receptors, allowing
signalling to continue through a positive feedback loop [138][139][140][141].
NF-κB also coordinates the transcription of genes whose products are required in critical
cellular responses and pathways. Cellular inhibitor of apoptosis (cIAP)-2 is critical in the
control of apoptosis. The role of NF-κB in apoptosis is complex and has been described as
both pro- and anti-apoptotic. The transcription of Bcl-2 and Bcl-XL suggests that activa-
tion could be pro-apoptotic as these proteins are required for the initiation of apoptosis.
In contrast to this, transcription of IAPs such as cIAP-2 in response to NF-κB stimu-
lation following inflammatory cytokine production leads to inhibition of apoptosis. This
prevents the initiation of apoptosis in response to inflammation to allow for resolution of
the problem rather than initiating programmed cell death [142][143].
NF-κB also controls the expression of genes that encode products involved in the cell
cycle through coordination with other key transcriptional regulators such as JunD and
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Figure 13. NF-κB Controls the Transcription of a Plethora of Genes. NF-κB pathway
activation culminates in the control of expression of a wide range of different genes. This
schematic does not show all target genes, and is designed to give an idea of the range and
number of genes that NF-κB has been linked to. Genes linked to activation of the NF-κB
pathways include those involved in the response to inflammation and infection such as
cytokines and chemokines as well as antigens and immunoreceptors. Other target genes
are linked with response to stress and apopotosis as well as growth factors, ligands and
enzymes. NF-κB also controls the expression of other transcription factors, highlighting
its importance in the activation of other pathways and the indirect control of expression
of other sets of genes [43].
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signalling transducers such as phosphoinositide-3-kinase (PI3K) family members [144].
Here NF-κB functions as a promoter of cell cycle progression in the early phase of the cell
from G1-phase to S-phase through direct control of cyclin D1 transcription. This regulates
cell growth and differentiation through encouraging proliferation and preventing G0-phase
[77][145].
In many cases NF-κB target genes encode proteins that act as part of a feedback loop
to control NF-κB pathway activation. In PI3K-Akt pathway activation PI3K phosphory-
lates phosphatidylinositol biphosphate (PIP2), this then phosphorylates phosphoinositide-
dependent protein kinase-1 (PDK1), which in turn phosphorylates Akt (Fig. 14). This
leads to activation of NF-κB. NF-κB controls the expression of PTEN, which acts as an
inhibitor of this activation through dephosphorylating phosphatidylinositol triphosphate
(PIP3), therefore preventing activation of PDK1 and Akt. PTEN expression therefore
blocks the activation of NF-κB in a negative feedback loop through the PI3K-Akt sig-
nalling cascade [144][146].
Figure 14. Crosstalk Between PI3K Signalling and the Canonical NF-κB Pathway. Fol-
lowing exposure to external stimuli such as cytokines and growth factors, the PI3K-Akt
signalling pathway is activated. This is in turn able to activate the canonical NF-κB
pathway through phosphorylation of key members of the IKK complex. In turn, NF-κB
regulates the expression of phosphatase and tensin homolog (PTEN), adding a further
level of feedback and control to the activation of these pathways. Figure adapted from
Kucuksayan et al., 2016 [146].
NF-κB is also a regulator of other key signalling pathways. This cross-talk does not
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only occur through coordinating the transcription of cell cycle regulatory proteins and
apoptosis, but through interactions with a plethora of other signalling pathways. NF-κB
is also directly involved in the expression of HIF-1α in the presence of hypoxic stress [147].
This transcription factor in turn controls the expression of other sets of genes associated
with the response to hypoxia [148].
Crosstalk between the canonical NF-κB pathway and other signalling pathways can occur
through many different mechanisms. This can occur through protein-protein interactions
upstream, following gene expression where NF-κB targets such as PTEN are involved
in independent pathways or where gene products of other transcription factors activate
NF-κB. One example of this that is relevant to this thesis is that of TAK1. As discussed
previously TAK1 is an upstream kinase of IKKβ, however it also acts as an upstream
kinase of the c-Jun N-terminal kinase (JNK) signalling pathway. This is one of three
mitogen-activated protein kinase (MAPK) signalling pathways that function as a cascades
through a series of kinases; MAP kinase kinase kinase (MAPKKK or MAP3K) such as
mitogen-activated protein kinase kinase (MKK)2/3, a MAP kinase kinase (MAPKK or
MAP2K) such as mitogen-activated protein kinase kinase (MEK)5, and a MAP kinase
(MAPK). The MAPK signalling cascades are named after the MAPK proteins; extracel-
lular signal-regulated kinase (ERK), JNK and p38. The ERK pathway is more commonly
associated with proliferation and differentiation, while the JNK and p38 pathways are
activated in response to cell stresses.
As well as coordinating the response to oxidative stress through promotion of HIF1α
expression, NF-κB is able to directly coordinate the expression of a wide range of genes
involved in the response to loss of ROS homeostasis. Expression of antioxidant enzymes
such as the Cu/Zn-superoxide dismutase superoxide dismutase 1 (SOD-1), the manganese
superoxide dismutase superoxide dismutase 2 (SOD-2) and the quinone oxidoreductase
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase are all controlled by NF-
κB subunits in the response to oxidative stress [149][150][151].
1.3 NF-κB, The PIKK Family and Critical Cellular Responses
As discussed previously, genotoxic stress, or DNA damage, is a known activator the NF-
κB pathway [92]. Coordination between the DNA damage response, the cell cycle and
the apoptotic pathways is required to ensure that the cell is able to respond to genotoxic
stress in the correct way. This complex network of signalling pathways is controlled
by PIKK family members, through the activation of ATM, ATR and DNA-Dependent
protein kinase (DNA-PK) in the response to DNA damage. Once active ATM and ATR
phosphorylate downstream targets to arrest the cell cycle while DNA is repaired, as well
as interacting with the NF-κB pathway. This ensures that the cells respond correctly to
DNA damage; pausing the cell cycle to carry out repairs and preventing or promoting
apoptosis through interactions with the NF-κB pathway as required.
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1.3.1 DNA Damage and Repair
DNA damage can occur as a result of exposure to endogenous sources such as following an
increase in cellular ROS levels or from exogenous or external sources following exposure to
different frequencies of radiation, exposure to chemical agents such as chemotherapeutic
drugs or through viral transposition. Some examples of endogenous damage include ox-
idation, alkylation, hydroylsis (deamination and depurination), bulky adduct formation,
mono- or di-adduct damage or base mismatch. Exogenous damage can include formation
of pyrimidine dimers, strand breaks, depurination and cross-linking. The ability of the
cell to detect and determine the form of damage is critical for DNA repair to occur. A
range of different repair mechanisms are used by the cell to repair each specific type of
DNA damage (Table 2).
DNA damage occurs at a high frequency, with thousands of lesions occurring in a given cell
every day, most of which cause changes in the tertiary structure of the DNA double strand
helix. It is critical that DNA damage is detected and repaired rapidly and appropriately
to prevent passing on the damage to daughter cells, accumulation of further damage and
loss of function. The accumulation of unrepaired DNA damage can lead to the initiation
of a plethora of cellular process such as senescence and apoptosis, and in extreme cases
can lead to unregulated cell division, uncontrollable proliferation and the development
of cancer. This loss of function occurs when damage occurs in parts of the genome that
are essential for key cellular mechanisms, however cells are often able to function almost
normally when mutations occur in non-essential genes.
Double-strand DNA damage or breaks can be repaired by three different mechanisms; non-
homologous end joining (NHEJ) (Fig. 15), microhomology-mediated end joining (MMEJ)
and homologous recombination (HR)(Fig. 16). Often the mechanism of repair is dictacted
by the position of the cell in the cell cycle, with HR acting exclusively in S- and G2- phase
as it requires templates in the form of sister chromatids, while NHEJ can be performed
in post-mitotic and G1-phase cells. The repair pathway initiated following double strand
breaks is dependent on whether homologous DNA is present on another chromosome or
DNA strand to act as a template [152][153][154]. The PIKK family members ATM, ATR
and DNA-PK play important roles in the response to double-strand and single strand
breaks, as their activity is crucial for interactions with other pathways to coordinate cell
cycle arrest, NF-κB activation and histone modification.
Like HR, single-strand DNA damage utilises complementary base pairing as a tool in
repair. Single-strand breaks often have a far smaller aberrations, usually consisting of one
or two damaged or incorrect bases on one strand of DNA rather than double stranded
breaks. There are 3 main types of single-strand break repair that often work to excise
and replace the offending lesions, these include; base excision repair (BER) (Fig. 17),
nucleotide excision repair (NER) (Fig. 18) and mismatch repair (Fig. 19).
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Figure 15. Non-Homologous End Joining. NHEJ occurs in the absence of sister chro-
matids, therefore the broken ends of the DNA are simply ligated together. Often over-
hangs of the broken DNA can be used as guides as small homologous sections, or micro-
homologies, can be present here. The initial stage of NHEJ involves the recognition and
binding of a Ku heterodimer (Ku70/Ku80) to the site of the lesion. Recruitment and
binding of the Mre11, RAD50 and Nbs1 (MRN) complex and DNA-PKs to the exposed
ends of the DNA follows, forming a complex with the Ku dimer and activating DNA-PK.
At this stage the exposed ends of the DNA are processed, this involves the removal of any
damaged bases by nucleases and the synthesis of new bases by DNA polymerases. The
DNA ligase IV complex (DNA ligase IV and XRCC4) is recruited and bound by the Ku
heterodimer to ligate the broken fragments of DNA together[155][156][157].
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Figure 16. Homologous Recombination. HR occurs when a template sequence such as a
sister chromatid is available. HR occurs during meiosis in the absence of DNA damage
to introduce variation between gamete cells. There are two main methods by which HR
occurs in human cells; the double strand break repair (DSBR) pathway and the synthesis-
dependent strand annealing (SDSA) pathway. The initial steps are the same; the MRN
complex is recruited to the site of damage [158], ATM is activated by the MRN com-
plex, leading to the phosphorylation of downstream targets such as checkpoint kinase 2
(Chk2) to block cell cycle progression and H2A histone family member, X (H2AX) to
control chromatin structure [159][160][161]. 5’ ends of the broken section of DNA are
then resected to form 3’ overhangs [162][163][164]. Replication protein A (RPA) then
binds the single stranded DNA and Rad51 forms a nucleoprotein filament, coordinating
strand invasion from one 3’ overhang. D-loop (displacement-loop) formation and new
DNA synthesis occurs [165]. This invading 3’ strand forms a cross-over with the template
DNA strand following synthesis, this is known as a Holliday junction. In the case of the
DSBR pathway, the second 3’ overhand also forms a Holliday junction; these are cut by
endonucleases and repaired. DSBR commonly results in chromosomal crossover. In con-
trast in SDSA the invading 3’ strand is extended along the template by DNA polymerase
in a process known as branch migration. Any remaining overhands are degraded and the
phosphodiester backbone is repaired by ligation. This mechanism of HR does not result
in any chromosomal crossover [166].
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Figure 17. Base Excision Repair. BER is responsible for the removal and replacement of
relatively small DNA adducts that do not alter the physical tertiary helical structure of
double stranded DNA [167][168] . Although small, it is important that this DNA damage
is resolved as it could lead to mispairing, mutations and even double strand breaks follow-
ing replication. Oxidised, alkylated or deaminated bases are sensed by legion-specific DNA
glycosylases, which then cleave out the damage base portion of the nucleotide leaving an
abasic (AP) site behind. This DNA backbone is then incised by an AP endonuclease leav-
ing a 3’ hydroxyl and a 5’ deoxyribosephosphate at the site of damage, the latter of which
is converted into a ligatable 5’ phosphate by tyrosyl-DNA phosphodiesterase 1 (TDP1)
[169]. DNA polymerase then completes the repair process through DNA synthesis followed
by ligation of the phosphodiester backbone by the XXRCC1/Ligase III complex, which
is recruited to the site of damage by the nuclear protein poly (ADP-ribose) polymerase
(PARP). This can be carried out by two mechanisms; short-patch repair or long-patch
repair, which depends on the length of DNA excised and replaced [170].
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Figure 18. Nucleotide Excision Repair. NER is used to repair bulkier, helix-distorting
DNA adducts [171][172]. There are two eukaryotic NER pathways; global genomic-NER
(GG-NER) and transcription coupled-NER (TC-NER) [173][174]. In the GG-NER path-
way, the bulky adducts are sensed by DNA-damage binding (DDB) and XPC-Rad23B
complexes due to helix distortion [175][176][177]. TC-NER is activated when RNA poly-
merase stalls at the site of a DNA damage lesion. At this stage the two pathways converge
as TFIIH is localised to the site of damage [178][179]. Other proteins are then recruited
sequentially to coordinate DNA unwinding. TFIIH is responsible for the dual excision of
the unwound damaged DNA [176]. The xeroderma pigmentosum group A-complementing
protein (XPA) and RPAs stabilise the single stranded DNA and recruit the xeroderma
pigmentosum group G-complementing protein (XPG) endonuclease and the ERCC1-XPF
to incise the damaged strand [180][181]. DNA is then synthesised using the complemen-
tary strand as a template. Sealing of the phospho-diester backbone is carried out by DNA
ligases to complete the process [182][183].
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Figure 19. Mismatch Repair. This process recognises and repairs mismatched bases as
well as small insertions and deletions. In eukaryotes the site of damage is recognised on
the newly synthesised strand of the DNA by the a MutS protein homolog 2 (Msh2)/MutS
protein homolog 6 (Msh6) protein dimer, the hydrolysis of ATP activates this complex and
leads to the recruitment and subsequent activation of PMS2/MutL homolog 1 (MLH1).
This dimer is able to move along the DNA in a 5’ or 3’ direction to scan for errors
in the DNA. Following this the DNA clamp proliferating cell nuclear antigen (PCNA)
translocates along the daughter strand of the DNA, this leads to the recruitment of the
exonuclease Exo1, starting from a nick in the DNA, this degrades the damages DNA
strand in a 3’ to 5’ direction. Following excision of 100s of nucleotides PCNA then binds
to DNA polymerase, which moves to the damaged site to synthesise new DNA using the
parent strand as a template. Ligation then occurs to seal the phosphodiester backbone
[184].
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DNA Damage and Repair
Source of Damage Damage Induced Repair Pathway
Alkylating Agents, UV
Radiation, Nitrosourease,
Streptoztocin, Methylation
Alkylated Bases, Pyrimidine
Dimers, O-6-methyl-guanine,
N-7-methyl-guanine
Direct Reversal
ROS, Ionising Radiation,
X-rays, Alkylating Agents,
Spontaneous Hydrolysis
Single Strand Breaks, Oxi-
dised Bases, 8-oxo-guanine,
Alkylated Bases, aba-
sic/apurinic/apyrimidinic sites,
Uracil
BER
ROS, Cigarette Smoke,
UV(C) Light
Cross Links (intra/inter-strand,
DNA-protein), Bulky Lesions, 6-4
Photoproduct, Cyclobutane
NER
Oxidation, Alkylation,
Replication Errors
Small Insertion Loops, A-G or T-C
Mismatched Bases, Deletions
MMR
Ionising Radiation, Repli-
cation Errors, Anti-Tumour
Agents, X-Rays, ROS
Double-strand Breaks, Intra-strand
Crosslinks
HR or NHEJ
Table 2. Table of DNA Damage Inducers, Effects and Repair Mechanism. There are
many different types of DNA damage that come from a wide range of different sources.
This are each resolved through activation of distinct and mechanistically complex repair
pathways.
1.3.2 The PIKK Family
The PIKK family of kinases encompasses several proteins including ATM, ATR, DNA-PK,
mammalian target of rapamycin (mTOR), transformation/transcription domain associ-
ated protein (TRRAP) and serine/threonine protein kinase (SMG1). They are closely
related to the PI3K family of protein kinases (Fig. 20). With the exception of TRRAP
function as protein kinases to activate downstream signalling pathways through phos-
phorylation of key serine and threonine residues [185][186][187][188]. Members of the
PIKK family are large proteins that are characterised by the presence of the catalytic do-
main FRAP, ATM and TRRAP C-terminal (FATC) and N-terminal α-helices that enable
protein-protein interactions and recruitment to targets [186].
ATM, ATR and DNA-PK are key responders to DNA damage events, and activate down-
stream targets to control DNA damage responses through coordination of cell cycle ar-
rest and initiating DNA repair. ATM, ATR and DNA-PK respond to different types of
damage, coordinating downstream targets to induce the most appropriate DNA repair
pathway. Both ATM and DNA-PK are essential for the cellular response to DNA double
strand break (DSB)s (Fig. 15, Fig. 16); ATM is involved in homologous recombination
repair and controls cell cycle progression through phosphorylation of its substrate Chk2
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Figure 20. The PIKK Family. The PIKK family of serine/threonine kinases are charac-
terised by the presence of a FAT and FATC domains. They are close relatives of the PI3K
family of kinases and work in a wide range of cell signalling pathways including the DNA
damage response as well as transcription and translation. They are large proteins and as
such their crystal structure has not yet been successfully characterised.
[189], while DNA-PK is involved in NHEJ [190]. ATR, on the other hand is involved in cel-
lular response to single-stranded DNA, such as errors encountered during DNA replication
(Fig. 16, Fig. 18). Activation of ATR leads to cell cycle arrest through phosphorylation
of proteins such as checkpoint kinase 1 (Chk1) [191].
Inactive ATM is present in the nucleus as an inactive homodimer; in response to DNA
DSBs ATM is activated though autophosphorylation of serine 1981. It then splits into 2
active monomers and phosphorylates the histone H2AX, which signals the site of DNA
damage to the cells and leads to the recruitment of MRN complex to the site of damage to
coordinate DNA repair [189]. Following full activation of ATM through aurophosphoryla-
tion on serines 367, 189 and 1981 [192] on recruitment to the MRN complex ATM is able
to phosphorylate a number of substrates directly or indirectly, both inside and outside of
the nucleus. These subsrates include Chk2, tumour protein p53 (p53) and mouse double
minute 2 homolog (Mdm2) to coordinate cell cycle arrest, allowing for this DNA repair
to take place. In addition, ATM activation leads to transcriptional changes through the
activation of transcription factors such as NF-κB [191].
Although ATM is considered to be the main kinase of H2AX, some publications have
demonstrated that both ATR and DNA-PK are able to phosphorylate H2AX at serine
139. Following hydrogen peroxide treatment and the resulting formation of single stranded
breaks, ATR is able to induce γH2AX independently of ATM [193]. Following exposure to
ionising radiation, DNA-PK carries out this phosphorylation of H2AX in an overlapping
manner with ATM [194], while another study described that this was stimulated by prior
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acetylation of histones [195].
As the name suggests, ATR is very similar to ATM, however rather than responding to
double strand breaks in DNA, ATR is activated during S-phase in the presence of a stalled
replication fork due to the presence of exposed single stranded DNA structures. These
can occur following the formation of base-crosslinks, following exposure to certain DNA
damaging agents and as an intermediate in DNA repair pathways in response to double
strand breaks [196][197]. This highlights the close connection and overlap in function that
exists between ATM and ATR [198].
ATR and the RAD9-RAD1-Hus1 (9-1-1) complex are recruited to the site of DNA dam-
age by RPA and through interactions with ATR interacting protein (ATRIP). This 9-1-1
complex in turn recruits the ATR activator Topoisomerase II binding protein 1 (TopBP1)
which induces ATR activation through phosphorylating ATR at threonine 1989 [199][200].
Autophosphorylation on serine 428 following exposure to other stresses such as UV ra-
diation or oxidative stress also leads to ATR activation [201]. Following activation ATR
phosphorylates a plethora of downstream targets such as Chk1 to control cell cycle pro-
gression and coordinate DNA repair[186].
1.3.3 The Cell Cycle
The cell cycle describes the process by which cells duplicate their DNA and divide. There
are several stages of the eukaryotic cell cycle; G1-phase (gap 1), S-phase (synthesis), G2-
phase (gap 2) and Mitosis (chromatid separation). The cell then splits into two daughter
cells through a process called cytokinesis. Proliferating cells then enter G1-phase again,
while differentiated cells leave the cell cycle and enter G0 phase. This process is highly
conserved in eukaryotic cells and is a tightly regulated process; loss of control of the
cell cycle can lead to increased proliferation, accumulation of DNA or cell death. Cell
replication is critical in multicellular organisms for the controlled development of specific
tissues and in the response to external stresses and is controlled by a complex series of
upstream activation pathways that respond to extracellular and intracellular signals to
coordinate replication in a timely and correct manner (Fig. 21).
Control of the cell cycle is tightly regulated through four main checkpoint controls; the
intra-S phase checkpoint, the spindle-assembly checkpoint, the spindle position checkpoint
and the DNA-damage checkpoint [205][206] (Fig. 21). The upstream kinases ATM and
ATR are essential in both the intra-S phase and DNA damage checkpoints. Here ATR
detects single stranded DNA on replication forks to determine whether DNA synthesis
has been completed [207]. ATM detects DNA damage events throughout the cell cycle
[208][209]. ATR and ATM are responsible for signalling between the DNA damage re-
sponse proteins and the downstream kinases Chk1 and Chk2 to arrest the cell cycle until
DNA damage has been resolved [210][211] (Fig. 21). If left undetected DNA damage
may be propagated forward to future generations, leading to accumulation of further mu-
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Figure 21. Regulation of the Cell Cycle. Progression through the cell cycle is controlled by
fluctuations in levels of cyclin proteins and cycin-dependent kinase (CDK)s [202][203][204].
Different combinations of these proteins function as heterodimers in different stages of
the cell cycle to coordinate the phosphorylation of downstream targets. Activation and
inhibition of cyclin-CDKs is therefore critical in the control of the cell cycle. Further
control occurs through checkpoint mechanisms at points in the cycle where changes in
expression or activity of these heterodimers changes. Sensing of DNA damage is essential
throughout the whole process and relies heavily on the upstream kinases ATM and ATR.
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tations, uncontrolled proliferation and diseases such as cancers. In the event the DNA
damage cannot be repaired apoptosis is initiated to prevent mutations from being passed
to future generations.
1.3.4 Apoptosis
There are two main forms of cell death; programmed cell death (apoptosis) and non-
physiological cell death (necrosis) [212]. The latter occurs as a result of massive injury or
damage to the cell from external sources, this results in autolysis and uncontrolled death
that causes an inflammatory response [213][214]. In contrast to this, programmed cell
death such as apoptosis occurs in a controlled and physiological way through initiation of
cell signalling pathways in response to internal factors. Apoptotic cells are easily identifi-
able under a microscope as they go through distinct morphological changes; cell shrinking,
cytoskeleton collapse, nucleus and chromatin condensing, fragmenting, blebbing and for-
mation of apoptotic bodies. Unlike necrosis, this allows the neighbouring macrophages to
engulf and degrade any by-products, rather than spilling their contents and causing harm
to neighbouring cells [215].
Apoptosis is intimately linked with other cellular processes such as autophagy. Autophagy
describes a predominantly cytoplasmic response as lysosomes degrade substrates in order
to obtain metabolic building blocks and obtain energy in circumstances where energy is
depleted. During amino acid starvation autophagy is able to prevent initiation of apoptosis
by degrading non-essential proteins to supply the cell with the amino acids that it needs
to survive. In addition it is responsible for maintaining organelle integrity, responding to
infection and clearance of aggregated proteins; functions essential for the health of the cell
and preventing apoptosis [216]. Apoptosis and autophagy are also closely linked through
the B-cell lymphoma (BCL) family of proteins, these control the permeabilisation of
the mitochondrial membrane to regulate the balance of pro-apoptotic and anti-apoptotic
signals, as well as regulating the initiation of autophagy. As such autophagy has a great
influence over whether a cell undergoes apoptosis or survives [216].
Apoptosis is critical in many aspects of cell biology and plays an important role in de-
velopment, removal of damaged cells and in the immune system to prevent autoimmune
responses [217]. Apoptosis is generally initiated either through the loss of a sensing of
trophic factors, which the cell receives to encourage it to survive, or through the detection
of a signal that initiates apoptosis. This section will predominantly focus on the latter
method of induction and will describe two forms of the signalling pathway used to initiate
apoptosis; the extrinsic and intrinsic pathways (Fig. 22).
Both the extrinsic and intrinsic apoptosis pathways involve the activation and signalling of
caspase proteins [218]. Caspase proteins are a family of proteases that are synthesised as
inactive precursers known as procaspases. There are several different caspases; 2, 8, 9 and
10 are initiator caspases, 3, 6 and 7 are executioner caspases, and 1 and 11 are not involved
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Figure 22. Extrinsic and Intrinsic Apoptosis Pathways. The extrinsic apoptosis pathway
is initiated following the binding of extracellular death ligands binding to a cell membrane
receptor [214]. The death domains of the receptor become activated and recruit adaptor
proteins that recruit an initiator procaspase such as caspase 8 or 10 [218]. This complex
is referred to as a death-inducing signalling complex (DISC) and leads to the cleavage and
activation of this initiator caspase. Control of apoptosis in this pathway occurs upstream
of the caspase proteins through binding of the adapter with the protein FLICE-like in-
hibitory protein (FLIP), which acts like a procaspase but does not contain proteolytic
activity, competing with procaspases in DISC formation. The intrinsic pathway is initi-
ated when the mitochondria releases the cytochrome C electron transport chain protein
into the cytoplasm [219][220]. In some instances the intrinsic pathway is activated or
repressed in response to the activation of the extrinsic pathway, to amplify or repress
apotosis induction. This involves the B-cell lymphoma 2 (Bcl2) family of intracellular
regulator proteins, which either promote or inhibit the release of cytochrome C from the
mitochondria in a pro- or anti-apoptotic manner respectively [221]. When cytochrome C
is released into the nucleus it forms a complex with apoptotic protease activating factor
1 (Apaf1), a pro-caspase activating adaptor protein. Seven Apaf1/cytochrome C dimers
form a heptamer complex in a ring shape; this is known as the apoptosome. The apop-
tosome acts in a similar way to the DISC complex in the extrinsic pathway, cleaving and
activating initiator procaspase 9 to begin the caspase cascade downstream and inducing
apoptosis.
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in apoptosis and work instead in the control of the inflammatory response, for example NF-
κB-dependent caspase-11 expression is up-regulated following lipopolysaccharide (LPS)
exposure in response to bacterial infection [222][223]. Caspases become activated following
cleavage at a specific aspartic acid site and form heterodimers comprising of a large and
small subunit. Two of these subunits assemble into an active tetramer; this active caspase
is able to cleave downstream procaspases to form other active caspases. The caspase
activation pathway is commonly described as a caspase cascade as an initiator caspase
activates executioner caspases to cleave and degrade a variety of other target proteins such
as nuclear lamin or endonucleases in an amplifying proteolytic cascade. The culmination
of the activation of these caspases is the degradation of multiple cellular components and
the onset of apoptosis [217].
A family of proteins known as the IAPs, have been shown to bind and inhibit activated
caspases due to the presence of baculovirus IAP repeat (BIR) domains. In some cases
IAPs are able to inhibit apoptosis through polyubiquitinating caspases, leading to their
subsequent targeting and degradation by the proteosome. The presence of these proteins
at certain levels prevents apoptosis from occurring as the caspase cascade cannot be
effectively activated. In mammalian cells this is overcome by the inhibitors of IAPs; the
anti-IAP proteins. The anti-IAP proteins such as second mitochondria-derived activator
of kinases (SMAC)/DIABLO are released from the mitochondria as the intrinsic pathway
is activated to ensure that apoptosis is carried out. SMAC is able to bind IAPs, releasing
caspases to activate apoptosis. The presence of IAPs and anti-IAPs is critical for the
control of apoptosis and adds another level of regulation to this import cellular response
[219][217].
NF-κB plays a role in the regulation of apoptosis, for example TNF binding activates
the extrinsic apoptosis pathway as well as the canonical NF-κB pathway. The exact
effect that NF-κB has on cell survival is dependent on a number of factors such as the
cell type, stimulus and temporal pattern of activation [116]. Although generally thought
of as being anti-apoptotic, NF-κB has been described has being both a promoter and
antagonist of cell death. Kaltschmidt et al. showed through colony formation assays
that after inhibition of NF-κB HeLa cells had increased survival after TNFα treatment
compared to untreated and no apoptosis after hydrogen peroxide treatment [224]. Fan
et al. showed that variation in cell death in response to different stimuli was in part
mediated by alternate post-translational modifications on serine or tyrosine residues of
IκBα [116].
1.3.5 The PIKK Family, NF-κB and Oxidative Stress
Previous research has implicated members of the PIKK family in the cellular response
to oxidative stress. In 2010, Guo et al. studied ATM activation and phosphorylation
of downstream targets in response to bleomycin induced genotoxic stress and hydrogen
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peroxide induced oxidative stress. Non-chromatin associated substrates of ATM, Chk2
and p53, were activated in response to both oxidative and genotoxic stress. In contrast
chromatin associated substrates of ATM such as KRAB associated protein 1 (Kap1) and
H2AX were only observed following genotoxic stress indicating that following hydrogen
peroxide treatment ATM is activated in the absence of DNA damage. In response to
hydrogen peroxide treatment, oxidised ATM is present as an activated disulphide cross-
linked dimer rather than an autophosphorylated active monomer. Activation of ATM
through oxidation was blocked through the mutations of cysteine residues in the ATM
FATC domain; residues critical for the formation of the disulphide bonds. This study
highlighted an alternative role of ATM in response to these two cell stresses [225]. In
unpublished work in the Kenneth laboratory we have observed that this form of ATM is
activated in response to chemical oxidants and is necessary for the activation of hydrogen
peroxide-induced NF-κB.
It has been demonstrated previously in tumours that ATR is activated in response to
hypoxia while ATM is activated in response to reoxygenation. In extreme hypoxia (0.2%
O2) ATR substrates p53 and Chk1 are phosphorylated indicating that ATR is phospho-
rylated and activated in response to this stress. In this extreme hypoxia, ATM was not
activated. This ATR activation is maintained throughout reoxygenation however ATM is
autophosphorylated and activated in response to reoxygenation in the presence of DNA
damage. The reoxygenation-induced ATM dependent phosphorylation of p53 was inhib-
ited after the treatment with the anti-oxidant N-acetyl cysteine (NAC) indicating that
ROS production was leading to this DNA damage [226]. These proteins could therefore
be critical in the response of NF-κB to oxidative stress, as sensors of stress or DNA
damage, as inducers of downstream pathways and potentially as activators of the NF-κB
pathways. This link between PIKK family members and NF-κB activation is not new,
genotoxic stress induced by chemotherapy or irradiation activates NF-κB in a manner
dependent on the protein kinase ATM [92].
1.4 Reactive Oxygen Species and Oxidative Stress
ROS such as free radicals are produced in the mitochondria as a by-product of aerobic
respiration; the oxygen-dependent process by which cells produce energy in the form of
ATP from organic compounds such as carbohydrates, fats and proteins [227]. These
ROS include species such as superoxide, peroxides, singlet oxygen and hydroxyl radicals.
Although initially considered as damaging to the cell due to the discovery of the SOD-
1 and SOD-2 enzymes [228], it has since become clear that ROS play an important
role in many aspects of biology such as the immune response [229][230][231], vasodilation
[232][233] and metabolic pathways [234]. Homeostasis of ROS is therefore vital for normal
cell function; an imbalance can lead to a state known as oxidative stress [235], where high
levels of ROS cause cell damage through chemical and structural aberrations of proteins,
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DNA and lipids [236][237].
Excessive ROS production and the resulting oxidative stress can occur after exposure to
a range of chemical, physiological and environmental stresses, examples of which include
chemotherapeutic drugs, irradiation and pollutants such as those found in cigarette smoke
[235]. Oxidative stress can also be induced as a result of ischemia and reperfusion; a
deficiency of oxygen in cells (hypoxia) followed by rapid reoxygenation, causing cell stress
and tissue damage [238]. This can occur as a result of physical trauma, stroke and is seen
in solid tumours due to poorly structured vasculature. Exposure of DNA, proteins and
lipids to high levels of ROS can lead to cell damage through the formation of chemical
aberrations and structural interference [237][236]. The initial cellular response is to reduce
the extent of the damage through the reduction of oxygen consumption and damage
repair, alongside removal of excess ROS through a series of enzyme catalysed chemical
reactions. When this damage is too severe it may not be resolved causing physiological
dysfuntion, cell cycle arrest, quiescence, apoptosis or necrosis. Oxidative stress through
ischemia and reperfusion causes and propagates a number of human diseases such as
atherosclerosis, cancers and neurodegenerative conditions; conditions also associated with
NF-κB dysfunction.
There are many forms of ROS that can cause oxidative stress, with each species having
alternate effects on the cell [239][240][241]. In order to remove these ROS enzymes in the
cell catalyse specific redox reactions, commonly resulting in the eventual production of
oxygen and water. In the process of removing a particular ROS, these enzymes produce
intermediate ROS. This occurs in a rapid and dynamic manner, as such the levels of a
particular species in an environment is constantly changing (Fig. 23) [242].
SOD-1, SOD-2, NADPH oxidase and ferritin are just some of the enzymes and cofactors
involved in the catalysis of these redox reactions. SOD-1 and SOD-2 catalyse the reac-
tion that converts excess superoxide free radicals to hydrogen peroxide and oxygen in the
response to ischemia and reperfusion [149][150]. SOD-1 is present in the intermembrane
space between the mitochondria and cytoplasm and binds copper and zinc ions, whereas
SOD-2 is present in the mitochondrial matrix and binds iron and manganese. In contrast,
NADPH oxidase functions in the removal of excess ROS through the production of reduc-
ing agents such as glutathione and functions throughout the cell [149][150][151]. FTMT or
ferritin is a mitochondrial ferroxidase enzyme that catalyzes the oxidation of iron, which
prevents hydrogen peroxide from reacting with iron and producing the harmful hydroxyl
radical [243] (Fig. 23). NF-κB has been implicated as a transcriptional regulator of all of
these oxidative stress linked genes, highlighting its role as an essential responder to loss
of ROS homeostasis.
The expression of these proteins allows the cell to remove excess ROS and restore ROS
homoeostasis. Failure to do so will not only affect ROS-dependent cell mechanisms such
as the immune response, vasodilation and metabolic pathways, but could lead to protein,
lipid and DNA damage. Damage caused by ROS could lead to the subsequent activation of
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Figure 23. Production and Removal of Reactive Oxygen Species through Enzyme Coor-
dinated Redox Reactions. Figure taken from Djamali and Arjang, 2007 [242].
multiple stress-activated signalling pathways, such as the NF-κB pathways, DNA damage
response pathways, apoptosis and the cell cycle. Restoration of ROS homoeostasis is
therefore critical to ensure the health of the cell and greater organism [244].
1.4.1 The NF-κB Pathway and Oxidative stress
Oxidative stress and NF-κB signalling are closely linked, however this interaction is com-
plex. Many NF-κB pathway activators trigger the production of ROS, and many antioxi-
dants such as NAC inhibit NF-κB pathway activation. For example TNF exposure leads
to the production of ROS through increased inflammatory responses initiated by the NF-
κB pathway, the resulting increased metabolism causes oxidative stress [245]. In some
situations activation of the NF-κB pathway can be protective resulting in the restoration
of ROS homeostasis. One example of this is following oxidative stress-induced ER-stress,
where NF-κB activation triggers autophagy to reduce ROS levels [246][245].
Global studies of oxidative stress induced gene expression have been carried out previously,
these have predominantly focussed on the role of oxidative stress in certain human diseases
or conditions. In 2010 a study on the effects of oxidative and UV stress on human dermal
fibroblasts highlighted changes in inflammatory and DNA damage response genes between
younger and older patients. The genes selected for analysis were limited in this study
and therefore did not cover many NF-κB target genes [247]. Another study focussed on
changes in gene expression of 1,152 genes in cardiac cells from atrial fibrillation patients.
Results highlighted decreases in gene expression of superoxide dismutase and NADPH
oxidase, two NF-κB dependent genes [248]. In addition, Murray et al. carried out a
41
cDNA microarray on HeLa cells and primary human fibroblasts that are cultured as
normal in the laboratory. Here, they studied changes in gene expression following a range
of different stresses including heat shock, ER stress and oxidative stress. This study failed
to highlight any oxidative stress specific regulated genes, however the authors comment
that many of the genes associated with heat shock and ER stress have pro- or anti-oxidant
roles [249]. As a result many of the oxidative stress-associated NF-κB target genes have
been identified through a more targeted approach rather than through a global gene
expression study.
Many NF-κB target genes are pro-oxidants, for example NADPH oxidase and the NOX2
subunit, gp91phox, both lead to the production of ROS [245]. Other pro-oxidants associ-
aed with NF-κB include xanthine oxidoreductase (XOR) [250], cyclooxygenase-2 (COX)
[251], inducible nitric oxide synthase (iNOS) [252] and lipoxygenase (LOX) [253]. In con-
trast to this, the activation of NF-κB can lead to the expression of anti-oxidant genes
such as SOD-1, SOD-2, thiredoxins, NAD(P)H dehydrogenase (quinone) 1 (NQO1) [254],
NADPH oxidase and ferritin, reducing ROS accumulation and decreasing lipid peroxida-
tion and protein oxidation [246][255]. As such, expression of these sets of genes are critical
for the removal of excess ROS and the restoration of ROS homeostasis (Fig. 24).
As discussed earlier, hydrogen peroxide is a known activator of NF-κB [102]. Schreck
et al. demonstrated that in Jurkat cells this activation occurs independently of the IKK
complex, results in the Y42 phosphorylation of IκBα and does not involve the degradation
of IκBα [102]. More recent findings have determined that this is not necessarily the case
in all cell lines, indeed later studies have shown that classical NF-κB activation occurs
in other T-cells and some epithelial cells (HeLa) following exposure to hydrogen peroxide
[256][257]. The difference in response is believed to be due to the presence or absence
of SH-2 containing inositol 5’ polyphosphatase 1 (SHIP-1). Without SHIP-1 the cell is
unable to activate the IKK complex in response to hydrogen peroxide exposure [257].
T-cells have very specific responses to oxidative stress as they are regularly exposed to
increased levels of hydrogen peroxide produced by macrophages and neutrophils in in-
flammatory tissues. Activation of T-cells occurs in response to ROS with this exposure
having anti-apoptotic effects on the cell [256]. Thus it follows that in this environment
hydrogen peroxide activates the NF-κB pathway in order to promote survival and increase
the number of T-cells present to react to the inflammation or infection appropriately.
In HeLa epithelial cells, a classical activation of the NF-κB pathway occurs in a manner
very similar to the T-cell response following exposure to hydrogen peroxide. However
rather than this activation being coordinated by SHIP-1, protein kinase D (PKD) is
responsible for the transduction of signal to the IKK complex [256]. In contrast in lung
epithelial cells, hydrogen peroxide exposure leads to the inhibition of NF-κB signalling
when combined with pro-inflammatory cytokine (TNF) treatment [256]. In this situation
hydrogen peroxide treatment leads to the oxidation of critical cysteine residues in the
IKK complex, preventing its activation.
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Other forms of ROS also have contrasting effects on the activation of the canonical NF-κB
pathway. Like hydrogen peroxide, singlet oxygen exposure has been reported to activate
the canonical NF-κB pathway [239]. Hypochlorus acid and peroxynitrite have both been
shown to inhibit pathway activation [240][241]. Like hydrogen peroxide, peroxynitrite is
produced under inflammatory conditions such as following myocardial infarction and heart
failure. Peroxynitrite treatment blocks IKKβ phosphoryation and induces Y66 and Y152
nitration on RelA. This reduces the DNA binding affinity of RelA, thereby increasing
the proportion of inhibitor p50 homodimers that are bound to the promoters of target
genes [241]. Hypochlorus acid is a strong oxidant that can react with amines to produce
chloramines. In turn these are able to oxidise IκBα at methionine 45, which has an
inhibitory effect on NF-κB activation in response to lipopolysaccharide exposure [240].
In addition to the oxidiation of methionine 45 on IκBα, other members of the NF-κB
signal transduction pathway can be oxidised. p50 can be oxidised on cysteine 62, reducing
its DNA binding affinity [258], while IKKβ can be oxidised on cysteine 179 following
hydrogen peroxide treatment, preventing TNF-induced activation of the NF-κB pathway
[259]. Oxidation of proteins that are not part of the main canonical NF-κB pathway
may also influence NF-κB activation. Oxidation of 8-kDa dyenin light chain (LC8), a
component of the dyenin motor complex, occurs following TNF exposure [260]. LC8
binds IκBα in a redox-dependent manner, preventing IκBα phosphorylation by IKKβ.
Following oxidation of LC8, it dissociates from IκBα allowing for the activation of NF-κB
[260].
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Figure 24. Oxidative Stress and the NF-κB pathway. A number of different ROS are able to promote or inhibit the activation of the canonical
NF-κB through diverse methods. The response is both cell line dependent and ROS dependent, and may consist of a ‘classic’ activation pathway
or one that is more atypical. This activation or inhibition leads to the control of a range of anti- or pro-oxidant genes, the transcription of
which controls the levels of ROS in the cell.
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1.4.2 Cellular Responses to Hypoxia and Rapid Reoxygenation
Hypoxia and reoxygenation, or ischemia and reperfusion, is defined as a drop in oxygen
levels below those normally seen in that particular environment (hypoxia), followed by a
rapid return to basal oxygen levels (reoxygenation) [238]. This can occur as a result of a
drop in oxygen level of blood that is reaching the tissue, or could be by physical blocking
of vessels that pass blood to tissues. In addition hypoxia can occur in inflamed tissues,
where the inflammatory response leads to an increase in metabolism, thus leading to a
decrease in oxygen levels.
Indeed, in many tissues hypoxia and reoxygenation play a fundamental role in normal,
healthy cell processes. An example of this is in the regulation of haemopoetic stem cell
differentiation and function. T lymphocytes are often exposed to fluctuations in oxygen
levels as they often change environment; the bone marrow is far more hypoxic than the
blood stream. As these cells encounter changes in oxygen in their environment, a range
of hypoxia sensing and signalling pathways are activated, altering the differentiation and
downstream effector mechanisms of the cell to respond to infection and inflammation as
appropriate [261]. In addition, epithelial cells of the intestine are usually hypoxic as they
are present on the luminal membrane of the highly anoxic intestinal lumen. These cells
are located at the lower end of a steep oxygen gradient, as they are positioned adjacent to
the highly vascularised lamina propria. Cells must be able to respond rapidly to changes
in oxygen demands, increasing blood flow and ‘reoxygenating’ cells during digestion as
cell metabolism increases [262] (Fig. 25).
Hypoxia and reoxygenation, or ischemia and reperfusion, is also linked to a wide range of
different diseases or conditions. As well as its role in inflammation as discussed earlier,
these include but are not limited to stroke, heart disease and physical injuries, it is often
seen in solid tumours due to inefficient and poorly structured vasculature [263]. This rapid
reoxygenation also contributes to the pathogenesis and development of several prevalent
diseases such as atherosclerosis [264][265], cancers and neurodegenerative conditions.
Atherosclerosis has strong links to oxidative stress through transient ischemia and reper-
fusion and the resulting production of ROS. Plaques are formed on the vascular endothe-
lium as a result of a chronic inflammatory response where low density lipoprotein (LDL)
interacts with ROS to become oxidised. In response to this lipid oxidation NF-κB is
activated, leading to the transcription of genes to regulate this inflammatory response
and LDL-ROS interaction [264][265]. The repeated cycling of oxygen levels leads to the
development of atherosclerosis, tissue damage, stroke or myocardial infarction. The de-
velopment of atherosclerosis in turn leads to further tissue damage through ischemia and
reperfusion injury and eventual fibrosis with NF-κB continuing to play an integral role in
this through transcriptional regulation. The myocardial endothelium is sensitive to reper-
fusion injury caused by ischemia followed by reoxygenation of tissues [266]. Like all cells,
endothelial cells produce ROS, however ROS play an integral role in the sensitivity of
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Figure 25. Hypoxia and Reoxygenation Overview. Although closely related, hypoxia and
reoxygenation have differing effects on cell signalling, gene transcription and chromatin
structure. In addition cycling hypoxia has been associated with a number of physiological
processes in normal healthy cells as well as several disease conditions. Although this figure
shows that reoxygenation leads to chromatin remodelling, this can also occur during
hypoxia. This figure depicts that changes in oxygen level affects chromatin structure,
the silencing of chromatin following hypoxia is a generalisation and this compaction not
necessarily the case across the whole genome.
endothelial cells to ischemia and reperfusion; endothelial preconditioning [267]. Changes
in ROS levels leads to cell damage, necrosis or apoptosis.
Tumours are also exposed to variations in oxygen levels due to abnormal vasculature
that can constrict or dilate causing transient cycles of hypoxia and reoxygenation within
the tumour microenvironment [263]. This reoxygenation and the associated formation of
reactive oxygen species can cause DNA damage in already cancerous, mutated cells. In
a cell that has lost the ability to repair DNA correctly, or has lost functional cell cycle
checkpoint response genes this can cause further problems [268]. Mutations will become
permanent as they are passed on to daughter cells allowing mutations to accumulate
over the generations through cell division. In a cell where mutations have contributed
to defects in apoptosis, positive selection of mutated cells will occur over those able to
undergo apoptosis leading to increased proliferation and metastasis [269]. It is important
to note that NF-κB plays a critical role in the progression of cancer due to its interaction
with multiple signalling molecules and pathways and the resulting initiation of a diverse
range of transcription factors.
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The link between hypoxia and reoxygenation and cancer can also be attributed directly
to the effects of these cycling oxygen levels, particularly in the context of DNA damage
and proliferation. Both hypoxia and reoxygenation have been previously linked to the
DNA damage response and cell cycle arrest. Frieberg et al. demonstrated that although
no DNA damage occurs during hypoxia, cells undergo a Chk2-mediated G2-phase cell
cycle arrest, and following reoxygenation this arrest is maintained in the presence of DNA
damage [270]. In contrast Pires et al. showed that hypoxia does induce DNA damage
as well as an S-phase arrest. These differences in findings could be due to variations in
protocol used, namely differences in oxygen levels [271].
In addition to DNA damage, hypoxia and reoxygenation have been shown to reduce and
promote cell proliferation respectively, due to variations in metabolic activity as hypoxic
cells are starved of the oxygen required to carry out aerobic respiration [272][273][274].
Somewhat alarmingly, in certain cell lines hypoxia exposure leads to an increase in prolif-
eration due to mutations in proteins involved in the response to replication stress, DNA
damage and the control of cell cycle progression [275][276]. Together these reports in-
dicate that hypoxia and reoxygenation can contribute to cancer progression through the
introduction of further mutations, the bypassing of critical cellular responses to damage
and the promotion of proliferation, migration and metastasis.
One of the main protein families involved in the cellular response to hypoxia is the HIF
family of transcription factors [277][278]. As discussed previously the most studied and
well-characterised form of HIF, hypoxia inducible factor-1α (HIF1α), is transcribed by
the NF-κB pathway in response to hypoxic stress and cytokines such as TNFα [148][147].
HIF is then able to coordinate the expression of over 100 genes required in the response
to oxidative or inflammatory stres, through restoration of ROS homeostasis, growth,
metabolism and survival [4].
The HIF1 heterodimer complex comprises a HIF1α subunit and a HIF1β subunit. The
stability and activity of this complex is dependent on HIF1α, which is rapidly degraded
in normal oxygen conditions through a series of post-translational modifications. In the
presence of oxygen, HIF1α is readily hydroxylated by proline hydroxylase (PHD)s. This
targets HIF1α for ubiquitination by the E3 ubiquitin ligase von Hippel-Lindau (VHL),
leading to the subsequent degradation of HIF1α [279][280]. In the absence of oxygen,
such as in a hypoxic environment, hydroxylation of HIF1α cannot be carried out by the
PHDs. This prevents ubiquitination and degradation, leading to the stabilisation of the
HIF1 complex and the initiation of transcription [281].
The control of gene transcription by transcription factors such as HIF1α and NF-κB is
tightly linked with chromatin modifications [4]. Chromatin is highly dynamic, and mod-
ifications to its structure can occur through post-translational modifications on histones
or epigenetic modifications on the DNA itself. The addition or removal of these groups
can lead to the compacting/silencing of chromatin, thereby preventing transcription, or
the opening/activation of transcription and the promotion of transcription. Some of the
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most commonly studied chromatin modifications are acetylation of the histone octamer
and histone methylation. These modifications provide binding sites for bromodomain-
containing chromatin remodelling complex (CRC)s, which in turn are able to modify the
structure of the chromatin [4]. The exact role for individual CRCs in the response to
hypoxia has not been extensively studied, the majority of detail in the literature is based
on speculation and untested hypotheses [4][282]. It has been established however that
the SWI/SNF family is required for full activation of HIF to occur [283], again the exact
mechanism for this is unknown at this stage.
Hypoxia and reoxygenation can lead to changes in chromatin structre through changes
in histone methylation, histone acetylation and DNA methylation [284][285]. These chro-
matin modifications can lead to the compaction or opening of the chromatin depending
on the context and the gene. The Jumonji family of histone demethylases are critical
regulators of chromatin structure in the response to hypoxia [286]. Not only are they
transcribed by HIF, they are also dioxygenase enzymes and therefore require oxygen to
work. The Jumonji family are therefore sensors of oxygen level, an decrease in oxygen re-
duces their activity therefore leading to an increase in methylated histones in the response
to hypoxia [4]. This increase in methylation levels can both promote or repress transcrip-
tion depending on the context; it can provide binding sites for transcription factors, but
can also recruit CRCs and lead to chromatin compaction [285][4].
Histone acetylation by histone acetyl transferase (HAT)s is associated with an increase in
transcription as charges on the acetyl groups opens up the chromatin structure [282]. Fol-
lowing hypoxia an increase in acetylation of HIF target genes such as vascular endothelial
growth factor (VEGF) and carbonic anhydrase 9 (CA9) is observed, contributing to their
increased transcription [287]. It is important to consider the complexity of chromatin
modifications, this acetylation does not occur across the whole genome and as such will
only lead to transcriptional changes in particular genes. In contrast to histone acetyla-
tion, DNA hypermethylation on the promoter of target genes prevents HIF binding [282].
Globally DNA methylation decreases following exposure to hypoxia, indicating that a de-
crease in gene transcription is occurring across some regions of the genome. It should be
noted however that although it is commonly associated with repression of transcription,
hypomethylation at critical CpGs can promote gene expression. These examples highlight
the contrasting effects of the different modifications across the genome, and demonstrate
the complexity of chromatin modifications in the regulation of transcription.
Reports on the effects of hypoxia and rapid reoxygenation on ROS production in cells is
conflicting. Advances in the techniques used to determine the presence of ROS over recent
years have failed to provide clear evidence of the exact changes in ROS levels following
hypoxia and rapid reoxygenation. Guzy et al. utilised a redox-sensitive FRET protein
sensor to determine the changes in protein oxidation during hypoxia; they concluded that
following exposure to hypoxia the mitochondria rapidly produces hydrogen peroxide and
not superoxide [288]. A FRET-based assay was again used by Bernandi et al. to deter-
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mine the effects of hypoxia exposure on ex vivo carotid body tissues and mitochondrial
suspensions [289]. Following hypoxia they found a rapid decrease in ROS production in
one population of samples and a rapid increase in ROS production in a second popula-
tion of samples. Another study published in 2012 demonstrates that the method of ROS
detection can have profound effects on experimental conclusions. They report that use of
lucigenin to detect ROS shows a decrease in ROS levels during hypoxia and an increase
following reoxygenation. The use of DHE oxidation shows the opposite result [290].
Studies that have shown a decrease in ROS production have predominately focussed
on NADPH and therefore ROS levels in the endoplasmic reticulum or mitochondria
[291][292][293]. These studies have shown a decrease in the removal of hydrogen per-
oxide through the Fenton reaction in hypoxia [291] or a decrease in hydrogen peroxide
release during hypoxia by the plasma membrane [292][293]. Collectively these experiments
have highlighted the complexity of oxidative stress through the species and location of
ROS production. This complexity is again increased when the complex network of ROS
removing redox reactions are taken into account (Fig. 23). As such there are still many
unknowns regarding the cellular responses to hypoxia and reoxygenation and the link to
ROS production.
1.4.3 The NF-κB Pathway Response to Hypoxia and Reoxygenation
It is well established that NF-κB is activated after hydrogen peroxide treatment due to
the formation of ROS [164]. Some studies have also demonstrated that both hypoxia and
reoxygenation lead to activation of the canonical NF-κB pathway, however the majority
of these studies have focussed on hypoxia. Publications on the effects of reoxygenation
on NF-κB pathway activation have failed to establish any precise mechanisms behind this
activation, they have however implicated the canonical NF-κB pathway in this response
[105][125]. The exact mechanism of NF-κB pathway activation following hypoxia and
reoxygenation is therefore not fully understood.
The mechanism behind hypoxia-induced NF-κB activation has been widely debated.
Early work demonstrated that the kinetics of NF-κB activation following hypoxia was
similar to that following hydrogen peroxide exposure. Here, activation occurs indepen-
dently of the IKK complex relying on tyrosine 42 phosphorylation of IκBα rather than
serine 32/36 phosphorylation to activate NF-κB [125]. More recent work has contradicted
this, Cummins et al. argue that IKKβ is involved in the response to hypoxia, as the
hydroxylation on the proline residue 191 in normoxic conditions decreases as this hydrox-
ylation is lost after a drop in oxygen levels, thus leading to IKKβ activation. This work
however utilised dimethyloxaloylglycine (DMOG), a cell permeable prolyl-4-hydroxylase
inhibitor, to simulate hypoxia, rather than hypoxia itself. As such whether this finding
is accurate following actual exposure to hypoxia is currently unknown [294]. Another
paper demonstrated that both IKKα and IKKβ are required for the response to hypoxia,
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however in this study rather than looking at kinetics of pathway activation, they studied
HIF1α levels as a readout of NF-κB pathway activation. Here knockout of one subunit
had no significant effect on HIF1α expression by NF-κB however knockout of both IKKα
and IKKβ completely blocked HIF1α expression [147]. Further investigations by Culver
et al. established a potential mechanism of NF-κB pathway activation following exposure
to hypoxia. They posit that under hypoxic conditions the IKK complex is activated in a
calcium/calmodulin-dependent kinase 2 (CaMK2)-dependent manner that requires TAK1
and Ubc13. In this context phosphorylation of IκBα occurs on serines 32 and 36, as well
as tyrosine 42, and sumoylation on critical lysine residues prevents IκBα degradation but
still allows NF-κB activation to occur [118].
Many studies that have focussed on hypoxia have used NF-κB target genes as a readout
of NF-κB pathway activation. Multiple studies have demonstrated that an increase in
transcription of IL-8 occurs following exposure to hypoxia. This has been shown in a
variety of cell backgrounds and contexts [295][296][297][298][299]. In one of these papers
Culver et al. demonstrated that an increase in IL-8 expression occurs after 16 hours of
hypoxia [118]. Two other genes regulated by NF-κB, PTEN and cIAP-2 [300][142][301],
have been previously linked with hypoxia. Both Culver et al. and Walsh et al. observed a
significant decrease in mRNA levels of the tumour suppressor PTEN following exposure to
hypoxia [118][302], while an increase in expression of cIAP-2 has been observed following
hypoxia [303].
In addition to these commonly studied NF-κB target genes, work has been carried out
focussing on expression of some of the antioxidant target genes that NF-κB controls the
expression of. No genome wide transcript profiling of mammalian cellular responses to
hypoxia have been performed previously, therefore many of the oxidative stress linked
target genes have been established through more targeted experimentation. Previous
work has shown changes in SOD-2 expression following exposure to hypoxia, however the
direction of change differs between studies probably due to differences in the cell lines
used and experimental design [304][305]. In addition Goralska et al. reported a decrease
in ferritin expression following exposure to hypoxia [306]. These changes indicate that
the cell is responding to an increase in ROS in a NF-κB-dependent manner to reduce
oxidative stress and to reinstate ROS homeostasis.
Reoxygenation has not been as widely studied as hypoxia, as such there are fewer reports
on the kinetics behind its activation. In 1995 Rupec et al. demonstrated that following
reoxygenation RelA/p50 NF-κB heterodimers were rapidly activated in HeLa cells as
measured by electrophoretic mobility shift assay (EMSA) and expression of a luciferase
reporter [105]. A year later Imbert et al. showed that this activation occurred through
the phosphorylation of IκBα at tyrosine 42 and did not result in IκBα degradation [125].
They did not identify the tyrosine kinase responsible for this phosphorylation event.
Aside from these two studies not much is known about the kinetics of NF-κB activation
in response to reoxygenation. More recent studies have shown that reoxygenation leads to
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changes in expression of NF-κB target genes, however the focus of these studies was not
NF-κB activation. Sun et al. reported that reoxygenation lead to an increase in PTEN
expression [307], while Lanoix et al. reported a decrease in levels of SOD-2 mRNA follow-
ing reoxygenation [308]. The expression of other genes of interest following reoxygenation
is unknown.
51

Aims
The principle aim of this project was to identify the mechanisms of canonical NF-κB
activation following exposure to hypoxia and reoxygenation. Although the former stimulus
has been investigated previously, there have been some differences in findings regarding
gene expression, proliferation, DNA damage and kinetics of activation. These differences
are possibly due to variations in the hypoxia protocol, such as the timings and oxygen
levels used, as well as the cell lines selected for the study. Reoxygenation has not been
extensively studied, particularly in the context of NF-κB signalling. As such, this project
aimed to uncover the molecular mechanism of NF-κB activation following reoxygenation,
the upstream kinases involved and the resulting changes in gene expression. To investigate
this the effects of hypoxia and reoxygenation on many aspects of cellular biology were
carried out, including cell cycle dynamics, DNA damage and cell proliferation. All of
which have been linked to hypoxia, reoxygenation and the NF-κB pathway previously.
Specific aims include:
1. Assess the effects of hypoxia and reoxygenation on the general health of the cell,
including investigating cell cycle dynamics, DNA damage and cell proliferation.
2. Determine the mechanism of NF-κB pathway activation following hypoxia and rapid
reoxygenation, and evaluate how this differs from the response to other stimuli.
3. Uncover potential upstream kinases or sensors of hypoxia and reoxygenation that
contribute to the activation of NF-κB in response to these stresses.
Together this information will further our understanding of the NF-κB response to hypoxia
and reoxygenation-induced stress, including the upstream signalling dynamics, the effects
on transcription and the overall cellular response to the stress. Understanding of these
critical mechanisms of cell biology is vital in our understanding of progression of ischemia
and reperfusion associated conditions, and may in time lead the way in the development
of novel treatments for stroke, cancer, atherosclerosis and other prevalent conditions.
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Materials and Methods
3.1 Mammalian Cell Culture
3.1.1 Cell Lines
U-2 OS cells were selected for use as they have responsive p53 and have wild type ver-
sions of all proteins of interest investigated throughout this project according to the Sanger
COSMIC Database [309]. The majority of experiments were therefore performed using
U-2 OS cells, a highly used immortalised cell line originally derived from a tibia osteosar-
coma of a 15 year old female. They have an epithelial adherant cell morphology and are
moderately differentiated.
The primary cell line human foreskin fibroblast-1 (HFF-1) was also used in key experi-
ments to confirm finding seen in U-2 OS cells. These are normal fibroblasts pooled from
two newborn individuals in 2003, as such these cell do not have mutations associated with
disease or affecting any of the pathways of interest discussed in this thesis.
3.1.2 Cell Culture Conditions
U-2 OS cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (LONZA;
#3235) supplemented with 10% sterile-filtered foetal bovine serum (FBS) (Gibco; #10270),
penicillin and streptomycin and l-glutamine (LONZA;#7779). Cells were kept in a hu-
midified incubator at 37oC with 5% CO2/21% O2. For passage, cells were washed once
with room temperature phosphate buffered saline (PBS) (LONZA; #3053) and dissoci-
ated from their surface using 1x trypsin (LONZA; #1366) at 37oC for no more than 10
minutes. Trypsin was inactivated through addition of fresh DMEM and cells were resus-
pended into a single cell suspension before either counting and seeding or splitting by a
dilution factor of 1:4-1:6. Cells were predominantly grown in 10cm plates, however 15cm
plates or T75 flasks were used in some circumstances. Cells were not grown beyond 80%
confluence and were split at 70-80% confluence.
The primary cell line HFF-1 was cultured in PromoCell Fibroblast Growth Medium (Pro-
moCell; #C-23010) but otherwise grown in the same conditions as U-2 OS cells. For
passage, cells were washed once with room temperature HEPES-BSS solution (Promo-
Cell; #C-40000) and dissociated from the plate through incubation with Trypsin/EDTA
solution (PromoCell; #C-41000) at room temperature for no longer than 10 minutes. The
same volume of Trypsin Neutralising Solution (PromoCell; #C-41100) was then added,
cells were agitated and aspirated into cell suspension and transferred into a 15cm falcon
tube. Cells were centrifuged at 220rcf for 3 minutes to pellet cells, the supernatent was
discarded and the cells were resuspended in growth medium. Cells were then counted and
seeded as required. Cells were passaged at 70% confluence and were not split at levels
harsher than 1:3-1:4.
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3.1.3 Frozen Cell Storage
Cells were washed once in room temperature PBS (LONZA; #3053) and dissociated from
their surface using 1x trypsin (LONZA; #1366) at 37oC for no more than 10 minutes.
Trypsin was inactivated through addition of fresh DMEM (LONZA; #3235) and cells
were resuspended into a single cell suspension before being centrifuged at 400r x g for
5 minutes to pellet out the cells. Supernatent was then carefully removed and the cells
were resuspended in 10% DMSO (Sigma-Aldrich; #D2650) in normal FBS-supplemented
growth media. 1ml of this cell suspension was then aliquoted into cryovials. Cells were
frozen slowly using Mr. FrostyTM (Sigma-Aldrich;#C1562) and stored at -80oC or in
liquid nitrogen (long-term).
To thaw cells, cryovials were removed from storage and kept on dry ice until the last
possible moment. Cryovials were placed in a 37oC water bath to quickly thaw the cells.
The contents of the cryovial was then immediately transferred into a pre-prepared flask
or plate of the correct size containing the appropriate growth media. Plates were stored
in the incubator overnight. After 24h of incubation media was replaced with fresh growth
media to remove any DMSO. Cells were then checked regularly to ensure healthy growth
before passage was carried out. Early passages were split at a lower ratio of 1:2-1:4
depending on the observed health of the cell.
3.1.4 Mycoplasma Contamination
Cells were tested for mycoplasma using the MycoAlertTM mycoplasma detection kit
(LONZA; #LT07) following the manufacturers protocol.
3.2 Treatment of Mammalian Cells for Experiments
3.2.1 Hypoxia and Rapid Reoxygenation
A humidified anaerobic chamber (RUSKINN INVIVO2400) was set to 5% CO2 and 1% O2
at 37oC for hypoxic conditions. Gas levels were checked regularly throughout each experi-
ment. Where necessary PBS (LONZA; #3053) or growth media was pre-equilibrated to a
hypoxic state before the start of the experiment. Media was changed as cells were moved
into the anaerobic chamber from a standard normoxic incubator to allow for immediate
exposure of cells to hypoxia. Media was either spent or fresh as described for individual
experiments, meaning that it either had or had not been used on cells previously.
For reoxygenation, cells were exposed to hypoxic conditions for 24 hours to allow cells
to acclimatise to the conditions. Cells were removed from the anaerobic chamber and
media was changed to allow for immediate reoxygenation. Again, this media was either
spent or fresh as described for individual experiments. After the media change cells were
incubated in normoxic conditions in a humidified incubator; 37oC with 5% CO2/21% O2
until harvesting.
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As indicated above, media changes were used to immediately expose cells to hypoxic
or normoxic conditions. Fresh media was stored in the anaerobic chamber for hypoxic
conditions, and either on the bench or in the standard incubator for normoxic conditions as
indicated for each experiment. Spent media was produced by plating out extra identical
plates of clones for each experiment and moving media from that plate to the plate
requiring treatment. These plates were either kept in the anaerobic chamber for hypoxic
conditions or in the standard incubator for normoxic conditions. Unless stated otherwise
media used to expose cells to certain gas states contained the standard volume of FBS
(Gibco; #10270).
Figure 26. Schematic of a Hypoxia and Rapid Reoxygenation Time Course. U-2 OS cells
were plated out on day zero and incubated in normoxic conditions for at least 48 hours.
Plates were then moved to and from the anaerobic chamber over the course of 3 days.
For example the 6 hour reoxygenation plates were moved into 1% O2 on day 2 at 9am,
48 hours after plating out, and returned to 21% O2 after 24 hours for a further 6 hours
prior to harvesting.
3.2.2 Chemically Inducing NF-κB Activation
Standard methods to activate the canonical NF-κB pathway or cause DNA damage were
used as controls in many experiments. The topoisomerase inhibitor etoposide was used
at 25µM and TNF treatments were performed at 10ng/ml unless stated otherwise for the
desired times. Hydrogen peroxide treatments were carried out as described in individual
experiments.
3.2.3 Treatment with Small Molecule Inhibitors of Proteins of Interest
Small molecule inhibitors targeting proteins of interest were used at standard concen-
trations as described in figure 3. All inhibitors were added directly to the plates 30
minutes prior to hypoxia, reoxygenation, hydrogen peroxide or etoposide. Inhibitors
were also added to any media that was used in the hypoxia or reoxygenation process.
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Other treatments used in this manner include the anti-oxidant scavenger NAC (Sigma-
Aldrich;#138061).
Small Molecule Inhibitors
Target Protein Inhibitor Concentration Source
ATM KU-55933 5µM Sigma; #SML1109
ATR VE-821 10µM Sigma; #SML1415
Chk-1 CCT245737 5µM SelleckChem
#CCT245737
IKKα IKKα 3µM Strathclyde
IKKβ TPCA 10µM Sigma; #T1452
IKKβ BMS-345541 5µM Sigma; #B9935
TAK-1 5Z-7-oxozeaenol 10µM Sigma; #O9890
Table 3. Table of Small Molecule Inhibitors. The IKKα inhibitor was kindly provided by
Prof. Simon Mackay of Strathclyde University.
The anti-oxidant NAC (Sigma; #A7250) was used at 10mM in the same manner. NAC is
an acetylated cysteine residue that acts as a potent anti-oxidant through the scavenging
of free radicals. The presence of this in cells is critical for the response of cells to oxidative
stress and the removal of ROS [310].
3.3 Detection of ROS after Induction of Oxidative Stress
ROS detection assays were carried out using the ROS-ID Total ROS/Superoxide Detection
Kit (ENZO; ENZ-51010) following the manufacturer’s instructions where possible. Some
deviations from the protocol provided where necessary and are described below. The
protocol was carried out using 96-well plates (NUNC; #165305) and analysed on a micro-
plate reader (BMG LabTech; POLARstar Omega).
3.3.1 Treatments and Conditions
Cells were plated at 2,500 cells/well on experimental day 1 into black polystyrene, optical
bottom 96-well plates (NUNC; #165305). Additional plates were plated at this time in
to standard 96-well plates to harvest spent media for treatments. Phenol-red-free media
(LONZA; #BE12-917F) was used to minimise interference with the fluorescence signal.
On day 3, plates designated for 24 hour hypoxia or reoxygenation treatments were put in
the humidified anaerobic chamber (RUSKINN INVIVO2400) (5% CO2, 1% O2 at 37
oC).
Additional plates for spent media extraction were also placed in hypoxic conditions.
On day 4 reagents and treatments were prepared following the manufacturers protocol.
The fluorescence dye-containing reagents were made up in either fresh or spent phenol-red-
free media harvested from the extra 96-well plates; this was carried out in the anaerobic
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chamber where necessary. Both reagents were made up into the same solution however
control wells containing either oxidative stress or superoxide sensing probes only were
carried out in parallel as a control for fluoresence overlap. Any drug treatments such
as hydrogen peroxide or NAC, were made up in this dye-containing media as described.
For cells undergoing hypoxia or reoxygenation, gas-equilibrated dye-containing media was
sufficient.
3.3.2 Procedure
All initial experiments had treatment times of 1 hour as the manufacturers protocol
stated that addition of the dye needed to occur 1 hour prior to reading and that this
should occur in parallel with any treatments. 24 hour hypoxia samples were exposed to
hypoxia for 23 hours, and the dye-containing media was added for the last hour before
reading fluorescence on the micro-plate reader.
The micro-plate reader was set to measure fluorescence from the bottom optic with 3mm
orbital averaging to mininise edge effect. Two filter settings were used, one for the ’oxida-
tive stress’ detection (Ex;485-12, Em;520) and one for the ’superoxide’ detection (Ex;544,
Em;620-10). Gain was automatically set using the highest fluorescing well on a positive
control plate.
3.3.3 Analysis
Fluorescence was normalised to readings taken from cell-free wells with dye-containing
phenol-red-free media on the same plate. Data was then plotted and analysed using
GraphPad PRISM, performing statistical analyses as described per experiment.
3.4 Protein Extracts
3.4.1 Whole Protein Extract by Urea Lysis
Media was aspirated and plates were washed once with room temperature, equilibrated
PBS. An 8M urea lysis buffer stock (8M urea, 300mM NaCl, 20mM Tris pH8, 20mM
Na2HPO4, 1% NP-40) was prepared in advance and stored at 4
oC until required. Into
10ml of this stock 1.25µM Na3VO4, 1µM DTT, 5mM NaF and 1 protease inhibitor tablet
was added (Roche; #04693159001). The phosphatase inhibitor Na3VO4 inhibits Ser-
ine/Threonine and acidic phosphatases, while NaF inhibits Tyrosine and alkaline phos-
phatases respectively. Protease inhibitors such as DTT and those present in the inhibitor
tablet prevent degradation of the whole protein through processes such as preventing ox-
idation. Depending on cell confluence 400-600µl of lysis buffer was added to cover the
surface of a 10cm plate. This stage was carried out in the anaerobic chamber where neces-
sary however after addition of the lysis buffer, cells could be removed from the anaerobic
chamber.
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Plates were scraped and the lysates stored in Eppendorf tubes. Lysates were flash frozen
and stored at -20oC before sonication. After thawing lysates were sonicated at 4oC for 30
seconds using Soniprep (MSE; Soniprep 150) or on high for 2 cycles of 30 seconds using
the Bioruptor (Bioruptor Next Gen; Diagenode).
3.4.2 Whole Protein Extract by RIPA Lysis
For cells lysed using RIPA lysis buffer (1% v/v NP-40, 50mM Tris-HCL pH 7.4, 50 mM
NaCl, 2mM EDTA, 0.1% SDS). 1.25µM Na3VO4, 1µM DTT, 5mM NaF and 1 protease
inhibitor tablet) was added to 10ml of this stock, 400-500µl of lysis buffer was added to
the plate depending on cell confluence and left for 10 minutes at 4oC ensuring complete
coverage of the plate. Plates were scraped and the lysates stored in Eppendorf tubes for
10 minutes on ice. Lysates were centrifuged at 4oC at 13,200 rpm for 10 minutes. The
supernatant was removed and stored in a fresh Eppendorf at -20oC.
3.4.3 Cytoplasmic and Nuclear Extraction
Cytoplasmic and nuclear extraction procedures were adapted from Dignam et al. 1983
[311]. Media was aspirated and plates were washed once with temperature/gas-equilibrated
PBS, followed by a fast wash with 1ml of cold buffer A (10 mM HEPES, pH 7.9, 1.5 mM
MgCl2, 10 mM KCl, 0.1 mM PMSF, and 0.5 mM DTT). 500µl of cold buffer A+ (buffer
A supplemented with a protease inhibitor tablet) was added to each plate. Cells were
scraped into Eppendorf tubes and put on ice for 15 minutes. At this stage cells harvested
inside the anaerobic chamber were removed from the chamber.
Cells were manually homogenised on ice and centrifuged at 16,100 x g for 15 minutes
at 4oC. The supernatant containing the cytoplasmic components was carefully removed,
transferred into fresh Eppendorf tubes and flash frozen for storage at -80oC. The pellet
was then resuspended in 500µl buffer A+ and centrifuged at 16,100 x g for 15 minutes
at 4oC. The supernatent was removed and discarded and the pellet containing nuclear
components was resuspended in 100µl buffer C (20 mM HEPES, pH 7.9, 0.42 M NaCl,
1.5 mM MgCl2, 0.2 mM EDTA, 0.1 mM PMSF, 0.6 mM DTT, and 25% glycerol). Extracts
were incubated at 4oC for 20 minutes prior to centrifugation at 16,100 x g for 15 minutes.
The supernatent containing the nuclear components was removed, transferred into fresh
Eppendorf tubes and flash frozen for storage at -80oC for use in western blots. These
extracts were used immediately for EMSA.
3.5 Protein Analysis
3.5.1 Bradford Assay
Protein concentrations of lysates were determined by a Bradford assay (Bio-Rad Protein
Assay Dye Reagent Concentrate; #500-0006) and read using POLARstar Omega (BMG
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LABTECH). BSA was used to produce a standard curve alongside the protein samples.
3.5.2 SDS-PAGE
Sodium dodecyl sulphate (SDS)-polyacrylamide gel electrophoresis (PAGE) gels were cast
to appropriate concentrations for resolving proteins of interest (Table 4). These were
poured in two layers; the separating gel at 6-12% acrylamide (Tris pH8.8) and the stacking
gel at 5% acrylamide (Tris pH6.8) with 10 or 15 wells as required. Equal amounts of
protein (10-40µg) were mixed with SDS loading buffer and heated to 95oC for 2-3 minutes.
Gels were assembled in the running cassette, combs were removed and the tank was filled
with running buffer. Samples were loaded into the wells and 5µl of PageRuler Protein
Ladder (ThermoFisher;#26616) was loaded into lane 1. Gels were run at 100V for 10
minutes (Bio-Rad; Mini-PROTEAN 3 Cell) and then 150-200V until the dye front reached
the bottom of the gel.
Buffers for SDS-PAGE
Buffer Ingredients
Tris pH6.8 1.5M Tris (Sigma; #TRIS-RO) in MQ H2O, pH6.8 using HCl
Tris pH8.8 1.5M Tris (Sigma; #TRIS-RO) in MQ H2O, pH8.8 using HCl
Stacking Gel 5% Acrylamide (Flowgen; #EC-852), 187.5µM Tris pH6.8,
1% (w/v) SDS (Sigma; #L3771), 1% (w/v) Ammonium Per-
sulfate (Sigma, #A3678), TEMED (Sigma; #T9281) to set
Separating Gel 6-15% Acrylamide (Flowgen; #EC-852), 187.5µM Tris pH6.8,
1% (w/v) SDS (Sigma; #L3771), 1% (w/v) Ammonium Per-
sulfate (Sigma, #A3678), TEMED (Sigma; #T9281) to set
10x Running Buffer 0.25M Tris (Sigma; #TRIS-RO), 1.92M Glycine (Sigma;
#G8898), 1% (w/v) SDS (Sigma; #L3771)
4x Loading Buffer 0.25 M Tris (Sigma; #TRIS-RO), pH 8.1 using HCL, 10 %
(w/v) SDS, 30% (w/v) Glycerol, 0.02% Bromophenol Blue,
10% (w/v) β-mercapthoethanol in MQ H2O
Table 4. Buffer Recipes for SDS-PAGE
3.5.3 Western Blot
Proteins were transferred onto nitrocellulose (ThermoFisher; #88018) or polyvinylidene
difluoride (PVDF) membrane (Immobilon-P; #IPVH00010). Membranes were activated
following the manufacturers instructions. Proteins were transferred AT 15-20V by semi-
dry transfer (Bio-Rad; Trans-Blot SD) for 1 hour and 30 minutes with two layers of
blotting paper to protect the gels and membranes 5. Membranes were blocked in 4%
Marvel/TBS-T for 1 hour at room temperature, washed 3 times in TBST for 5 minutes,
then incubated with primary antibodies (Table 6) overnight at 4oC or for 1 hour at
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Buffers for Western Blot
Buffer Ingredients
10x Transfer Buffer (Semi-
Dry)
0.48M Tris (Sigma; #TRIS-RO), 0.39M Glycine (Sigma;
#G8898), 0.1% (w/v) SDS (Sigma; #L3771)
1x Transfer Buffer (Semi-
Dry)
80% MQ H2O, 10% 10x Transfer Buffer and 10% Methanol
TBS-Tween20 (TBS-T) 20mM Tris-HCL ph 7.6, 120mM NaCl and 0.02% Tween20
(Sigma; #P1379)
Blocking Buffer 4% Marvel Milk Powder in TBS-T
Primary Antibody Mix 2% bovine serum albumin (BSA) (Sigma; #A9647) in TBS-T
Secondary Antibody Mix 4% Marvel Milk Powder in TBS-T
Table 5. Buffer Recipes for Western Blot
room temperature. After primary antibody incubation, membranes were removed and
antibody solutions were stored at 4oC. Membranes were washed 3 times in TBS-T for 5
minutes prior to incubation for 1 hour at room temperature in appropriate HRP-tagged
secondary antibody (5µl antibody in 10ml 4% Marvel/TBS-T). Cells were washed 3x in
TBS-T for 5 minutes before being treated with PierceTM Enhanced chemiluminescence
(ECL) western Blotting Substrate (ThermoFisher; #32106) following the manufacturers
protocol. Membranes were developed on x-ray film using an automatic x-ray film processor
(Xograph Compact X4), exposure times varied depending on the strength of the signal.
The antibody for PRDX-3 was kindly provided by Dr. Elizabeth Veal.
Densitometry was carried out using ImageJ following the protocol described [312][313].
Significance was determined using GraphPad PRISM using analysis of variance (ANOVA)
tests to test for differences in the mean band density across different groups, as three
or more groups were present in all experiments. Multiple comparisons were accounted
for using Sidak’s or Tukey’s test depending on the comparisons being made within an
individual experiment [314][315].
3.5.4 EMSA
This was performed by Adam Moore (Perkins Lab) as radiation training is required. A 4%
0.25x tris-borate-EDTA (TBE) gel was poured in the lab and pre-run in 0.25x TBE buffer
for 1 hour at 7.5V. 2µM of nuclear extract (obtained as described above) was incubated
at room temperature with 1 µg of poly(dI-dC) in modified buffer D (20 mM HEPES, pH
7.9, 50 mM KCl, 0.2 mM EDTA, 0.1 mM PMSF, 0.5 mM DTT) up to 20µl. 0.1µl of
the 32P-radiolabelled probes κB-EMSA-oligo-1 (GAT CCA GGG ACT TTC CGC TGG
GGA CTT TCC A) and κB-EMSA-oligo-2 (GAT CTG GAA AGT CCC CAG CGG AAA
GTC CCT G), were added and run on pre-run 4% 0.25x TBE gel [316]. Autoradiography
was performed overnight at -80oC.
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Primary Antibodies
Target Protein Concentration Secondary Source Catalogue
No.
Total Actin 1:10000 M Sigma-Aldrich A5441
Phospho ATM (S1981) 1:1000 M Cell Signaling 4526
Total ATM 1:1000 Rb Cell Signaling 2873S
p-ATR (S428) 1:1000 Rb Cell Signaling 2853
Total ATR 1:1000 Rb Cell Signaling 13934
p-Chk1 (S298) 1:1000 Rb Cell Signaling 2349
Total Chk1 1:1000 M Cell Signaling 2360
p-Chk2 (T68) 1:1000 Rb AbCam ab32148
Total Chk2 1:1000 Rb OncoGene PC483T
p-Erk1/2 (T202/Y204) 1:1000 Rb Cell Signaling 9101
Total Erk1/2 1:1000 Rb Cell Signaling 9102
Total HIF-1α 1:1000 M BD Bioscience 610958
p-IκBα (S32/36) 1:1000 M Cell Signaling 9246
Total IκBα 1:1000 Rb Cell Signaling 9242
p-IKKα/β (S176/177) 1:1000 Rb Cell Signaling 2078S
Total IKKα 1:1000 Rb Cell Signaling 2682
Total IKKβ 1:1000 Rb Cell Signaling 8943
Total IKKγ/Nemo 1:1000 Rb Cell Signaling 8330
p-Kap1 (S824) 1:1000 Rb AbCam ab133440
K48-linked Ub 1:1000 Rb Cell Signaling 4289
K63-linked Ub 1:1000 Rb Cell Signaling 5621
p-SAPK/JNK
(T183/Y185)
1:1000 Rb Cell Signaling 9251S
Total Jnk 1:1000 Rb Cell Signaling 9252
p-p38 (T180/Y182) 1:1000 Rb Cell Signaling 4631
Total p38 1:1000 Rb Cell Signaling 9212
Total p52 1:1000 M Santa-Cruz sc-7386
Total PARP 1:2000 Rb Cell Signaling 9542
Total PRDX-3 1:1000 Rb Abcam ab73349
p-RelA (S536) 1:1000 Rb Cell Signaling 3033
Total RelA 1:1000 M Santa-Cruz sc-8008
p-Stat3 (Y705) 1:1000 Rb Cell Signaling 9131
Total Stat3 1:1000 M Cell Signaling 9139
Total β-Tubulin 1:5000 Rb Cell Signaling 2146
Table 6. Table of Primary Antibodies and Concentrations Used.
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3.6 mRNA Analysis
3.6.1 Harvesting Cells for mRNA Extraction
Media was aspirated from plates and RNA was extracted following the manufacturer’s
protocol (PeqLab peqGOLD Total RNA; #123014). Where necessary lysis buffer was
added to hypoxia treated plates in the anaerobic chamber, plates were removed once they
had been fully lysed. mRNA from a 10cm plate was eluted into 50µl of nuclease-free
water, this was flash frozen and stored at -80oC.
3.6.2 Analysis of mRNA Concentration and Quality
RNA concentration and purity was analysed using a spectrophotometer (Thermo Scien-
tific; NanoDrop 2000c) blanked to nuclease-free H2O. Measurements were read at 260nm,
280nm and 230nm to determine the quantities of nucleic acids, aromatic amino acids and
other contaminants respectively. The 260/280 ratio was calculated to determine nucleic
acid purity value compared with aromatic amino acids (acceptable ratios were 1.8-2.2) and
the 260/230 ratio was calculated to determine the purity compared to other contaminants
(accepted at 1.7<) [317].
3.6.3 Reverse Transcription
Reverse transcription was performed using 1µg of RNA following the manufacturer’s pro-
tocol (Qiagen QuantiTect Reverse Transcription Kit; #205310 or Quanta Biosciences
qScriptTM cDNA Synthesis Kit; #95047). DNA removal steps were carried out as de-
scribed in the protocol for the Qiagen kit, however an additional DNase kit (Quanta
Biosciences PerfeCTa DNase I; #95150) was used in conjunction with the Quanta reverse
transcription kit. cDNA was diluted 1 in 20 in nuclease-free water before further use.
3.6.4 Primer Design and Validation
A literature search was performed to establish appropriate NF-κB or HIF transcribed
genes. Establised primers found in the literature or well-characterised primers already
present in the laboratory were used (Table 7). Primers for real-time quantitative poly-
merase chain reaction (PCR) were designed using Ensembl and Primer Blast and checked
alongside the UCSC Genome browser. Primers were ordered from IDT DNA and tested
before use using temperature gradient checks and standard curves. The reference gene
RPL13A was selected as this has been shown not to be affected by exposure to hypoxic
conditions.
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Primers
Target Gene Forward Primer Reverse Primer
RPL13A CCT GGA GGA GAA GAG
GAA AGA GA
TTG AGG ACC TCT GTG
TAT TTG TCA A
IL-8 CCA GGA AGA AAC CAC
CGG A
GAA ATC AGG AAG GCT
GCC AAG
PTEN CGG TGT CAT AAT GTC
TTT CAG C
TGA AGG CGT ATA CAG
GAA CAA T
IκBα CTG AGC TCC GAG ACT
TTC GAG G
CGT CCT CTG TGA ACT
CCG TG
p100 AGC CTG GTA GAC ACG
TAC CG
CCG TAC GCA CTG TCT
TCC TT
cIAP-2 GTC AAA TGT TGA AAA
AGT GCC A
GGG AAG AGG AGA GAG
AAA GAG C
Ferritin CCA GAA CTA CCA CCA
GGA CTC
ACA GGT AAA CGT AGG
AGG CG
SOD-2 TGG AAA AAT GGG GTA
ACT TAG CAG
CGC TTT GGT ACT CTT
GTC TCT AAT
CA9 CTT TGC CAG AGT TGA
CGA GG
CAG CAA CTG CTC ATA
GGC AC
VEGF CCT GGT GGA CAT CTT
CCA GGA GTA CC
GAA GCT CAT CTC TCC
TAT GTG CTG GC
Table 7. Table of Primers.
3.6.5 Agarose Gel Electrophoresis
Agarose gel electrophoresis was used for temperature gradient analysis of primer sets and
troubleshooting real-time quantitative PCRs. Depending on the size of the product to be
resolved, 1% or 2% agarose gels (Helena; #8201) were made up in 1x tris-acetate-EDTA
(TAE) buffer (40mM Tris, 1:1000 Glacial Acetic Acid, 1mM EDTA pH8). The solution
was heated until boiling in the microwave, after a brief period of cooling 2.5µl of SYBR
safe (ThermoFisher;#S33102) was added to 100µl. Gels were then poured and left to set.
DNA samples were mixed 1:1 with 5x Green Go-Taq Flexi Buffer (Promega;#M8911)
and 10-20µl was loaded per well. 100bp or 1Kb ladders (Invitrogen; #10488) were used
depending on the size of the product to be resolved. Gels were then run at 150V (HU13
System) until the dye front almost reached the edge of the gel. Bands were visualised
using Fujifilm LAS-4000.
3.6.6 Real-Time Quantitative PCR
For each reaction 5µl of the diluted cDNA was added to 15µl of master mix (4µl H2O,
4µl 5x GoTaq Colourless Reaction Buffer, 3µl 2mM dNTPs, 3.2µl MgCl2, 0.8µl 10mM
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Primer Mix, 0.2µl 1:200 Syber Green/DMSO, 0.2µl GoTaq G2 DNA Polymerase; Promega
#M7845). Real-time quantitative PCR was carried out using using the SYBR green
method using Qiagen Rotor-Gene Q with the following settings: 95oC for 30 seconds,
60oC for 30 seconds and 72oC for 30 seconds for 40 cycles. Readings were taken after the
annealing step of each cycle. A final 10 minute gradual increase in temperature from 60oC
to 95oC was used to produce a melt curve. DNA-free controls were used for each primer
per run. Each reaction was carried out in triplicate with the reference gene RPL13A used
in each reaction.
Following completion, threshold values were set at 0.1 across all runs, ensuring that this
crossed the exponential increase phase of the reaction. At this point outliers were excluded
and the melt curve analysed for double products or unusual curves. Ct values were then
exported for further analysis.
3.6.7 Data analysis
Data was normalised using the ∆ ∆ CT method using the reference gene RPL13A [318].
Hypoxia treatments were normalised to normoxia values and reoxygenation treatments
were normalised to 24 hour hypoxia values. Graphs were plotted using GraphPad Prism
and statistically analysed as described per figure.
Raw Ct values were also plotted using GraphPad Prism to ensure that the reference gene
was not moving (data not shown) and that this method of analysis was not skewing the
data presented in its final form.
3.7 Flow Cytometry
All cells used for flow cytometry analysis were grown on 15cm plates to ensure that enough
cells were present for analysis.
3.7.1 Fixing Cells for FACS Analysis
Media was aspirated and plates were washed once in PBS. 1x Trypsin/PBS was added
to cover the surface, plates were left in the humidified incubator for up to 10 minutes to
allow cells to unadhere from the surface. At this stage cells could be removed from the
anerobic chamber where necessary. Cells were then resuspended in PBS and centrifuged
for 5 minutes at 400 x g to pellet out the cells. Supernatent was removed and cells were
resuspended in 1ml PBS and fixed in 3.7% formaldehyde (Sigma; #F8775) in PBS for 10
minutes at room temperature. Cells were centrifuged at 400 x g for 5 minutes and were
washed in PBS. After a final centrifugation step pellets were resuspended in 100µl PBS
and 1ml of 70% ethanol was added and mixed in. Cells were then stored at -20oC until
staining.
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3.7.2 BrDU Incorporation
BrDU (0.1mM) was added 1:1000 to plates 1 hour before harvesting to allow for incorpo-
ration into the DNA. On the day of staining, samples were removed from the -20oC freezer
and allowed to acclimatise for 10 minutes. Samples were then centrifuged at 400 x g for
5 minutes to pellet out the cells. Supernatent was removed and the pellet was washed
2x in 1ml PBS, after centrifugation the pellet was resuspended on 100µl of PBS. 1ml
of HCl-Triton x100 (2mM HCl, 0.5% Triton x100) was added to samples for 30 minutes
in the dark at room temperature. Cells were centrifuged for 5 minutes at 400 x g and
supernatent was removed. Pellets were resuspended in 200µl of 0.1M Sodium Tetrabo-
rate, samples were incubated for 5 minutes in the dark at room temperature. Cells were
centrifuged for 5 minutes at 400 x g and supernatent was removed. Pellets were then
washed and pelleted twice before staining.
FITC-conjugated anti-BrDU antibody (BD Biosciences; 347583) was diluted 1:100 in PBS
- 1% BSA and 50-100µl was added to each pellet. A negative control of PBS-1%BSA only
was carried out in parallel. Samples were left to incubate for 1 hour in the dark at
room temperature. 400µl of 1:5000 DAPI stain was added to each tube (200µl if 50µl of
antibody was used). Samples were incubated for 1 hour in the dark at room temperature
before being analysed by fluorescence-activated cell sorting (FACS).
3.7.3 γH2AX Staining for DNA Damage Analysis
On the day of staining, samples were removed from the -20oC freezer and centrifuged at
400 x g to pellet out the cells. Cells were washed once in 1ml of PBS and centrifuged
at 400 x g for 5 minutes. Supernatent was removed and PBS-1% Triton was added for
15 minutes at room temperature. Samples were centrifuged at 400 x g for 5 minutes
and the supernatent removed. After resuspending in 1ml of PBS each sample was split
into 2 tubes before the centrifugation step was repeated and supernatent was removed.
Pellets were resuspended in either 50µl of 1:100 FITC-conjugated γH2AX antibody (BD
Biosciences; #560445) in PBS-1% BSA or 50µl of 1:100 FITC-conjugated IgG antibody
(BD Biosciences; #557782) in PBS-1% BSA (negative control for each sample). Samples
were incubated in the dark for one hour at room temperature. 450µl of 4’,6-diamidino-
2-phenylindole (DAPI) was then added and samples were incubated in the dark for one
hour at room temperature before being analysed by FACS.
3.7.4 Data Analysis
Data was collected using FACS Canto II at 10,000 events per sample measuring Log SSC-
A and Lin FSC-A. In all experiments FITC was measureed at 488nm and DAPI controls
were measured at 405nm. Data was analysed using BD FACSDIVA software. Graphs
were plotted using GraphPad Prism and appropriate statistical analyses were carried out
as described.
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3.8 Microscopy
3.8.1 Fixing Cells for Immunofluorescence Microscopy
8000 cells per well were plated out on 8-well slides (Nunc Lab-Tek II Chamber SlideTM
System; #154543) on experimental day 1. 24 hour hypoxia and reoxygenation slides were
exposed to the humidified anaerobic chamber on day 3. Shorter hypoxia and reoxygena-
tion time points were carried out on day 4 before immediate fixing.
To fix cells, media was removed and cells were washed 3x in PBS. 3.7% formadehyde-PBS
(Sigma; #F8775) was added to wells and slides were incubated at room temperature for
20 minutes. Formadehyde-PBS was removed from the wells and cells were washed 3x
in PBS. PBS was added to each well one final time and slides were stored at 4oC until
staining. Slides were stored for no longer than 2 weeks.
3.8.2 Fixing and Staining Cells for Immunofluorescence
Slides were removed from 4oC and left to acclimatise for 10 minutes before PBS was re-
moved. PBS-1% Triton-0.05% Tween 20 was added to each well and slides were incubated
at room temperature for 15 minutes. Slides were then blocked in 5% BSA-PBS-Tween
20 for 1 hour at room temperature. This was then aspirated and primary antibodies
were added. IKKβ (Santa-Cruz; #7330) antibody was added in a 1:150 dilution in 5%
BSA-PBS-Tween 20 and IKKγ (Cell Signaling; #8330) antibody was added in a 1:200
dilution in 5% BSA-PBS-Tween 20. Negative control slides without primary antibodie
were carried out in parallel using 5% BSA-PBS-Tween 20 only. Slides were then incu-
bated in a dark wet chamber at room temperature for 1 hour and 30 minutes. Slides
were then washed 3x with PBS-Tween 20. Secondary antibodies were made up 1:200
in 5% BSA-PBS-Tween 20 (if not conjugated to the primary antibody) and slides were
incubated in a dark wet chamber at room temperature for 1 hour. Negative control slides
containing no secondary antibody were performed in parallel with 5% BSA-PBS-Tween
20 only. Slides were washed 3x in PBS-Tween 20 before removal of wells and mounting in
DAPI-containing mounting solution. Slides were left to cure in the dark overnight before
sealing and storing at -20oC before analysis.
3.8.3 Microscopy
Fluorescence microscopy was carried out using a Zeiss Axiolmager without apotome, using
Zeiss’ Zen software. Images were processed using ImageJ using plug-ins to automate the
relative nuclear and cytoplasmic signal.
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3.9 Cell Survival
3.9.1 Clonogenic Assay
After an accurate cell count was performed, 4 x 105 U-2 OS cells were seeded in 6-well
plates and incubated in normoxic conditions overnight. Cells were exposed to hypoxia
for 24 hours, treated with the IKK inhibitor 3-Thiophenecarboxamide (TPCA) or NAC
at concentrations of 10µM prior to a 3 hour reoxygenation. Untreated controls for both
normoxic and reoxygenated cells were performed in parallel and each condition was per-
formed in triplicate. Following the 3 hour reoxygenation media was aspirated, plates
were washed once with PBS and the cells were trypsinsed and resuspended in DMEM.
Cells were counted and seeded in 10cm plates at 100, 500, 1000 or 2000 cells per plate.
Plates were incubated in normoxic conditions for 2 weeks to allow for colony formation.
After 2 weeks media was aspirated and cells were fixed with acetic acid for 20 minutes
then stained with crystal violet for a further 20 minutes. Colonies were counted using
OpenCFU [319] and checked manually. Raw data was plotted using GraphPad PRISM
and appropriate statistical analyses were carried out as described.
3.9.2 Presto-Blue Assay
Cells were plated out in 96-well plates at 2,500 cells/well with 200µl of media. Plates
were exposed to hypoxia and reoxygenation and the required time points however with
PrestoBlue readings observed after 4 days in all cases, regardless of treatment times so
that cells had been proliferting for the same time. PrestoBlue assays were performed
following the manufacturers protocol. Absorbance was recorded at 570nm after a 60
minute incubation of cells with the PrestoBlue reagent using an automatically set gain.
Cell viability was expressed as a percentage relative to untreated controls. Graphs and
statistical analyses were carried out using GraphPad Prism as described.
3.10 Statistical Analyses
Statistical analyses were carried out where at least 3 experimental replicates were avail-
able, the exact number of repeats is described in the corresponding figure legend. All
statistical tests and graphs were produced using GraphPad PRISM and all error bars
show standard deviation. Significance was determined using GraphPad PRISM using the
Student’s t-test where comparisons were being made between two groups, while analysis of
variance (ANOVA) tests were carried out to determine statirtical differences across mul-
tiple groups and parameters. Where three or more groups were being compared, multiple
comparisons were accounted for using Sidak’s or Tukey’s test depending on the compar-
isons being made within an individual experiment [314][315]. Statistics were reported as
an adjusted p-value (* - p <0.05, ** - p <0.01, *** - p <0.001, **** p <0.0001). All tests
carried out are described in the corresponding figure legend.
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Chapter 4: Characterising the Cellular Response to
Hypoxia and Rapid Reoxygenation
Hypoxia and rapid reoxygenation is linked to a plethora of clinical conditions such as
stroke, cancer and atherosclerosis [263][264][265]. Improving our understanding of the
molecular mechanisms and cellular responses to these stresses would contribute to a
greater ability to treat patients that have undergone ischemic injury. Many of the dis-
eases associated with ischemia and reperfusion have been previously linked to the NF-κB
family of rapidly acting transcription factors, although there have been conflicting reports
regarding the mechanism behind this activation [105][125][320]. As discussed in section
1.4 there have also been variations in findings concerning the effects of this activation on
gene expression, which appear to be due to the use of different cell lines and variations in
experimental design.
The first part of this project therefore aimed to confirm the effects of hypoxia and rapid
reoxygenation on NF-κB activation using the experimental design presented in section
3.2, as well identifying the upstream signalling mechanisms that lead to this activation.
The data presented in this chapter uncovers that the previously established method of
inducing hypoxia and reoxygenation activates the canonical NF-κB pathway, indepen-
dently of other stimuli. Thus the data presented in the second part of this chapter is
entirely novel, because an alternative, improved protocol was followed to induce hypoxia
and rapid reoxygenation than has been used in previous studies.
Using this novel method for inducing hypoxia and rapid reoxygenation, experiments were
designed to determine the precise mechanism behind the activation of the canonical NF-
κB pathway, as well as the effects of this activation on transcription of target genes. These
experiments were carried out through the use of western blots, EMSA, real-time qPCR
and immunofluorescence microscopy.
As discussed in section 1.4 reports describing the effects of hypoxia and rapid reoxygena-
tion on ROS production have conflicting findings. This appears to be mostly dependent
on the technique used to analyse ROS production [290], as well as the sample being stud-
ied [289]. A second aim of this chapter was therefore to determine the nature of the
ROS produced following hypoxia and rapid reoxygenation. Understanding this is key to
understanding the physiological mechanisms occurring within the cell, and would give in-
sight into the fundamental effects of hypoxia and rapid reoxygenation on the cell. These
investigations were carried out through western blots, ROS detection assays and real-time
qPCR.
The final aim of this chapter was to understand the downstream effects of hypoxia and
rapid reoxygenation on the cell, again using the novel method for inducing hypoxia and
rapid reoxygenation. Uncovering how hypoxia and rapid reoxygenation affects the pro-
liferation, survival and cell cycle progression of a cell is critical for understanding which
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upstream pathways are implicated and why. Previous work has indicated that across most
cell lines hypoxia leads to a reduction in proliferation due to a reduction in metabolic ac-
tivity as the cell is starved of oxygen [272], however the opposite is true in some cancer cell
lines [272][275][276]. Following reoxygenation, proliferation has been reported to increase
[273][274]. The effects of hypoxia and reoxygenation on proliferation on U 2-OS cells has
not previously been assessed. This final aim is key to the design of future experiments
presented later in this thesis and was investigated using western blot, colony formation
assays, PrestoBlue assays, flow cytometry and microscopy.
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4.1 Hydrogen Peroxide Treatment Activates The Canonical NF-
κB Pathway in U-2 OS cells
The NF-κB pathways are activated in response to a wide range of cell stresses including,
inflammation, infection, DNA damage and oxidative stress. Previous work in the Kenneth
laboratory has demonstrated that hydrogen peroxide treatment leads to the activation of
the canonical NF-κB pathway in HEK-293 cells. To confirm these results in U-2 OS cells,
cells were treated with 20µM of hydrogen peroxide for the times indicated (Fig. 27),
whole cell lysates were extracted and analysed by western blotting for proteins associated
with canonical NF-κB activation. Results presented here confirm that the oxidative stress
caused by hydrogen peroxide treatment activates the canonical NF-κB pathway.
Phosphorylation of IKKα/β and RelA are well-established markers of canonical NF-κB
activation [321]. The former is an upstream signalling factor responsible for downstream
transduction of the signal, while the latter is a canonical NF-κB subunit. Phosphory-
lation of IKKα/β and RelA was observed following treatment with hydrogen peroxide,
indicating that hydrogen peroxide treatment leads to the activation of the canonical NF-
κB pathway (Fig. 27). Quantification of these blots showed that effects observed across 3
independent experiments were significant with regard to phosphorylation of IKKα/β but
not phosphorylation of RelA at this particular residue.
The data presented in this section verifies previous data from the Kenneth laboratory
that sees activation of the canonical NF-κB pathway following hydrogen peroxide treat-
ment. This information is useful knowledge to have for future experiments focussing on
the more physiologically representative and more technically complex stimuli of hypoxia
and rapid reoxygenation. It will allow for comparisons to be made between the three
methods of inducing oxidative stress as well as its role as a useful positive control in
several experiments.
4.2 ROS Production Following Exposure to Hydrogen Peroxide,
Hypoxia and Rapid Reoxygenation
As described in Chapter 1 Section 1.4, there are conflicting reports regarding whether
hypoxia and rapid reoxygenation produce ROS [288][289][290]. This appears to be de-
pendent on the method used to detect ROS and the tissue, cell type or organelle being
studied.
To try to elucidate whether hypoxia and rapid reoxygenation leads to the production of
ROS an ENZO total ROS/superoxide detection kit was used (ENZO; #51010). Using a
microplate reader the cell permeable probe named ‘oxidative stress’ provided fluoresced
in the presence of ROS (hydrogen peroxide (H2O2), peroxynitrite (ONOO
-), hydroxyl
radicals (HO), nitric oxide (NO) and peroxy radical (ROO)). The second probe provided
reacts specifically with superoxide (O2
-). Probes were made up in combination in phenol
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Figure 27. Hydrogen Peroxide Treatment leads to Canonical NF-κB Activation in U-2 OS
Cells. Cells were treated with 20µM of H2O2 for between 30 minutes and 3 hours. Whole
cell lysates were extracted using 8M urea lysis buffer and western blots were performed for
phosphorylation events associated with canonical NF-κB activation. Quantitative analysis
of western blots (n=3) demonstrates that this activation is significant with regard to IκBα
phosphorylation (one-way ANOVA analyses using Tukey’s test for multiple comparisons).
A - Representative western blot from 3 independent experiments. B - Relative density of
p-IKKα/β(S176/177) normalised to actin and total IKKβ. C - Relative density of p-RelA
normalised to actin and total RelA.
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red-free pre-equilibrated media alongside any additional treatments and were added for 1
hour before detection on the microplate reader as described in the manufacturer’s protocol
(ENZO; ENZ-51010).
The initial phase of this experiment aimed to establish whether the kit was working as
planned. Cells were treated with 20µM of hydrogen peroxide for 1 hour in combination
with the probes. The ROS scavenger NAC was used in parallel as a negative control
to confirm that hydrogen peroxide treatment was causing the production of ROS and
superoxide. Data shows that treatment with hydrogen peroxide causes an increase in
the amount of ROS detected by the oxidative stress probe (p = 0.0002) and an increase
in the amount of superoxide (p <0.0001)(Fig. 28). NAC treatment alongside hydrogen
peroxide exposure significantly reduced the levels of ROS and superoxide detected by
the kit. These results indicate that the kit can successfully detect changes in ROS and
superoxide levels in U-2 OS cells.
After confirmation that the ROS/superoxide detection assay was working focus turned to
analysing ROS/superoxide production after hypoxia and rapid reoxygenation (Fig. 29).
Once again the probes were made up in combination with pre-equilibrated media and
treatments were carried out in parallel with addition of the probes for 1 hour before reading
fluorescence on the microplate reader. Normoxia only and 24 hour hypoxia samples were
treated with the probe for one hour before analysis, for the last hour of the time course
(eg: 23 hours hypoxia + 1 hour hypoxia with new probe-containing media).
After 1 hour of hypoxia a decrease in ROS detected by the ‘oxidative stress’ probe was
observed (p = 0.0023) (Fig. 29A). ROS levels returned to basal levels following 24 hours
of hypoxia and remained unchanged after 1 hour of rapid reoxygenation. Addition of the
free-radical scavenger NAC leads to a significant decrease in ROS levels following hypoxia
(p = 0.0039) and an increase following rapid reoxygenation (p = 0.0145). An increase
in in ROS levels following treatment with a free-radical scavenger is unexpected and the
precise reasons for this are unknown, clearly the NAC treatment is having the anticipated
effect following hypoxia, therefore it must be some characteristic of reoxygenation that
is leading to this effect. Perhaps the response of cells to reoxygenation is faster than
that to hypoxia, thus we may have missed a critical early time point where the scavenger
does have an effect. In this hypothesis the complex network of redox reactions presented
earlier (Fig. 23) allows the cells to compensate for this decrease in ROS, leading to the
increase observed here. Undoubtedly this would have to be investigated further in future
experiments.
An increase in superoxide production was observed after 1 hour of hypoxia (p <0.0001), in-
dicating that superoxide is the main contributor to oxidative stress in hypoxia (Fig. 29B).
This is the opposite observation from changes in ROS species detected by the ‘oxidative
stress’ probe. Perhaps it is these polarised differences in superoxide and global ROS levels
following hypoxia that has contributed to some of the opposing findings presented in the
literature [289][290].
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Figure 28. Hydrogen Peroxide Treatment causes Oxidative Stress and Superoxide Pro-
duction in U-2 OS Cells. Cells were treated with 20µM of hydrogen peroxide for 1 hour
with or without the presence of the ROS scavenger NAC, and oxidative stress and super-
oxide levels were detected using the ENZO ROS kit. Hydrogen peroxide treatment causes
production of oxidative stress species (p = 0.0002) and superoxide species (p <0.0001)
and NAC treatment is able to partially rescue the cells from this stress (p = 0.0022, p
= 0.0061). Data was analysed using two-way ANOVA with Tukey’s multiple comparison
test on the means of 3 independent experiments.
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Figure 29. Hypoxia and Rapid Reoxygenation Treatment Causes Changes in Oxidative
Stress and Superoxide Production in U-2 OS Cells. Cells were exposed to hypoxia for 1
hour, hypoxia for 24 hours, or hypoxia for 24 hours followed by rapid reoxygenation for
1 hour with or without the presence of the ROS scavenger NAC. Oxidative stress species
(A) and superoxide levels (B) were detected using the ENZO ROS kit after 1 hour of
treatment and exposure to the probes. Hypoxia and rapid reoxygenation have significant
effects on ROS and superoxide levels as determined by two-way ANOVA using Tukey’s
multiple comparison test on the means of 3 independent experiments.
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After 24 hours of hypoxia, oxidative stress and superoxide levels return to those seen
in normoxia, indicating that after 24 hours in 1% O2 cells become accustomed to the
conditions and no longer produce ROS. Superoxide levels do not change following 1 hour
of reoxygenation. As predicted treatment of all samples with NAC leads to a significant
reduction in oxidative stress and superoxide species.
An explanation for the lack of ROS and superoxide production following reoxygenation
could be due to the use of a single 1 hour time point; an earlier spike in oxidative stress
could have been missed. Previous work has demonstrated that changes in superoxide
production are almost immediate, and levels decrease rapidly in the first 10 minutes of
reoxygenation [290]. As demonstrated in figure 23 of the introduction, an increase in
production of different ROS leads to a series of complex chemical reactions to remove the
species. Superoxide for example is readily converted to peroxynitrate, hydroxyl radicals or
hydrogen peroxide. It is therefore possible that at the time point used here, species that
has been originally produced following hypoxia have already been converted or scavenged
and are therefore no longer detectable by the probes. To test this hypothesis, and to gain
a greater understanding of the mechanics of ROS production following hypoxia and rapid
reoxygenation, this experiment could be performed again across a series of shorter time
points.
The change in levels of oxidative stress and superoxide species after 1 hour of hypoxia
was startling, especially in comparison to other treatments. It was therefore important
to take a closer look at the raw data to confirm whether this could be having some effect
on the results presented in figure 29. Raw data from the blank wells on each plate were
plotted for both the oxidative stress detecting probe and the superoxide detecting probe
(Fig. 29). The plotted raw data (not normalised) shows that there is definite variation
in background fluorescence levels in the absence of cells both between treatment times
and within the same treatments. These blank wells contained no cells, only the phenol
red-free media containing the different probes, therefore any changes observed could only
be due to the oxygen content of the surrounding air. The largest observable change seems
to be in the hypoxia samples where fluorescence from both the oxidative stress detection
probe and the superoxide detection probe goes up in all hypoxia samples (both 1 hour
and 24 hour). This suggests that exposure to 1% O2 has an effect on the probes in some
way. Although these background readings are subtracted from the sample readings, the
fact that oxygen levels impact on the probes used means that the data obtained using
this ROS detection kit must be treated with caution.
To assess whether hypoxia and rapid reoxygenation causes oxidative stress through other
methods western blots were carried out probing for changes in total peroxiredoxin-3
(PRDX-3) levels (Fig. 31). Peroxiredoxin-3 is a mitochondrial protein with antioxi-
dant function that is responsible for metabolising hydrogen peroxide [322]. Oxidation of
PRDX-3 during reduction of hydrogen peroxide leads to dimerisation of PRDX-3, observ-
able as a higher band on a western blot. However since total protein extracts of U-2 OS
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Figure 30. Hypoxia Exposure causes changes in Background Fluorescence of Oxidative
Stress and Superoxide Probes. Raw data from blank wells (wells containing phenol red-
free media with the different fluorescence probes) was taken from the data presented in
figure 29 was plotted. Large amounts of variation in background fluorescence from both
oxidative stress and superoxide probes is observed between different treatment types, in
particular plates exposed to hypoxia directly before reading on the microplate reader.
Smaller variations can been observed between plates of the same treatment.
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cells were obtained here using RIPA buffer, both dimer and monomer bands are visible
on the blot even in the absence of oxidative stress. An improved method of extraction
would be to use trichloroacetic acid (TCA); this would allow for the analysis of the ox-
idative state of protein as it prevents the spurious oxidation events (such as disulphide
bond formation) that occur during protein extraction under native non-acidic conditions.
Future work should be carried out to determine whether PRDX-3 is oxidised following
exposure to both hypoxia and reoxygenation.
Results presented in figure 31 show an increase in PRDX-3 levels following both hypoxia
and rapid reoxygenation, with an initial decrease in signal occurring immediately after
reoxygenation. The results observed here indicate that total protein levels are changing
across the time course. There is evidence of sequence homology for several transcription
factors and enhancers at the promoter of the PRDX-3 gene [323], some of which have
links to stress responses. Binding sites for transcription factors of note include: aryl
hydrocarbon receptor nuclear translocator (ARNT) , otherwise known as HIF1β, the
second subunit of the HIF1 heterodimer, Forkhead box protein A2 (FOXA2), a protein
involved in glucose homeostasis [324] and SMAD family members that are transducers
for the transforming growth factor beta (TGF)β superfamily [325]. Due to the role of
PRDX-3 in the removal of hydrogen peroxide, the change in total PRDX-3 levels across
the time course presented in figure 31 indicates that hydrogen peroxide is produced during
hypoxia and rapid reoxygenation, either directly or as a by-product during the removal
of different ROS (Fig. 23).
4.3 Hypoxia and Rapid Reoxygenation Activates The Canonical
NF-κB Pathway in U2-OS cells
As discussed earlier, hydrogen peroxide is a known activator of NF-κB. Although previous
studies have shown a link between hypoxia and rapid reoxygenation and NF-κB activation
[124][105], it was important to validate these findings as part of the project in U-2 OS cells.
This section demonstrates that both hypoxia and rapid reoxygenation lead to activation
of the canonical NF-κB pathway through western blot analysis and EMSA.
U-2 OS cells were exposed to 1% O2 for the times indicated to observe the effects of
hypoxia (Fig. 32), while rapid reoxygenation was carried out by incubating cells in 1%
O2 for 24 hours then returning plates to 21% O2 for the times indicated. Membranes were
probed for specific phosphorylation events associated with canonical NF-κB activation
alongside the total protein levels. In addition to the use of actin as a loading control,
membranes were probed for HIF1α as a control for hypoxia as it is stabilised in low oxygen
conditions. A 30 minutes 25µM etoposide treatment was run as well as a positive control
of canonical NF-κB activation [94].
The increase in HIF1α observed throughout all hypoxia time points demonstrates that
HIF1α has become stabilised in response to the low oxygen conditions (Fig. 32B). This
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Figure 31. Hypoxia and Rapid Reoxygenation leads to Oxidative Stress as Measured
by Peroxyredoxin Signal. U-2 OS cells were exposed to 1% O2 for the indicated times.
Reoxygenated samples were exposed to 1% O2 for 24 hours prior to rapid reoxygena-
tion. Proteins were extracted using RIPA lysis buffer with added protease inhibitors
and western blots were performed probing for PRDX-3. A - Both hypoxia and rapid
reoxygenation lead to changes in band intensity of peroxyredoxin-3, indicating that both
hypoxia and rapid reoxygenation lead to oxidative stress. B - Quantification of western
blots was carried out normalising to the loading control, actin. Relative density of 3 inde-
pendent experiments shows that these findings are significant based on two-way ANOVA
analysis using Tukey’s test for multiple analyses. P-values presented show the statistical
significance compared to the normoxia control.
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Figure 32. Both Hypoxia and Rapid Reoxygenation lead to Canonical NF-κB Activation
in U-2 OS Cells. A - Representative blot of canonical NF-κB pathway activation following
hypoxia and rapid reoxygenation. Cells were exposed to hypoxia (1% O2) or reoxygenated
(21% O2) for the times indicated prior to lysis with 8M urea lysis buffer. A positive control
of 25µM of etoposide treatment for 30 minutes was run alongside the experimental samples
to confirm that antibodies were working as expected. B-D - Relative density of bands
was determined across 4 independent experiments, normalising to actin and total protein.
Two-way ANOVA analyses were carried out to assess statistical significance.
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demonstrates that the hypoxic incubator was working as expected as in the absence of
oxygen HIF1α does not become hydroxylated by the PHDs, is not targeted for degrada-
tion, and is stabilised [279][280]. Following rapid reoxygenation the opposite is true. The
PHDs are able to hydroxylate HIF1α leading to its subsequent ubiquitination and degra-
dation as observed due to the sudden loss of HIF1α signal following reoxygenation. The
second control of actin demonstrates that wells have been loaded evenly and the results
presented are not due to changes in total overall protein level.
The western blot shown in figure 32 demonstrates that both hypoxia and rapid reoxy-
genation activate the canonical NF-κB pathway. Phosphorylation of IKKα/β and IκBα
is observed following both hypoxia and rapid reoxygenation. Phosphorylation of both
IKKα (lower band) and IKKβ (higher band) is observed indicating that both kinases of
the canonical IKK complex are involved in the response to these stimuli. This is un-
expected as IKKα is predominantly associated with the activation of the non-canonical
NF-κB pathway. Quantification of relative band density from 4 independent experiments
shows that this phosphorylation of IKKα/β is not significant, however changes in phos-
phorylation of IκBα are. The fact that changes in IKKα/β phosphorylation are not
significant in spite of clear changes observed on the western blot presented is most likely
due to variability in the signal strength of the antibody across multiple repeats.
Another notable observation is the decrease in IκBα phosphorylation following 24 hours
of hypoxia exposure (Fig. 32). This indicates that the cells have adapted the low oxygen
conditions and have adjusted their signalling accordingly. This demonstrates that IκBα
is phosphorylated following both hypoxia and reoxygenation. For these reasons it was
important to expose cells to hypoxia for 24 hours before rapid reoxygenation as if phos-
phorylation events and signal pathway activation had not subsided it would be impossible
to tell whether an increase in phosphorylation was due to reoxygenation or a prolonged
response to hypoxia. In all reoxygenation experiments presented in this thesis, cells were
therefore exposed to 24 hours before rapid reoxygenation would take place.
In addition, it is clear that total IκBα levels remain constant throughout hypoxia and
rapid reoxygenation even though the protein itself is phosphorylated. Culver et al. have
observed this effect after hypoxia exposure previously, although their observations were
focussed on tyrosine rather than serine phosphorylation events [118]. Phosphorylation
at serines 32/36 is commonly associated with the subsequent K48-linked ubiquitination
and degradation of IκBα by the proteosome [78][126][127][128]. Following hypoxia and
rapid reoxygenation we observe stabilisation of IκBα; previous studies have shown that
sumoylation of this ubiquitination site prevents degradation of IκBα as ubiquitination is
blocked [129][130]. Additional experiments should be carried out to explore this hypothesis
further. In addition, alternative methods of protein extraction could be carried out to
observe some of the finer details of protein degradation; the urea lysis buffer used here is
a rigorous method of whole cell extraction, which in some cases can mask small effects.
Nuclear and cytoplasmic extracts could be carried out to confirm whether any degradation
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Figure 33. Rapid Reoxygenation leads to p65/p65 homodimer and p65/p50 heterodimer-
DNA binding in U-2 OS Cells. U-2 OS cells were exposed to hypoxia for 24 hours, were
reoxygenated for 2 hours or were treated with 25µM etoposide or 10ng/ml TNF for 1
hour and 30 minutes respectively. Nuclear extracts were probed for RelA/p65 as part of
an EMSA. 24 hour hypoxia samples showed no p65 DNA binding however reoxygenation,
etoposide and TNF treated samples showed DNA association of NF-κB.
is occurring.
The blot presented in figure 32 demonstrates that the IκBα, the final protein involved
in activation of the canonical NF-κB pathway and the protein responsible for the release
and translocation of RelA, is phosphorylated in the response to both hypoxia and rapid
reoxygenation. To confirm that this activation leads to binding of RelA to κB sites on
DNA an EMSA was carried out on nuclear U-2 OS cell extracts (Fig. 33). U-2 OS cells
were exposed to hypoxia, reoxygenation, 25µM etoposide or 10ng/ml TNFα for the times
indicated. This allowed comparison of binding of RelA across multiple activators of the
canonical NF-κB pathway.
No DNA binding of RelA/p65 is observed in the normoxia and 24 hour hypoxia samples,
while RelA/p65 DNA binding occurs following 2 hours of rapid reoxygenation (Fig. 33).
As expected etoposide and TNF treatments lead to DNA binging of RelA/p65, these
are potent activators of the canonical NF-κB pathway and lead to the binding of NF-
κB subunit homodimers and heterodimers as observed by two distinct bands on the gel
[94][87][88]. Without performing supershifts it is not possible to be certain which dimers
have formed in response to these stimuli. Data presented in Kenneth et al. 2014 using
the same probes and methods showed similar patterns of binding and confirmed by that
they were p65/p50 and p50/p50 dimers [316]. Although it is not possible to be certain
without further analysis the same dimer pairs could be binding here.
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This section has shown that the upstream canonical pathway is activated following hy-
poxia and reoxygenation (as indicated by phosphorylation events on proteins of interest)
(Fig. 32) and the EMSA has shown that NF-κB homodimers and hetrodimers are present
on the DNA following these stimuli. Interestingly the signal from the reoxygenated sam-
ple is just as strong as those seen in the positive control samples of etoposide and TNFα
treatments. This demonstrates that rapid reoxygenation is also a potent activator of the
canonical NF-κB pathway and confirms findings shown in figure 32. The positive controls
of etoposide and TNF used here are representative of two of the most well-established
activators of the NF-κB pathway; DNA damage and cytokine detection through extracel-
lular receptors respectively. This led the project towards evaluating the potential roles of
extracellular and autocrine signalling as a potential activator of, or response to, hypoxia
and rapid reoxygenation. The effects of DNA damage on canonical NF-κB activation will
be explored in a later section.
4.4 Investigating the Potential Role of an Autocrine Feedback
Loop in the NF-κB Response to Rapid Reoxygenation
One of the main mechanisms behind canonical NF-κB pathway activation is through ex-
tracellular receptor signalling, for example detection of members of the TNF receptor
family or other chemokines and cytokines via a range of cell surface receptors [43]. Indeed
many of the classical inducers of the NF-κB signalling pathway act through cell surface
receptor interactions. Figure 33 demonstrated that similar levels of RelA-DNA binding
occurs following both reoxygenation and TNF stimulation. To investigate whether an au-
tocrine feedback mechanism similar to TNF signalling was responsible for the signalling
pathway activation observed after rapid reoxygenation, experiments were carried out that
involved swapping media between normoxic and reoxygenated plates. The initial hypoth-
esis behind these experiments was that reoxygenation causes cells to produce chemokines
or cytokines that could be exported from the cell into the surrounding media. Once in the
media these cellular products would be sensed by extracellular membrane receptors, which
would in turn activate signalling pathways downstream, leading to the NF-κB response
described in section 1.2.
To investigate this autocrine feedback hypothesis U-2 OS cells were reoxygenated for 1
hour as described in previous sections. Again, media was changed to fresh gas-equilibrated
media when plates were reoxygenated to induce immediate changes in oxygen level. To
establish whether this new media on reoxygenated plates was able to activate the canon-
ical NF-κB pathway, this media was taken off the reoxygenated plate after 1 hour of
reoxygenation and added to an otherwise untreated normoxic plate (Fig. 34). The result-
ing plate was therefore never exposed to changes in oxygen levels, only the media from
a reoxygenated plate that would contain any chemokines or cytokines secreted from the
reoxygenated cells. An additional etoposide only treatment was again used as a positive
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control of NF-κB activation, as well as a plate that had simply undergone a change of me-
dia (completely in normoxic conditions). Whole cell lysates were obtained using urea lysis
buffer and western blots were carried out probing for phosphorylation events associated
with canonical NF-κB pathway activation.
As seen in previous sections, activation of the canonical NF-κB pathway was not ob-
served following normoxia and 24 hour hypoxia samples (Fig. 34). Results from 1 hour
of reoxygenation were also consistent with earlier experiments, showing an increase in
phosphorylation events associated with canonical NF-κB activation (Fig. 34B). Quanti-
tative analysis shows that again, phosphorylation of RelA at serine 536 is not significant
following reoxygenation or indeed following etoposide treatment. The latter is most likely
due to experimental variation as indicated to by the large error bars (Fig. 34C).
Interestingly, exposure to media taken from the reoxygenation plate (lane 4) induces
phosphorylation of both IκBα and RelA (Fig. 34). This data suggests that the addition
of media taken from a plate of U-2 OS cells to an otherwise untreated plate of cells is
enough to activate the canonical NF-κB pathway. However, the use of the final control
presented in lane 7 (Fig. 34A) demonstrates clearly that this increase in canonical NF-κB
activation is due to the sudden presence of fresh media rather than as a result of cells
being exposed to reoxygenation plate media. Quantitative analysis demonstrates that
these changes in phosphorylation of IκBα and RelA are significant and indicates that
an unknown factor in the fresh media is able to activate the canonical NF-κB pathway.
This unconsidered variable may be contributing to the effect observed in previous work
carried out using fresh media to ensure rapid transition between oxygen environments. It
is impossible to know whether the activation seen in previous figures is due to changes in
gas levels and the resulting oxidative stress or due to this fresh media phenomenon.
It was therefore of importance to explore how the addition of fresh media was leading
to the activation of the canonical NF-κB pathway. A new and improved hypoxia and
reoxygenation protocol was needed for use in future experiments. There were multiple
possible reasons for this fresh media induced activation, one of which was the CO2 levels
of the media. Media that was pre-equilibrated in the hypoxia chamber was exposed to 5%
CO2 and plates that were incubated in the normal incubator were also kept at 5% CO2,
however fresh media was warmed in the bottle at normal atmospheric CO2 levels (0.04%).
This change in CO2 levels could be responsible for NF-κB activation in the experiments
presented here, similar experiments have been carried out previously investigating the role
of CO2 in NF-κB activation [294]. The change in CO2 levels can also lead to a change
in the pH of media, which could also explain the changes in signalling levels. Further
experiments therefore used CO2 equilibrated media.
The presence of fresh serum in the media could also be leading to this NF-κB activation.
To investigate whether this is the case, experiments were performed to investigate the role
of serum in this phenomenon (Fig. 35). U-2 OS cells were kept in normoxic conditions
and were exposed to fresh equilibrated media (5% CO2-equilibrated), serum-free media or
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Figure 34. Exposure of Untreated U-2 OS Cells to Fresh Media leads to Canonical NF-
κB Activation. U-2 OS cells were exposed to different stimuli and media changes to
determine whether reoxygenated cells produce cytokines or chemokines that can activate
the canonical NF-κB pathway in cells that have not been exposed to any other stimuli. To
control for the media change involved in this an otherwise untreated plate was exposed to
fresh media for 1 hour. A - Extracts were analysed by western blots probing for proteins
associated with canonical NF-κB activation. B and C - Quantification of 3 independent
experiments and statistical analyses by two-way ANOVA confirms that these findings are
significant according to Tukey’s test.
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Figure 35. Fresh Serum in Media is able to Activate the Canonical NF-κB Pathway in U-2
OS Cells. U-2 OS cells were exposed to normoxia only and treated with fresh equilibrated
media (5% CO2), serum-free media or spent media for one hour. A control plate that
underwent no media changes was harvested alongside. A - Extracts were analysed by
western blots probing for proteins associated with canonical NF-κB activation. B and C -
Quantification of relative band density was carried out across 3 independent experiments
(one-way ANOVA, Tukey’s test).
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spent media (media previously used on identical cell populations) for one hour alongside
a control plate that underwent no media changes. Protein was extracted using urea lysis
buffer and samples were again analysed for phosphorylation of proteins associated with
canonical NF-κB activation.
Figure 36. Fresh Media Leads to Changes in NF-κB Target Gene Expression. U-2 OS cells
were exposed to normoxia only for 4 days after seeding and treated with fresh equilibrated
media (5% CO2) for 6 hours on day 4 before being harvested for total RNA. A control
plate that underwent no media changes was harvested alongside the fresh media plates.
Reverse transcription was carried out followed by real-time qPCR to assess the relative
abundance of the NF-κB target genes IL-8 and PTEN, using RPL13A as a housekeeping
gene. Results show a significant increase in IL-8 expression following the media change
(p = 0.0353) as confirmed by two-tailed paired t-test.
An increase in canonical NF-κB activation is observed after one hour exposure to fresh
media compared with untreated plates (Fig. 35). No change in phosphorylation is ob-
served in both the serum-free and spent media samples. This clearly demonstrates that
fresh serum in media is able to activate the canonical NF-κB pathway independently of
other treatments. It follows that after seeding, cells use up nutrients and growth factors
present in the media and in turn secrete waste products. After 3-4 days of this the media
in a plate will be very different from fresh media containing fresh serum.
To determine whether the state of the media affects the control of gene expression by NF-
κB real-time qPCR experiments were carried out. Two plates containing U-2 OS cells
were seeded on day 0 and left to grow for 4 days at 37oC in a normal incubator. On day 4
the media on one plate was changed for fresh media while the other remained unchanged.
Cells were lysed for total RNA 6 hours later and reverse transcription was carried out
to produce cDNA. Real-time qPCR was carried out probing for NF-κB target genes IL-8
and PTEN, using RPL13A as a reference gene. Results were normalised using the ∆ ∆Ct
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method, and graphs were plotted and statistically tested using GraphPad Prism.
Data presented in figure 36 demonstrates that changing media on plates to fresh media
affects NF-κB target gene expression. Following exposure to fresh media, expression of
IL-8 significantly increased over ten-fold (p = 0.0353), while PTEN expression decreased
on average although not to significance. This shows that in the absence of any other
stimulus, simply changing the media on plates is enough to activate NF-κB as measured
by real-time qPCR.
The effects of fresh serum on NF-κB pathway activation could be masking any effects that
occur after hypoxia and rapid reoxygenation so an alternative method of inducing rapid
changes in gas levels should be used. One option would be to use gas-equilibrated serum-
free media for transitions between oxygen conditions, however this starvation of cells
would introduce other confounding factors into experiments; it would be impossible to
determine the extent to which oxygen state and starvation is contributing to observations.
An alternative option is to use spent media for these transitions; in this protocol identical
plates would be set up in parallel purely for harvesting of spent media to be used for
rapidly transitioning cells to or from hypoxia. This was the preferred option as it removed
as many potential variables from the experiment as possible. All experiments from here
on, unless stated otherwise, were carried out using this novel spent media protocol for
rapid oxygen state transition.
As discussed in the introduction, the canonical NF-κB pathway is closely linked with other
signalling pathways to coordinate specific and controlled cellular responses. To determine
which of these pathways are affected by hypoxia and rapid reoxygenation, a western blot
was performed on several proteins of interest; phospho-signal transducer and activator
of transcription 3 (STAT3), phospho-Chk1, total HIF1α and phospho-Akt. The results
showed that the state of the media, whether fresh, CO2 equilibrated or fresh, had no effect
on signalling through any of these proteins (data not shown).
This finding brings into question whether observations from previous experiments that
have involved fresh media changes to induce hypoxia should be reassessed. For example
Culver et al. [118] showed that exposure to hypoxia leads to an increase in IL-8 expression
and a decrease in PTEN expression. Data presented here (Fig: 36) suggest that their
findings could in fact be due to the fresh media change that is used to induce hypoxia
rather than the exposure to a hypoxic environment itself. Further experiments need to
be carried out to confirm this. It should be noted however that in many cases, such as
during hypoxia and rapid reoxygenation time courses, media changes to fresh media are
the current standard protocol. The change to fresh media is therefore not commonly
considered in experimental design and is therefore not typically controlled for.
Due to the findings presented in this section experiments carried out in the rest of this
thesis used spent rather than fresh media to carry out time courses. This was with the
aim of removing any uncertainties regarding the causes of any observable effects.
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4.5 ROS Production Following Hypoxia and Rapid Reoxygena-
tion when a Spent Media Protocol is Used
To determine whether hypoxia and rapid reoxygenation lead to the production of ROS
when spent media is used for rapid gas transition, the ENZO total ROS/superoxide detec-
tion kit was used again (ENZO; #51010), taking into consideration the caveat presented
earlier that oxygen levels impact on the reactivity of the probes used (Fig. 30). As before,
a microplate reader was used to detect fluorescence of the cell permeable ‘oxidative stress’
probe showing general ROS levels (hydrogen peroxide (H2O2), peroxynitrite (ONOO
-),
hydroxyl radicals (HO), nitric oxide (NO) and peroxy radical (ROO)). Detection of the su-
peroxide probe (measuring superoxide (O2
-) levels only) was carried out in parallel. Data
presented in figure 37 is therefore a direct repeat of the experiment described previously
(Fig. 29) except using spent rather than fresh media.
After 1 hour of hypoxia a significant decrease in ROS as detected by the ‘oxidative stress’
probe was observed (Fig. 37A). This returned towards levels seen in normoxic samples fol-
lowing 24 hours of hypoxia and no further significant changes in ROS levels were observed
following reoxygenation. Addition of NAC had no significant effect on ROS production
following hypoxia however a significant increase was observed following reoxygenation.
Superoxide levels remained unchanged throughout this experiment, however treatment
with NAC lead to a significant decrease in levels across all time points (Fig. 37B).
The effects of NAC treatment on the production of ROS or superoxide remains constant
between this experiment and the earlier fresh media experiment. This suggests that NAC
is predominately a superoxide scavenger as the opposite effect is observed in the levels
of ROS as detected by the ‘oxidative stress’ probe. The increase in ROS levels could be
explained by the chemistry of these species, as they react to form one another in closely
linked chemical pathways. A decrease in superoxide in one part of the pathway could have
a knock-on effect elsewhere, leading to an increase in levels of other ROS measured in
this experiment. The use of alternative anti-oxidants or ROS scavengers either separately
or in combination would further our understanding of ROS production following hypoxia
and rapid reoxygenation.
Some clear differences were observed between the ROS levels detected when a spent media
protocol was used to carry out hypoxia and reoxygenation time courses compared with a
fresh media protocol. Here the data carried out from both sets of ROS detection (fresh or
spent media) experiments have been plotted together to allow direct comparisons to be
made (Fig.38). Focussing on the oxidative stress species data first, the normalised data
presented shows that there is no signifcant difference in ‘oxidative stress’ species levels
following treatment with fresh or spent media after 1 hour of hypoxia or reoxygenation.
After 1 hour of hypoxia however, a 4-fold decrease in superoxide levels is observed after
spent media is used to achieve changes in oxygen levels compared with fresh media (p
= 0.0052). No significant differences are observed in superoxide levels when comparing
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Figure 37. ROS Production in U-2 OS Cells After Hypoxia and Rapid Reoxygenation
using Spent Media. U-2 OS cells were exposed to 1% O2 for 1 hour, or were reoxygenated
(21% O2) for 1 hour after exposure to hypoxia for 24 hours. Cells underwent transition
between these oxygen states using spent media with or without NAC treatment. A -
Oxidative stress (OS) and B - superoxide (SO) levels were detected using a microplate
reader following the manufacturer’s protocol (ENZO Total ROS Detection Kit). Data
shows that there is a decrease in ROS levels after 1 hour of hypoxia exposure compared
to normoxia levels. NAC treatment leads to a decrease in superoxide levels compared to
NAC-free samples across all treatments.
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Figure 38. ROS Production in U-2 OS Cells Changes Depending on Whether Fresh or
Spent Media is used during Oxygen State Transition. U-2 OS cells were exposed to
hypoxia (1% O2) for 1 hour, or were reoxygenated (21% O2) for 1 hour after exposure
to 24 hours of hypoxia. Cells underwent transition between these oxygen states using
either fresh or spend media and; A - oxidative stress, and B - superoxide levels were
detected using a microplate reader following the manufacturer’s protocol (ENZO Total
ROS Detection Kit). These results show that the use of fresh or spent media can have
an effect on superoxide production following 1 hour of hypoxia (p = 0.0052). Data was
analysed and presented as graphs using GraphPad Prism. Two-way Anova tests were
performed and p-values were corrected for multiple comparisons using Sidak’s test.
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fresh and spent media usage following 1 hour of reoxygenation. This indicates that the
freshness of the serum in the media used in hypoxia and reoxygenation experiments has
an effect on oxidative stress and superoxide levels after hypoxia in U-2 OS cells. Once
again though, it is important to consider the effects of hypoxia on the effectiveness of this
ROS/superoxide detection kit. As discussed previously hypoxia exposure seems to affect
the blank/background fluorescence readings, in the absence of cells (Fig. 30).
Once again this data does not clarify the effects that hypoxia and rapid reoxygenation
have on ROS production and only adds to the body of conflicting reports on the effects of
hypoxia and reoxygenation on the production of ROS [288][290][289][326]. As discussed
earlier, a repeat of this experiment following a series of time points would give insight as
to whether earlier bursts of ROS production have been missed, indeed constant monitor-
ing of ROS would be a preferable approach to this experiments as shown in previously
published work [288][290][289]. In addition, alternative methods to detect ROS could be
implemented due to the complication encountered using the ENZO ROS detection kit in
that the probes were influenced by the level of oxygen available.
4.6 NF-κB is Activated by Hypoxia and Rapid Reoxygenation
when Spent Media is used
Following the observation that the presence of fresh serum in the media was able to
activate the canonical NF-κB pathway, independently of other stimuli, experiments were
carried out to determine whether the use of a novel, modified protocol to carry out hypoxia
and rapid reoxygenation still triggered activation of the canonical NF-κB pathway (Fig.
39). Phosphorylation of STAT3 was analysed as an additional marker of hypoxia alongside
HIF1α, as STAT3 is also known to be activated in response to hypoxia. It has also been
shown to interact with RelA [327][328][329].
94
Figure 39. The Effects of Hypoxia and Reoxygenation on NF-κB Activation. U-2 OS cells were exposed to 1% O2 for the indicated times.
Reoxygenated samples were exposed to 1% O2 for 24 hours prior to rapid reoxygenation. Etoposide was used as a positive control for canonical
NF-κB activation. Proteins were extracted using urea lysis buffer with added protease inhibitors and western blots were performed probing for
markers of canonical and non-canonical NF-κB activation as well as markers of hypoxia. A - Representative blot of 3 independent experiments.
B-F - Relative density of 3 independent western blots, significance was determined using two-way ANOVA using Sidak’s test for multiple
comparisons.
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The hypoxia controls of total HIF1α and STAT3 phosphorylation significantly increased
as expected upon exposure of cells to 1% oxygen, confirming that a hypoxic state has
been induced (Fig. 39A, D and E). Upon examining read-outs of canonical NF-κB acti-
vation, it was observed that exposure to hypoxia leads to the significant phosphorylation
of both IKKα and IKKβ, whereas after reoxygenation phosphorylation of IKKα was
more prominent although not to a significant level (Fig. 39A). A significant increase in
phosphorylation of IκBα at serines 32 and 36 also occurs following both hypoxia and
rapid reoxygenation, (Fig. 39A, B and C). Phosphorylation of these signalling factors is
a well-established indicator of canonical NF-κB pathway activation although it is inter-
esting to note that IKKα activation is more commonly associated with activation of the
non-canonical NF-κB pathway. However, the non-canonical pathway response of p100 to
p52 cleavage was not observed upon hypoxia and reoxygenation (Fig. 39A and F), thus
providing further evidence for the involvement of the canonical pathway.
Once again, no change in total IκBα levels are observed. As discussed earlier phosphory-
lation of IκBα at the residues analysed here is commonly associated with degradation of
IκBα [78][126][127][128]. More recent studies have indicated that sumoylation of IκBα can
prevent its ubiquitin-mediated degradation [129][130]. It would be interesting to inves-
tigate whether this sumolyation is occurring following hypoxia and rapid reoxygenation.
Further experiments should be carried out to explore the effects of sumoylation further.
Collectively these results demonstrate that hypoxia and reoxygenation lead to canonical
NF-κB pathway activation via the canonical pathway, under conditions involving the use
of spent media. Thus, the activation of the canonical NF-κB pathway following hypoxia
and rapid reoxygenation, observed in earlier experiments (Fig. 32), is not soley due to
the addition of fresh serum at the point of oxygen state transfer.
In addition to phosphorylation, understanding ubiquitination of proteins is essential in
understanding cell signalling pathways as ubiquitination is required for targeting proteins
for degradation by the proteosome. The same lysates run on the western blot presented in
figure 39 were re-analysed by SDS-PAGE and western blot and probed for K48 and K63-
linked ubiquitination events to determine whether ubiquitination was occurring under
hypoxia and rapid reoxygenation (Fig. 40).
The western blot shown in figure 40 shows changes in ubiquitin levels after hypoxia and
reoxygenation; the smears show increases in global ubiquitination of various proteins.
In the blots presented, K48-linked ubiquitination reduces following 24 hours of hypoxia
exposure. After rapid reoxygenation an increase in K48-linked ubiquitination is observed.
No changes in K63-linked ubiquitination occur throughout the time course.
This experiment should be repeated before any firm conclusions can be drawn, how-
ever, if statistically significant differences in K48-linked ubiquitination were detected this
could indicate that the unfolded protein response is being activated following reoxygena-
tion. Certain stresses such as oxidation can cause proteins to misfold during folding
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Figure 40. Hypoxia and Rapid Reoxygenation leads to Changes in Ubiquitination Events
in U-2 OS Cells. U-2 OS cells were exposed to 1% O2 for the indicated times. Reoxy-
genated samples were exposed to 1% O2 for 24 hours prior to rapid reoxygenation. Cells
were lysed with urea lysis buffer with added protease inhibitors and western blots were
performed probing for K48- and K63-linked ubiquitination events.
and oligomerisation in the endoplsmic reticulum [330]. This production of possible non-
functional proteins may be detrimental to the health and function of the endoplasmic
reticulum and the cell. In these circumstances the misfolded proteins are chaperoned into
the cytosol, and targeted for degradation by the proteosome through K48-linked ubiqui-
tination; this process is known as ER-associated degradation [331]. The preliminary data
presented here could indicate that reoxygenation is triggering oxidation and misfolding of
proteins that must subsequently be degraded.
After confirming that hypoxia and rapid reoxygenation lead to canonical NF-κB activation
in U-2 OS cells (Fig. 39) it was important to establish whether this occurs in other cell
lines. A primary cell line of human foreskin fibroblasts was selected to confirm the U-2
OS cell findings. As primary cells, they are genetically, biologically and molecularly more
similar to cells in a living organism. Experiments were carried out as described previously
(Fig. 39), however spent media was not used in these experiments. The serum used to
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culture primary cells is synthetically produced rather than from a biological source as
used in immortalised cell lines. The serum was therefore not expected to have as much
of an effect on cell signalling pathway activation. Further tests should be carried out to
confirm this.
The results presented in figure 41A are similar to those shown in figure 39; exposure to
hypoxia and rapid reoxygenation leads to the activation of the canonical NF-κB pathway
as measured by IKKα/β and IκBα phosphorylation. Further analysis of the kinetics of
this activation through quantification of band density (n = 3) reveals that these changes
in phosphorylation are mostly not statistically significant, again this is most likely due to
experimental variation in band density. The only significant change in phosphorylation
levels observed in this experiment is that of IκBα phosphorylation following reoxygena-
tion. Thus, this data indicates that reoxygenation leads to the activation of the canonical
NF-κB pathway through IκBα (Fig. 39C), again in the absence of IκBα degradation. It is
possible that the use of fresh media to carry out these experiments could be contributing
to the activation of the canonical NF-κB pathway in this instance, further experiments
should be carried out to determine whether this is the case.
So far this section has predominantly focussed on canonical NF-κB pathway activation,
although other NF-κB pathway-linked pathways of interest have been explored such as
HIF1α and STAT3. Another series of pathways that are known to crosstalk with NF-
κB activation are the MAPK pathways. The next experiment aimed to determine how
hypoxia and rapid reoxygenation affect MAPK signalling following the same experimental
design described earlier (Fig. 39). Western blot analysis was performed to look at total
levels and phosphorylation of all three MAPK proteins, ERK, p38 and JNK [332].
Following exposure to hypoxia there are no changes in the phosphorylation and subse-
quent activation of ERK1/2, p38 or JNK (Fig. 42). Following rapid reoxygenation no
significant change in p38 or JNK phosphorylation occurs as determined by statistical
analysis of relative band density (Fig. 42C and D), however a significant increase in phos-
phorylation and activation of ERK1/2 is observed (Fig. 42B). This increase in MAPK
signalling through ERK suggests that reoxygenation is able to trigger proliferation and
differentiation of cells.
The data presented in figure 42 demonstrates that exposure to hypoxia followed by rapid
reoxygenation causes changes in MAPK signalling. This could indicate cross-talk is oc-
curring between the canonical NF-κB pathway and the MAPK pathways, however since
TAK1 as an upstream kinase of the JNK and p38 mitogen-activated protein kinase (p38)
pathways and not ERK, it could be activated entirely independently of canonical NF-κB
signalling [333]. Regardless of the kinetics of its activation, detection of MAPK path-
way activation gives insight into the overall responses of U 2-OS to sudden exposure to
hypoxia and rapid reoxygenation. The elevation in signalling through the ERK cascade
indicates a potential increase in cell proliferation following rapid reoxygenation. This data
infers that reoxygenation allows a reversal of reduction of proliferation that occurs during
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Figure 41. Hypoxia and Rapid Reoxygenation leads to NFκB Activation in HFF cells.
HFF-1 cells were exposed to 1% O2 for the indicated times. Reoxygenated samples were
exposed to 1% O2 for 24 hours prior to rapid reoxygenation. Cells were lysed with urea
lysis buffer with added protease inhibitors and western blots were performed probing for
markers of canonical NF-κB activation. A - Representative blot of 3 independent experi-
ments. B and C - Mean relative density of 3 independent experiments. Statistical analyses
were performed using two-way ANOVA with Sidak’s test for multiple comparisons.
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Figure 42. Hypoxia and Rapid Reoxygenation leads to Changes in MAPK Signalling
in U-2 OS Cells. U-2 OS cells were exposed to 1% O2 for the indicated times. Reoxy-
genated samples were exposed to 1% O2 for 24 hours prior to rapid reoxygenation. Cells
were lysed with urea lysis buffer with added protease inhibitors and western blots were
performed probing for MAPK signalling pathway activation. A - Representative west-
ern blot of 3 independent experiments. B-D - Mean relative density of 3 western blots,
statistical analyses were carried out using two-way ANOVA and Sidak’s test for multiple
comparisons.
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hypoxia. Indeed previous work has indicated that in the majority of cell lines, a decrease
in proliferation is observed following exposure to hypoxia [272], and is associated with
reduced metabolic activity. An increase in proliferation has also been observed following
reoxygenation, albeit following different hypoxia and reoxygenation protocols (4 hours of
hypoxia only). Sung et al., demonstrated that the PI3K/protein kinase B (PKB) and
ERK signalling pathways were involved in this response in neuronal cells [274].
4.7 Hypoxia and Rapid Reoxygenation Leads to Changes in the
Expression of NF-κB Target Genes
Data presented so far in this thesis has demonstrated that the upstream canonical NF-
κB pathway is activated after both hypoxia and rapid reoxygenation. It was therefore
important to investigate whether this NF-κB activation induces transcription of target
genes, and which genes were transcribed. Real-time quantitative PCR experiments were
carried out after 6 hours of hypoxia or reoxygenation to determine this. The time point
of 6 hours was selected due to personal communication with other laboratory members,
as well as through observations that no changes of note occur at earlier time points (2
hours).
As discussed in section 1.4, the genes selected for analysis here are commonly associated
with NF-κB activation or oxidative stress. While some of them have been previously
implicated in the response to hypoxia or reoxygenation, the cell lines, oxygen levels and
time points reported in these publications differ to those used here. Additionally the
novel spent media method for gas exchange was most likely not utilised in previous work,
therefore carrying out the following real-time qPCR experiments presented here is of great
value when trying to understand the cellular response to hypoxia and reoxygenation.
For all real-time qPCR experiments U-2 O S cells were exposed to 1% O2 for 6 hours to
induce hypoxia. Reoxygenated samples were exposed to 1% O2 for 24 hours followed by
reoxygenation (21% O2) for 6 hours (Fig. 44). The spent media method of inducing hy-
poxia or reoxygenation was used in all experiments. Total RNA was extracted, analysed
and reverse transcription was carried out to produce cDNA. Real-time quantitative PCR
was performed on the aforementioned target genes alongside the reference gene RPL13A.
Data was analysed by the ∆ ∆ Ct method, hypoxia samples were normalised to nor-
moxia/untreated samples and reoxygenated samples were normalised to 24 hour hypoxia
samples. Some genes have more repeats than others as they were investigated further in
later sections of the thesis due to interesting preliminary data.
To ensure that the hypoxia chamber was working as expected, real-time qPCR was per-
formed to amplify genes known to be induced by hypoxia; VEGF and CA9. VEGF is
transcribed in response to low oxygen levels by HIF1α and HIF1β to promote vasculoge-
nesis and angiogenesis to restore oxygen to cells [334][335]. CA9 is a zinc metalloenzyme
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that catalyses the hydration of carbon dioxide in hypoxic conditions [336][337]. Expres-
sion of hypoxia inducible genes, VEGF and CA9, increase after exposure to hypoxia, thus
confirming that the anaerobic chamber was working correctly (Fig. 43). Some samples
do not appear to have increased levels of VEGF or CA9, however inspection of the raw
data reveals that these points do not come from the same sample. These differences are
therefore more likely to be a result of technical issues rather than a problem with the
hypoxic incubator, as such, these data sets were not discarded from analysis.
Figure 43. The Effects of Hypoxia on Levels of Hypoxia Control Genes. U-2 OS cells
were exposed to 1% O2 for 6 or 24 hours. Total RNA was extracted, reverse transcription
was performed and cDNA was analysed by qPCR focussing on CA9 (A) and VEGF (B)
expression using RPL13A as a reference gene. The ∆ ∆ Ct method of analysis was
used, normalising to 24 hour hypoxia samples. Statistical analyses was carried out using
one-way anovas using Tukey’s test for multiple comparisons.
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Figure 44. The Effects of Hypoxia on Levels of Genes of Interest. U-2 OS cells were exposed to 1% O2 for the indicated times. Total RNA was
extracted, reverse transcription was performed and cDNA was analysed by qPCR using RPL13A as a reference gene (A = IL-8, B = p100, C
= IκBα, D = cIAP-2, E = PTEN). The ∆ ∆ Ct method of analysis was used, normalising to normoxia/untreated samples. Statistical analyses
was carried out using two-tailed paired t-tests.
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The first set of target genes to be analysed were genes commonly associated with NF-κB
activation across a wide range of stimuli. Following 6 hours of hypoxia, expression of IL-8
and cIAP-2 decreased significantly (Fig. 44A and D) (p <0.0001 and p = 0.0004 respec-
tively). No significant change is observed in p100, IκBα or PTEN expression following
exposure to hypoxia for 6 hours (Fig. 44B, C and E). Since the preliminary data from
these genes did not show any major changes in expression following hypoxia, these genes
were not selected for further analysis.
An interesting observation presented in figure 44 is the decrease in IL-8 expression follow-
ing 6 hours of hypoxia. As discussed in section 1.4, multiple studies have observed a signif-
icant increase in IL-8 mRNA levels following exposure to hypoxia [295][296][298][299][118].
However many of the experiments presented in these publications were carried out fol-
lowing different methods from those shown here, as well as from each other regarding the
cell lines used and the experimental design itself. Time of exposure varied from as low
as 1 hour up to 48 hours, and some researchers opted to use serum-free methods of gas
exchange while others did not. It is possible the use of spent rather than fresh media
used here, as established earlier, has contributed to the difference in results presented in
this thesis (Fig. 36). One could argue that the use of spent media is the most stringent
method for inducing hypoxia; removing serum or adding fresh media adds potential addi-
tional stresses into the experiment, while using spent media does not. Indeed, this could
also account for the contrasting data from the other genes, for example a decrease in
cIAP-2 expression was observed here (Fig. 44), while Wang et al. observed a significant
increase in cIAP-2 expression. [303].
The data presented in figure 44 indicate that activation of NF-κB could lead to the
active repression of expression of target genes. This has been discussed previously in the
context of other stimuli [119], and highlights the diverse nature of the NF-κB pathway.
Different stimuli lead to slight variations in the activation mechanisms of NF-κB and the
subsequent expression or repression of different genes. In the case of hypoxia, IL-8 and
cIAP-2 expression is repressed; both of which play important roles in the inflammatory
and immune response. The change in IL-8 expression is unexpected due to its role as
a promoter of angiogenesis, one would expect an increase in new vasculature growth
following hypoxia and therefore an increase in IL-8 expression. The decrease in cIAP-2
expression indicates that an increase in apoptosis may be occurring.
Investigations into the expression of genes associated with oxidative stress were also car-
ried out with the aim of determining the kind of oxidative stress induced by exposure to
1% O2 (Fig. 45). Expression of ferritin mRNA varied between biological repeats after
exposure to hypoxia (Fig. 45A), as such after 6 hours of hypoxia no significant change in
the levels of ferritin mRNA is observed. This indicates that production of hydrogen per-
oxide is not occurring after hypoxia as ferritin prevents the formation of harmful hydroxyl
radicals through reacting with hydrogen peroxide [243]. The kinetics of antioxidant gene
expression may of course differ from that of the the other NF-κB target genes studied
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here, depending on the timings and type of ROS produced. As demonstrated in figure
23, production of ROS could include a plethora of different species that react with one
another in a dynamic, ongoing manner. Thus the requirement for increased expression of
antioxidant genes may change over time as the kinetics of ROS production alters following
exposure to a stimuli.
Figure 45. The Effects of Hypoxia on Levels of Genes of Interest Associated with Oxidative
Stress. U-2 OS cells were exposed to 1% O2 for the indicated times. Total RNA was
extracted, reverse transcription was performed and cDNA was analysed by qPCR using
RPL13A as a reference gene (A = Ferritin, B = SOD-2). The ∆ ∆ Ct method of analysis
was used, normalising to normoxia/untreated samples. Statistical analyses was carried
out using two-tailed paired t-tests. Data shows a significant decrease in SOD-2 expression
following hypoxia expression (p <0.0001).
In contrast, after 6 hours of hypoxia a significant decrease in SOD-2 expression is observed
(p<0.0001) (Fig. 45B). This indicates that following hypoxia exposure there is a reduction
in the requirement for SOD-2 in the mitochondria, suggesting that there is a drop in
superoxide produced due to a decrease in aerobic respiration. Ferritin was not examined
further following this preliminary analysis as no large changes in expression were observed.
Figure 46 shows the effects of reoxygenation on the expression of genes commonly as-
sociated with NF-κB signalling activation. Rapid reoxygenation leads to a significant
increase in the expression of IL-8 and cIAP-2 after 6 hours of treatment (p = 0.0315 and
p = 0.0095 respectively) (Fig. 46A and D). This is the opposite response to that seen
following exposure to hypoxia, highlighting the differences between the two stimuli. This
could indeed be a return to basal expression levels following return to a normoxic state.
Expression of p100, IκBα and PTEN does not change following reoxygenation.
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Figure 46. The Effects of Rapid Reoxygenation on Levels of Genes of Interest. U-2 OS cells were exposed to 1% O2 for 24 hours followed by
reoxygenation for the indicated times. Total RNA was extracted, reverse transcription was performed and cDNA was analysed by qPCR using
RPL13A as a reference gene (A = IL-8, B = p100, C = IκBα, D = cIAP-2, E = PTEN). The ∆ ∆ Ct method of analysis was used, normalising
to 24 hour hypoxia samples. Statistical analyses was carried out using two-tailed paired t-tests.
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Expression of the NF-κB-transcribed oxidative stress-linked genes ferritin and SOD-2 was
also investigated following rapid reoxygenation (Fig. 47). Changes in the expression of
ferritin varied between biological replicates resulting in inconclusive data (Fig. 47A).
SOD-2 expression does however change following rapid reoxygenation. After 6 hours of
reoxygenation SOD-2 mRNA levels increase significantly (p = 0.0428). This increase in
expression of SOD-2 following rapid reoxygenation indicates that there is an increased
need for SOD-2 protein in the mitochondria. Since SOD-2 is required to catalyse the
breakdown of superoxide after aerobic respiration this suggests that reoxygenation leads
to an increase in superoxide production or an increase in respiration [338]. The latter is
consistent with data presented earlier that shows an increase in ERK1/2 phosphoryla-
tion following reoxygenation (Fig. 42), indicating an increase in proliferation; an energy
requiring process.
Figure 47. The Effects of Rapid Reoxygenation on Levels of Genes of Interest Associated
with Oxidative Stress. U-2 OS cells were exposed to 1% O2 for 24 hours followed by
reoxygenation for the indicated times. Total RNA was extracted, reverse transcription
was performed and cDNA was analysed by qPCR focussing on ferritin (A) and SOD-2
(B) expression using RPL13A as a reference gene. The ∆ ∆ Ct method of analysis was
used, normalising to 24 hour hypoxia samples. Statistical analyses was carried out using
two-tailed paired t-tests.
Interestingly many target genes selected for observation presented in figures 44, 45, 46 and
47 show very little changes in expression after exposure to 1% O2 and rapid reoxygenation.
This was unexpected and as discussed previously could be due to the use of spent media
method of inducing rapid gas changes in cells.
This section has demonstrated that both hypoxia and rapid reoxygenation lead to changes
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in the expression of NF-κB target genes. Hypoxia leads to a decrease in the expression of
IL-8, cIAP2 and SOD-2, while the opposite is seen following reoxygenation. This suggests
that active repression of gene expression occurs following hypoxia and that this is reversed
following reoxygenation. Again this highlights the differences and similarities between the
two stimuli.
4.8 Hypoxia and Rapid Reoxygenation have effects on Prolifer-
ation and Cell Survival
NF-κB activation has previously been linked with changes in proliferation and cell survival
[42]. This can occur through regulation of NF-κB target gene transcription as well as
through cross-talk with closely linked molecular signalling pathways. Previous work in
this chapter has demonstrated that NF-κB is activated in response to hypoxia and rapid
reoxygenation, alongside the ERK1/2 MAPK signalling pathway, suggesting that cell
proliferation may be affected by exposure to these stimuli. In addition to this the change
in expression of cIAP-2 following hypoxia and reoxygenation indicates that changes in
oxygen levels may activate or repress apoptosis.
Proliferation was assessed using PrestoBlue assays. This measures viability through the
reducing abilities, or mitochondrial activity of cells under the assumption that more cells
correlates to greater mitochondrial activity. The blue resazurin is reduced to produce
a red dye product by the cells and change can be measured by a spectrophotometer to
determine viability. The initial experiment carried out here was to assess the growth of
the cells over time. U-2 OS cells were plated out at 2,500 cells per well on a 96-well plate
on day 0 and incubated in normoxic conditions. Plates were measured using PrestoBlue
assays every 24 hours for 4 days. The results show a steady increase in proliferation over
time, with a doubling rate of just over 24 hours (Fig. 48). Data was is presented as a
percentage of the total cells on day 4.
Following analysis of the proliferation and growth of U-2 OS cells in normoxia over time,
an experiment was performed to determine the effects of hypoxia and rapid reoxygenation
on proliferation (Fig. 49). Cells were again plated out at 2,500 cells per well on 96-well
plates on day 0 and left in a normoxic incubator for at least 24 hours. Five different time
courses were carried out simultaneously, normoxia only, hypoxia for 24 hours, hypoxia for
48 hours, reoxygenation for 24 hours and reoxygenation for 48 hours. For the hypoxia
time courses plates were exposed to 1% O2 on day 2 or day 3, for 48 and 24 hours
respectively before analysis. Reoxygenated samples were exposed to hypoxia for 24 hours
before their return to 21% O2. They were exposed to 1% O2 on day 1 and day 2, followed
by reoxygenation on day 2 and day 3 for 48 and 24 hours respectively. All plates were
read 4 days after plating out so had the same amount of time to grow although in different
conditions. Data is presented as a percentage of total proliferation in control plates.
U-2 OS cells show a decrease in overall proliferation after exposure to hypoxia. The effect
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Figure 48. Proliferation of U-2 OS Cells in Normoxia. U-2 OS cells were plated out at
2,500 cells per well in 96-well plates on day zero and incubated in normoxic conditions.
Cell proliferation was assessed using PrestoBlue assays every 24 hours for 4 days.
is statistically significant after 24 hours (p = 0.0239), and as the level of proliferation
drops further after 48 hours of hypoxia the significance increases (p = 0.0018) (Fig. 50A).
24 hour hypoxia samples were moved into the hypoxia chamber after 3 days of normoxic
growth and the percentage of proliferating cells is comparable to those observed on day
3 of growth assay (Fig. 48). This could suggest that rather than slowing proliferation,
exposure to hypoxia stops proliferation, however without carrying out further experiments
it is impossible to say for certain whether proliferation stops completely once cells enter
hypoxia.
Cells were exposed to hypoxia for 24 hours prior to reoxygenation, therefore the results for
the proliferation after rapid reoxygenation were compared directly to the results for pro-
liferation after 24 hours of hypoxia (Fig. 50B). 24 hours post-reoxygenation an increase
in proliferation is observed compared with those only exposed to hypoxia (p = 0.0305).
Interestingly after 48 hours of reoxygenation levels of proliferation decrease again com-
pared with those that were reoxygenated for 24 hours (p = 0.0056). This data suggests
that the shorter term effects of rapid reoxygenation differ from the longer term effects. An
immediate increase in proliferation could suggest a reversal of cell cycle arrest, however
the decrease in proliferation that follows could be a result of further chronic damage to
cells, perhaps due to DNA damage and induction of apoptosis.
The data presented here again highlights the profound differences between hypoxia and
109
Figure 49. Schematic of Hypoxia and Rapid Reoxygenation Time Course for Proliferation
Assays. U-2 OS cells were plated out at 2,500 cells per well in 96-well plates on day zero
and incubated in normoxic conditions for at least 24 hours. Plates were then moved to
and from the anaerobic chamber as the schematic demonstrates over the course of 4 days.
For example the 24 hour reoxygenation plates were moved into 1% O2 on day 2, 48 hours
after plating out, and returned to 21% O2 after 24 hours for a further 24 hours before
reading proliferation by PrestoBlue.
rapid reoxygenation, and indicates that although rapid reoxygenation has an immediate
positive effect on cell proliferation and health, the longer term implications may be differ-
ent. To determine the chronic effects of reoxygenation on U-2 OS cells colony formation
assays were performed over the course of 2 weeks. Here, cells were exposed to hypoxia for
24 hours, followed by rapid reoxygenation for 3 hours. Cells were then seeded sparsely
onto 10cm plates. After 2 weeks surviving colonies were fixed, stained and imaged. Images
were then blinded and colonies counted both computationally and manually and compared
to control plates that contained normoxia only exposed colonies. Data presented is the
percentage of manually counted colonies formed compared with total cells seeded. Results
were plotted using GraphPad Prism and significance was calculated through two-tailed
paired t-tests.
The results of the clonogenic assay show that reoxygenation has a significant effect on the
ability of U-2 OS cells to form colonies (p = 0.0055) (Fig. 51). This result demonstrates
that reoxygenation following 24 hours of hypoxia has long-term effects on the health
and survival of U-2 OS cells. This indicates that although cells respond positively to
reoxygenation in the short-term, long-term damage could be occurring within cells. The
decrease in colonies formed following reoxygenation shows loss of cell survival and suggests
that apoptosis or even necrosis could be occurring, possibly as a result of DNA damage.
This will be explored in section 7.1.
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Figure 50. The Effects of Hypoxia and Rapid Reoxygenation on Proliferation of U-2 OS
Cells. U-2 OS cells were treated as described in figure 49. Proliferation was analysed
using PrestoBlue after 1 hour. Mean values of 3 independent experiments were plotted
using GraphPad prism to determine the effect of hypoxia (A) and reoxygenation (B) on
proliferation. P values were calculated using one-way ANOVA and correcting for multiple
comparisons using Tukey’s test.
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Figure 51. Reoxygenation Following 24 Hours of Hypoxia Affects Colony Formation and
Cell Survival. U-2 OS cells were exposed to 1% O2 for 24 hours prior to rapid reoxy-
genation. Following 3 hours of rapid reoxygenation, cells were trypsinised, counted and
re-plated in a range of concentrations in twelve 10cm plates. Normoxia only control plates
were plated out in parallel. Plates were left in 21% O2 for 2 weeks to allow for colony
formation. Colonies were fixed and stained using crystal violet before being blinded and
counting both computationally and manually (manually counted data presented). Data
presented is the percentage of colonies formed compared with total cells seeded. Means of
three independent experiments were plotted using GraphPad Prism and significance was
calculated through two-tailed paired t-tests.
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4.9 Summary and Brief Discussion of Chapter 4
The data presented in this section have demonstrated that exposure to both hypoxia and
rapid reoxygenation leads to the activation of the canonical NF-κB pathway. The data
has also highlighted some key differences between the cellular responses to hypoxia and
reoxygenation, particularly with regard to changes in gene expression and proliferation.
The initial experiments described in this chapter revealed that the use of fresh media
(specifically fresh serum) to carry out the current protocol for the induction of hypoxia and
rapid reoxygenation leads to activation of the canonical NF-κB pathway independently of
these stimuli. Further investigations showed that the presence of fresh serum affects the
formation of ROS as well as the transcription of NF-κB target genes. This in itself is an
interesting discovery, and highlights that the effects of media changes should be considered
when studying NF-κB even in the contexts of other stimuli. Spent media was therefore
used to carry out subsequent hypoxia and reoxygenation protocols, as data is presented
showing that this does not affect the activation of NF-κB independently of hypoxia or
reoxygenation stimuli. Thus the data presented using this revised protocol is unique; all
previously published studies regarding hypoxia and reoxygenation-induced activation of
NF-κB have employed fresh media when altering O2 levels [105][125][320][118].
This modified protocol has allowed us to demonstrate with certainty that hypoxia and
rapid reoxygenation trigger activation of the canonical NF-κB pathway. This activation
appears to be similar to that of hydrogen peroxide treatment, where upstream signals are
transduced through IKKβ to activate RelA. Previous studies have demonstrated that in
the response to hydrogen peroxide treatment, IκBα is phosphorylated on tyrosine 42 and
does not undergo degradation as it does in response to other stimuli such as TNF [164].
Activation of NF-κB in response to hypoxia and reoxygenation is similar to this, however
following hypoxia both IKKα and IKKβ are phosphorylated (Fig. 39), as opposed to
just IKKβ or IKKα following hydrogen peroxide or reoxygenation treatment respectively
(Fig. 27 and 39). Aside from this difference the downstream kinetics of canonical NF-
κB signalling appear similar between hypoxia and reoxygenation, as observed in previous
hydrogen peroxide studies, although IκBα is phosphorylated it is not degraded [164].
As discussed in section 4.3, the serine 32/36 phosphorylation of IκBα observed here is
commonly associated with K48-linked ubiquitination and degradation of IκBα by the
proteosome [78][126][127][128]. There have been reports that sumoylation of this residue
prevents its ubiquitination, leading to the stabilisation of the protein [129][130]. Indeed
this could be an explanation for the lack of IκBα degradation observed in this project.
Activation of RelA is still possible in the absence of IκBα degradation as reported previ-
ously [164][129][130]. Culver et al. described this mechanism in the context of hypoxia,
hypothesising that sumoylation alone on this critical lysine residue is sufficient to allow
dissociation of IκBα from RelA. As long as RelA is no longer bound by IκBα it is able to
translocate into the nucleus to control gene expression. Post-translational modifications
113
on RelA would then allow further control of transcription through regulation of RelA’s
binding to the promoters of target genes [42]. As discussed in section 4.4, Culver et al.
used a different protocol for inducing gas exchange, as such the findings presented here
(Fig. 36) contradict their reported findings [118]. Future experiments should therefore in-
vestigate whether this sumoylation is occurring following hypoxia and rapid reoxygenation
to further uncover the process behind the activation of NF-κB observed here.
As discussed earlier, some of the genes selected for real-time qPCR analysis have been
studied following exposure to hypoxia and reoxygenation previously, however there was
some conflicting reports regarding these changes. This could be due to the cell lines,
oxygen levels and time points used, there was therefore still value in analysing these
genes. Changes in gene expression have not previously been examined using this mod-
ified protocol, here we observed a significant decrease in IL-8, cIAP-2 and SOD-2 fol-
lowing hypoxia, which is reversed upon reoxygenation. Again this further contradicts
earlier reports, for example IL-8 expression is thought to increase following hypoxia
[118][295][296][297][298][299], while SOD-2 expression is reported to decrease on reoxy-
genation [308]. This highlights the effects that scientific method can have on the outcome
of an experiment, and reinforces the need for clear reporting on protocols used.
The results of real-time qPCR have indicated that active repression of several key genes
could potentially be occurring following exposure to hypoxia, as observed by the decrease
in expression of several genes of interest. This repression is reversed after reoxygena-
tion of cells. Previous reports on the mechanism of NF-κB-regulated active repression
have predominantly focussed on the response to DNA damage-induced NF-κB activa-
tion [119]. Here the active repression of anti-apoptotic genes such as Bcl-XL occurs in a
RelA-dependent manner to promote apoptosis in the response to stress [119]. This could
implicate genotoxic stress as a factor in hypoxia.
To investigate whether this decrease in gene expression under hypoxic conditions is due to
NF-κB-dependent active repression, rescue experiments should be carried out. For exam-
ple if active repression is occurring here, cells treated with siRNA to induce knockdown
of RelA would show no change in gene expression following hypoxia, while those treated
with off target, scrambled siRNA would still show the decrease [119]. The changes in
expression of target genes presented here confirms the activation of the NF-κB pathway
in response to stress but also implicates apoptosis in the response to these stresses due
to the changes in cIAP-2 expression. In addition to this, changes in SOD-2 expression
implicates superoxide as one of the ROS involved in this response. Alternatively, due to
its role in the electron transport chain, a decrease in ROS indicates that a decrease in aer-
obic respiration, metabolism and proliferation is occurring in the cell following hypoxia,
which is reversed following reoxygenation.
Although previous studies have aimed to characterise the species of ROS produced follow-
ing hypoxia and reoxygenation, these reports have had conflicting findings. As discussed
in section 1.4 the method used for detection [290] as well as the samples tested [289] can
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affect the results of the experiment. This highlights the difficulty in defining the species
of ROS produced within a cell or tissue. In this project characterisation of the ROS pro-
duced following hypoxia and reoxygenation has proven challenging due to the effects of
hypoxia on the probes in the absence of cells (Fig. 30). Details of the exact probes used
and the mechanism by which the redox sensitive dyes work is not available, as such one
cannot be certain that the kit is accurately detecting oxidative stress or superoxide as it
claims to. Future work should focus on more robust methods for determining oxidative
stress such as detection of PRDX-3 oxidation.
A final aim was to explore the downstream effects of hypoxia and rapid reoxygenation in
mammalian cells, as this would give insight into other pathways and proteins implicated in
the cellular responses to these stimuli. These investigations were important in the creation
of hypotheses to test in the coming chapters. Previous publications have described that
in the majority of cell lines hypoxia leads to a reduction in proliferation as an oxygen
starved cell struggles to carry out respiration and thus reduces its metabolic activity
[272]. However it is also noted that many cancer cells proliferate at the same or an
increased rate following exposure to hypoxia [272] due to mutations in key regulators of
replication stress, the cell cycle and DNA damage response. This is particularly true of
cell lines derived from osteosarcoma cancers [275][276]. Investigations in to the effects of
reoxygenation have demonstrated that reoxygenation leads to an increase in proliferation,
metastasis and invasion [273][274]. The effects of hypoxia and reoxygenation on U-2 OS
cells had not previously been investigated.
Proliferation and cell survival was analysed using both PrestoBlue and colony formation
assays, demonstrating that hypoxia leads to a decrease in proliferation but that reoxy-
genation causes proliferation to increase over 24 hours, but decrease again after 48 hours.
Indeed, the results of the colony formation assays show that following reoxygenation there
is a 50% decrease in survival compared with normoxic only cells. This highlights the po-
tential differences between short and long term effects of rapid reoxygenation, indicating
that apoptosis or necrosis is occurring, perhaps due to irreparable DNA damage. This
will be explored in a later chapter.
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Chapter 5: The Role of the IKK Complex and TAK1
in NF-κB Activation after Hypoxia and Rapid Reoxy-
genation
Data presented in chapter 4 demonstrated that the canonical NF-κB pathway is activated
in response to hypoxia and rapid reoxygenation. It is clear that IκBα is involved in this
activation, as highlighted by the significant increase in its phosphorylation following both
hypoxia and rapid reoxygenation (Fig. 39). Although phosphorylated in response to these
stresses, the role of the IKK complex in this activation however remains elusive.
The main member of the IKK complex that is associated with the activation of the
canonical NF-κB pathway is IKKβ. IKKβ knockout mice have a similar phenotype to
RelA knockout mice, highlighting the importance of this subunit in the activation of
the canonical NF-κB pathway [339]. In addition, studies of IKKβ deficient embryonic
fibroblasts have shown a marked reduction in canonical NF-κB activation following TNFα
or interleukin 1-α treatment [340][341][342]. A previous study has concluded that IKKβ is
required for the activation of the canonical NF-κB pathway following exposure to hypoxia,
hypothesising that this occurs through loss of hydroxylation of IKKβ and subsequent
phosphorylation and activation [343].
Aside from the scaffolding subunit, NEMO/IKKγ, the other main component of the
canonical IKK complex is IKKα. IKKα homodimers are associated with the non-canonical
NF-κB activation pathway more than the canonical pathway [339]. Some studies have
shown that IKKα is dispensable in response to cytokine treatment, with canonical NF-
κB activation occurring independently of the presence of this subunit [344] however other
more recent studies have disputed this [345][346][347]. The role of IKKα in the activation
of the canonical NF-κB pathway is therefore debated, with different stimuli, cell lines and
groups presenting alternate conclusions regarding whether IKKα is involved in canonical
NF-κB activation and to what extent. Interestingly, a previous study has implicated both
IKKα and IKKβ as being critical in the response to hypoxia, as measured by stabilisation
of HIF1α. Here they show that silencing of one subunit has little effect on HIF1α stabili-
sation, while loss of both completely blocks it [147]. As the HIF1α gene is transcribed by
NF-κB this highlights a possible role for both subunits in the response to hypoxia.
The data presented in results chapter 1 has implicated IKKα in the response to hypoxia
and rapid reoxygenation; phosphorylation of IKKα is observable by western blotting
following exposure to these stresses. However, due to variation between experimental
replicates only the increase in phosphorylation of IKKα/β following hypoxia, and not
reoxygenation, was significant (Fig. 39). In addition data from primary cells was not
significant with regard to IKKα/β phosphorylation (Fig. 41).
This section aimed to determine the role of IKKα and IKKβ in the transduction of
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upstream signals to IκBα and RelA. In this chapter targeted inhibition of these kinases
was carried out using small molecule inhibitors to determine the importance of each
subunit in the transduction of the signal downstream. Upstream kinases of each of these
proteins were also investigated in the same manner; TAK1 and NIK act upstream of IKKβ
and IKKα respectively. The effects of these proteins on canonical NF-κB activation was
determined by western blot analysis.
Another aim of this section was to investigate the cellular location of proteins of interest
following hypoxia and rapid reoxygenation. Work presented in this section therefore
explored whether different proteins such as the members of the IKK complex and RelA
move into the nucleus following hypoxia and rapid reoxygenation. This would give insight
into the roles of these proteins in response to these stimuli; for example localisation of a
protein into the nucleus could suggest a role in transcription. This was carried out using
immunofluorescence microscopy, and cytoplasmic and nuclear fraction analysis by western
blot.
Finally, investigations into the downstream effects of canonical pathway activation were
performed, focussing on gene expression, proliferation and survival. Real-time qPCR was
employed for the gene expression analysis, and proliferation and cell survival were assayed
using Presto Blue and colony forming assays, respectively, as in Chapter 4.8.
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5.1 IKKα has a Potential Role in the Activation of the Canon-
ical NF-κB Pathway After Rapid Reoxygenation
Data presented in chapter 4 demonstrated that key proteins in the canonical NF-κB
pathway are activated following hypoxia and rapid reoxygenation. The experiments in
this section aimed to determine whether the IKKα subunit is critical in the activation of
the canonical NF-κB pathway in response to reoxygenation. These experiments utilised
a small inhibitor of IKKα to competitively inhibit its activity during reoxygenation. The
small molecule inhibitor was kindly provided by Prof. Simon Mackay of Strathclyde
University. A recent publication demonstrated that these inhibitors are specific to IKKα
by showing that canonical NF-κB pathway activation by TNF is not affected by this
inhibition [348], while non-canonical signalling is. The specificity and half life of this
inhibitor is unpublished, however the doses and timings used in this project followed
advice given by the Mackay laboratory.
U-2 OS cells were exposed to hypoxia and rapid reoxygenation for the times indicated
(Fig. 52), alongside control plates of normoxia only and hypoxia only treated cells. Plates
targeted for IKKα inhibiton were exposed to 3µM of IKKα inhibitor for 30 minutes prior
to reoxygenation, and spent media used for rapid reoxygenation was pre-treated with the
inhibitor before use. Cells were harvested for whole cell extracts using urea lysis buffer
and analysed by western blot as before probing for phosphorylation events associated with
canonical NF-κB activation.
The phosphorylation of IKKβ does not change following rapid reoxygenation compared
with normoxia and hypoxia only treatments as shown in this western blot (Fig. 52A and
B). The only band visible on these western blots is the higher band of the larger IKKβ
subunit, therefore the consequences of this inhibitor treatment on the phosphorylation of
IKKα are unknown.
The effects of the IKKα inhibitor can be observed further down this signalling transduc-
tion pathway; activation of both IκBα and RelA following reoxygenation is significantly
reduced in cells pretreated with the IKKα inhibitor (Fig. 52A, C and D). The results
here indicate that IKKα plays an essential role in the activation of IκBα in the response
to rapid reoxygenation.
To assess whether the effects of IKKα inhibition during rapid reoxygenation differ from
IKKα inhibition following other stimuli, experiments were carried out using etoposide and
TNF time courses (Fig. 53). U-2 OS cells were treated with 25µM of etoposide (Fig. 53A)
or 10ng/ml of TNF (Fig. 53B) for the times indicated. Again, prior to this stimulation,
cells undergoing IKKα inhibition were pretreated with 3µM of IKKα inhibitor. Cells
were harvested for whole protein extracts and canonical NF-κB pathway activation was
analysed as before. As this was not the main focus of this project, this experiment was
not repeated sufficient times to allow for statistical analysis. Thus, this needs to be taken
into consideration when discussing the results.
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Figure 52. IKKα Inhibition blocks Canonical NF-κB Activation following Rapid Reoxy-
genation in U-2 OS Cells. U-2 OS cells were exposed to 1% O2 for 24 hours prior to rapid
reoxygenation for the times indicated, with or without treatment with a small molecule
inhibitor of IKKα inhibitor (Strathclyde University). Whole cell extracts were harvested
using urea lysis buffer with added protease inhibitors and western blots were performed
probing for proteins and phosphorylation events associated with canonical NF-κB activa-
tion (A). Relative density of bands taken from 3 independent experiments was calculated
and analysed using one-way ANOVA (Sidak’s test) (B-D).
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The pattern of activation presented in figure 53 differs from those seen after exposure
to reoxygenation (Fig. 52). This highlights the fact that although the canonical NF-κB
pathway is activated in response to both stimuli, the mechanism behind this can vary in
response to different stresses.
As expected both etoposide and TNF treatments lead to the activation of the canonical
NF-κB pathway as measured by phosphorylation of key proteins of interest (Fig. 53A
and B). In addition to these markers of activation, degradation of Total IκBα is observed
following TNF treatment. The timings of these responses appear to vary between the
treatments, with phosphorylation events, as well as the subsequent dephosphorylation
events, occurring earlier following TNF treatment.
Surprisingly, inhibition of IKKα appears to attenuate signalling through the canonical NF-
κB pathway following treatment with etoposide or TNF (Fig. 53A and B). The effects are
slight in the etoposide treated samples, however a decrease in IκBα phosphorylation is
clearly observable. Inhibition of IKKα prior to TNF treatment does not block activation
fully, rather it seems to delay the activation of the canonical NF-κB signalling pathway.
Phosphorylation of IκBα and RelA still occurs in the presence of the inhibitor, but at a
later time point than when the inhibitor is absent. These experiments should be repeated
to validate the findings from this preliminary data.
Phosphorylation of both IKKα and IKKβ occurs following treatment with etoposide or
TNF (Fig. 53), and an increase in signal from both the phospho-IKKα/β blot and the
total IKKβ blot is observed following treatment with the inhibitor. Further analysis of
the kinetics of this activation is required to determine whether an increase in IKKα/β
phosphorylation occurs or the increase in signal is purely due to an increase in total IKK
levels. The exact reason for this observation can only be hypothesised at this stage, it
appears as though treatment with this inhibitor causes increase in total/phosphorylated
protein through a feedback mechanism, perhaps with the aim of overcoming the effects of
the inhibitor.
The western blots presented in this section indicate that IKKα could have a surprising role
in the canonical NF-κB pathway response to both DNA damage (etoposide) and cytokine
treatment (TNF). The results of the TNF experiment are particularly surprising, as this
is a direct replicate of the experiment carried out by the Mackay laboratory which found
that the IKKalpha inhibitor did not block TNF triggered NFkB activation based in IκBα
phosphorylation [348]. The contrasting results between the work presented here and
that shown in Anthony et al. indicates that the particular batch of inhibitors used in this
project were not as effective as those presented in the paper. This brings into question the
specificity of the inhibitor used here and highlights the importance of carrying out parallel
experiments using alternative methods of protein inhibition such as siRNA treatment.
Thus, further experiments should be carried out to investigate the role of IKKα in the
response to reoxgenation.
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Figure 53. IKKα Inhibition Blocks Canonical NF-κB Activation following Etoposide and
TNF Treatments in U-2 OS Cells. U-2 OS cells were treated with 25µM of etoposide (A)
or 10ng/ml of TNF (B) for the times indicated, with or without treatment with an IKKα
inhibitor (Strathclyde University). Whole cell extracts were harvested using urea lysis
buffer supplemented with protease inhibitors and western blots were performed probing
for phosphorylation events associated with canonical NF-κB activation.
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5.2 A Role for TAK1 in the Activation of NF-κB after Hypoxia
and Rapid Reoxygenation
The data presented so far has demonstrated that rapid reoxygenation leads to canonical
NF-κB activation, however key upstream kinases involved in this activation have yet to
be identified. To investigate this further, the effects of inhibition of the NIK and TAK1
kinases that regulate IKKα and IKKβ respectively, was examined through the use of
small molecule inhibitors (Fig. 12).
To determine the role of NIK in the cellular response to rapid reoxygenation, a small
molecular inhibitor of NIK was used (NIK SMI1) [349][350]. The data sheet states that
aside from NIK1, this inhibitor has off-target effects on 3 out of 222 other kinases tested,
and only at doses much higher than those used here. It has a predicted half life of 3.5
days [351]. The experiment was carried out as before (Fig. 52), however cells were treated
with 150nM of the NIK inhibitor rather than the IKKα inhibitor.
In the western blot presented here, there is no significant difference in the phosphorylation
of the markers of canonical NF-κB pathway activation following reoxygenation, when
comparing samples treated with or without the NIK inhibitor (Fig. 54). The results from
this experiment therefore indicate that NIK is not involved upstream of the canonical
NF-κB signalling pathway in the response to rapid reoxygenation.
Next, the role of the TAK1 kinase was investigated. One consideration to be made when
studying the role of TAK1 is that in addition to phosphorylating and activating IKKβ
as part of the canonical NF-κB pathway, TAK1 is also an upstream kinase for the JNK
pathway [113][115][352][353]. However earlier experiments presented in this thesis have
shown that activation of the JNK pathway is not significant following hypoxia and rapid
reoxygenation (Fig. 42).
Cells were pretreated with 10µM of 5z-7-oxozeanol for 30 minutes prior to rapid reoxy-
genation (dosage selected based on personal communication). This inhibitor is an ATP-
competitive irreversible inhibitor, which has been used extensively in previous studies
[354][355]. Since the cysteine in its ATP target site is also present in ERK2, MKK7 and
MEK1 it also targets these proteins [356], however since the major point of crosstalk be-
tween these two pathways is through TAK1 itself, this shouldn’t affect signalling through
the canonical NF-κB pathway more than an inhibitor that specifically targets TAK1 would
[332]. The Dundee Kinase Screen does not highlight any other potential off-targets of this
inhibitor [357]. The predicted half life of this compound is 2.77 days, far longer than
the time points used in this experiment [351]. Analysis of markers of canonical NF-κB
activation was carried out as before.
As with previous experiments, the effects of reoxygenation on IKKα/β phosphorylation
is not significant regardless of inhibition of upstream kinases. In contrast, phosphoryla-
tion of IκBα is significantly reduced following treatment with the TAK1 inhibitor during
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Figure 54. NIK Inhibition has no effect on Canonical NF-κB Activation following Rapid
Reoxygenation in U-2 OS Cells. U-2 OS cells were exposed to 1% O2 for 24 hours prior to
rapid reoxygenation for the times indicated, with or without treatment with 150nM NIK
SMI1. Whole cell extracts were harvested using urea lysis buffer with added protease
inhibitors and western blots were performed probing for proteins and phosphorylation
events associated with canonical NF-κB activation (A). Quantification of relative density
was carried out across 3 independent experiments and analysed by one-way ANOVA
(Sidak’s test) (B-D).
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Figure 55. TAK1 Inhibition Blocks Canonical NF-κB Activation following Rapid Reoxy-
genation in U-2 OS Cells. U-2 OS cells were exposed to 1% O2 for 24 hours prior to rapid
reoxygenation for the times indicated, with or without treatment with 10µM of the small
molecule inhibitor of TAK1; 5z-7-oxozeaenol. Whole cell extracts were harvested using
urea lysis buffer with added protease inhibitors and western blots were performed probing
for proteins and phosphorylation events associated with canonical NF-κB activation (A).
Relative density was carried out across 3 independent experiments and statistics were
carried out by one-way ANOVA (Sidak’s test) (B and C).
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reoxygenation. This indicates that TAK1 is involved in the transduction of signalling
through the canonical NF-κB pathway.
5.3 Hypoxia and Rapid Reoxygenation Leads to Changes in
Sub-Cellular Localisation of Key Proteins Involved in Canon-
ical NF-κB Activation
As discussed in the introduction, following activation RelA and other NF-κB subunits
translocate into the nucleus to control the expression of target genes. Data presented in
previous sections of this thesis have demonstrated that the canonical NF-κB pathway is
activated following both hypoxia and reoxygenation, with a reduction in activation follow-
ing 24 hours of hypoxia. One would therefore expect to observe movement of RelA into
the nucleus following shorter hypoxia time points, movement out of the nucleus following
24 hours of hypoxia, then movement into the nucleus again following reoxygenation.
It has also been reported that members of the IKK complex are able to move in and out
of the nucleus in a complex with other proteins of interest. For example, following DNA
damage ATM is thought to phosphorylate NEMO or IKKγ in the nucleus, NEMO has
also been shown to couple with ATM to drive nuclear export of ATM [358]. In addition
to this, IKKα has been demonstrated as having a nuclear role through phosphorylation of
histone H3 in response to cytokine treatment [359]. Investigations into the location and
phosphorylation of these proteins of interest would therefore give great insight into the
roles that these proteins play in response to hypoxia and rapid reoxygenation.
To determine the cellular localisation of key proteins of interest involved in the activation
of the canonical NF-κB pathway, U-2 OS cells were exposed to hypoxia and reoxygenation
as before (Fig. 39). This time, cells were lysed for nuclear and cytoplasmic extracts before
western blot analysis of proteins associated with canonical NF-κB activation (Fig. 56).
In all repeats of this experiment (n = 5) apart from the one presented here, PARP and
beta-tubulin were used as nuclear and cytoplasmic controls. Unfortunately they were not
carried out for the blot presented, however all other extracts produced by this method
during this project that were probed for these control proteins had no cross-contamination
between nuclear and cytoplasmic extracts. This particular blot was selected for presen-
tation as it is representative of all the other blots and is the only set of extracts that a
complete, clean blot was available for all proteins of interest.
The most striking finding presented in figure 56 is the movement of all three members of
the canonical IKK complex into the nucleus following hypoxia. Statistical analyses of rel-
ative density of these blots confirm that this movement is significant, although variations
in the timings and levels of significance does occur (Fig. 56A, C, D and E). Following
reoxygenation, although all members of this complex appear to leave the nucleus to some
extent, this is only significant in the case of IKKα. These results indicate that a small
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Figure 56. Hypoxia and Rapid Reoxygenation leads to Changes in Protein Localisation
Events in U-2 OS Cells. U-2 OS cells were exposed to 1% O2 for the indicated times.
Reoxygenated samples were exposed to 1% O2 for 24 hours prior to rapid reoxygenation.
Nuclear and cytoplasmic proteins were carefully extracted and analysed by western blot
probing for key proteins involved in canonical NF-κB activation (A). Relative density of
blots from 5 independent experiments was analysed and statistically analysed (one-way
ANOVA, Sidak’s test) (B-I).
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proportion of IKK proteins move into the nucleus following hypoxia where they are se-
questered in preparation for the return of oxygen. From western blotting, it is impossible
to tell whether the three proteins move as the canonical IKK complex, as part of a larger
complex with other proteins, or independently of each other. Additional experimentation,
for example through the use of co-immunoprecipitation, would give further insight into
the mechanics and role of this response.
Analysis of phosphorylation events is more difficult after nuclear/cytoplasmic extraction
as it does not preserve phosphorylation events as effectively, even in the presence of phos-
phatase inhibitors. Although some variation can be observed, no significant changes in
phosphorylation of IKKα/β, IκBα or RelA occur here (Fig. 56A, B, F and H). This could
be due to variation in the preservation of phosphorylation events between independent
experiments, as well as the variability in effectiveness of these phospho-antibodies.
Following hypoxia and reoxygenation a surprisingly small increase in nuclear accumula-
tion of RelA occurs. As such, this change in band density is not statistically significant
following both stimuli (Fig. 56A and I). As we have observed previously, RelA is bound to
chromatin following reoxygenation (Fig. 33), therefore this result is surprising. Personal
communication with Perkins laboratory members, Dr. Yemm and Dr. Schlossmacher, re-
veals that RelA does not show strong nuclear accumulation in U-2 OS cells, even following
stimulation with the potent RelA activator TNF.
The use of a second technique, immunofluorescence microscopy, to determine the location
of IKKβ and NEMO was used to confirm whether translocation of the IKK complex does
occur following hypoxia and rapid reoxygenation. IKKβ was selected for analysis as it
is the main kinase associated with canonical NF-κB pathway activation and its apparent
ability to translocate into the nucleus is a novel finding. In contrast, NEMO was selected
as its translocation has been previously linked to genotoxic stress, confirmation of this
movement could indicate that DNA damage is occurring following hypoxia and rapid-
reoxygenation.
U-2 OS cells were plated out on 8-wells slides at 8,000 cells/well on day 0 and were left for
72 hours to grow prior to the start of the time course. Cells were exposed to hypoxia for
2 or 24 hours, or reoxygenated for 2 hours, and the cellular location of IKKβ and NEMO
was determined by immunofluorescence using a Zeiss Axiolmager at 10x zoom. Images
were analysed using ImageJ to automatically determine relative nuclear and whole cell
signal intensity. From this the relative movement of protein in and out of the nucleus
could be determined.
Data presented in figure 57 shows different results from that obtained by cell fractionation
and western blotting (Fig. 56) with regard to the movement of IKKβ following hypoxia
and reoxygenation. Microscopy data shows movement of IKKβ out of the nucleus following
2 hours of hypoxia (p = 0.0186), which continues up to 24 hours of hypoxia (p = 0.0032).
Following rapid reoxygenation levels of nuclear IKKβ return to basal levels. This would
128
Figure 57. Hypoxia and Rapid Reoxygenation leads to Changes in Cellular Location of
IKK Complex Subunits in U-2 OS Cells. U-2 OS cells were plated out on microscope
growth slides and left to grow for 72 hours. U-2 OS cells were exposed to 1% O2 for
2 hours or 24 hours. Reoxygenated samples were exposed to 1% O2 for 24 hours prior
to rapid reoxygenation for 2 hours. Cells were fixed and immunostained for proteins
of interest. Images were taken at 10x zoom using a Zeiss Axiolmager without apotome
and Zeiss’ Zen software. Images were analysed using ImageJ software, to quantify the
difference in nuclear signal compared with signal coming from the cell on its own. Points
presented from 4 separate slides were statistically tested using one way anova tests using
Sidak’s test for multiple comparisons.
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indicate a cytoplasmic role of IKKβ in the response to hypoxia. The opposing results
obtained from the fractionation and microscopy approaches makes it difficult to formulate
any conclusions; potential reasons for such discrepancies are expanded on in the discussion.
The results from the NEMO microscopy experiment showed the same trend as those
from the nuclear/cytoplasmic fractionation experiments (Fig. 57). Following 2 hours of
hypoxia NEMO translocated into the nucleus (p = 0.0009) and remained there up to 24
hours of hypoxia. Following 2 hours of rapid reoxygenation NEMO translocated back
out of the nucleus into the cytoplasm. This is consistent with the findings observed in
figure 56 and suggest a nuclear role for NEMO in the response to hypoxia. These findings
could indicate a role for ATM or DNA damage during hypoxia, as NEMO and ATM have
previously been shown to interact following DNA damage [358].
5.4 Further Analysis of IKK Complex Movement during Hy-
poxia and Rapid Reoxygenation
This section aimed to further evaluate the role of IKKβ and its upstream kinase, TAK1, in
the response to hypoxia and rapid reoxygenation, with particular focus on translocation
of the IKK complex. This was carried out using the cellular fractionation protocol used in
figure 56, but utilised small molecule inhibitors of TAK1 and IKKβ to determine whether
they have a role in the control of translocation of the IKK complex in and out of the
nucleus following hypoxia and reoxygenation.
The small molecular inhibitor of IKKβ, TPCA, was used in parallel to hypoxia and
reoxygenation treatments to block IKKβ function [360][361]. Cells undergoing IKKβ
inhibition were pretreated with 10µM of TPCA for 30 minutes prior to exposure to hypoxia
or reoxygenation, doses and timings were determined by personal communications with
members of the Perkins laboratory, who frequently use this compound on U-2 OS cells.
The data sheet describes TPCA as a potent selective inhibitor of IKKβ, and has an IC50
to IKKβ that is over 20-fold lower than to the nearest off-target IKKα [362]. It also has
a predicted half life of 6.11 days [351], longer than any time course used here.
The western blot presented here was selected as it shows the complete set of proteins of
interest that were analysed and is representative of the effects observed across other blots
(Fig. 58). Unfortunately, there are loading issues with the 24 hour hypoxia sample in this
particular blot, however the graphs depict the impact of this treatment on the cellular
localisation of proteins of interest.
Movement of IKKα, IKKβ and NEMO in and out of the nucleus following hypoxia and
reoxygenation respectively, is consistent with data presented in figure 56. Analysis of
the kinetics of translocation and the significance of these translocations as determined by
quantification of band density differs however (Fig. 58). Again this is most likely due to
variability between repeats when using this method of determining cellular localisation of
proteins. Treatment with TPCA has no significant effect on the movement of the IKK
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Figure 58. Effects of IKKβ Inhibition on Nuclear-Cytoplasmic Translocation following
Hypoxia and Rapid Reoxygenation in U-2 OS Cells. U-2 OS cells were exposed to 1% O2
for the indicated times. Reoxygenated samples were exposed to 1% O2 for 24 hours prior
to rapid reoxygenation. Cells undergoing IKKβ inhibition were treated with 10µM of
TPCA for 30 minutes prior to exposure to hypoxia and rapid reoxygenation. Nuclear and
cytoplasmic proteins were carefully extracted and analysed by western blot probing for key
proteins involved in canonical NF-κB activation. A - Representative blot of 6 independent
experiments, B-E - Relative density of bands statistically analysed by one-way ANOVA
(Sidak’s test).
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Figure 59. Effects of TAK1 Inhibition on Nuclear-Cytoplasmic Translocation following
Hypoxia and Rapid Reoxygenation in U-2 OS Cells. U-2 OS cells were exposed to 1%
O2 for the indicated times. Reoxygenated samples were exposed to 1% O2 for 24 hours
prior to rapid reoxygenation. Cells undergoing TAK1 inhibition were treated with 10µM
of 5Z-7-oxozeaenol for 30 minutes prior to exposure to hypoxia and rapid reoxygenation.
Nuclear and cytoplasmic proteins were carefully extracted and analysed by western blot
probing for key proteins involved in canonical NF-κB activation. A - Representative blot
of 4 independent experiments, B-E - Relative density of bands statistically analysed by
one-way ANOVA (Sidak’s test).
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subunits, indicating the IKKβ is not responsible for the translocation events observed
here.
A second set of experiments was carried out to determine whether the upstream kinase of
IKKβ, TAK1, is implicated in the translocation of the canonical IKK complex following
hypoxia and reoxygenation. The experiment presented in figure 58 was therefore repeated
with the addition of 10µM of the TAK1 inhibitor 5Z-7-oxozeaenol rather than TPCA.
Once again statistical significance of relative density of proteins of interest varies between
this experiment (Fig. 59) and those carried out previously using this technique (Fig. 56
and 58). This highlights the need for these hypotheses to be tested using an alternative
method that gives more consistent results. It is likely that the difference in findings and
statistical significance from each set of repeated experiments is due to the magnitude
of change in band density, this is particularly observable in the IKKβ and IKKγ blots
presented here (Fig. 59A). The lack of consistent experimental repeats therefore makes
it impossible to determine the impact of the TAK1 inhibitor on nuclear localisation of
IKKβ and NEMO.
Although there have been inconsistencies in findings from most of the proteins analysed by
nuclear and cytoplasmic fractionation, the movement of IKKα has remained consistent.
Again, significant increases in nuclear IKKα is observed following hypoxia, which decreases
following reoxygenation. Data presented in figure 59 demonstrates that inhibition of
TAK1 significantly reduces the levels of nuclear IKKα following hypoxia, and significantly
increases nuclear IKKα levels following reoxygenation. This suggests that TAK1 has a
role in the control of IKKα localisation following hypoxia and reoxygenation, most likely
through coordination of nuclear and cytoplasmic movement or control of stability of the
protein to prevent or induce degradation by the proteosome.
5.5 The Role of IKKβ in Gene Transcription by NF-κB in Re-
sponse to Hypoxia and Rapid Reoxygenation
Data presented in results chapter 1 showed that changes in the expression of IL-8, cIAP-2
and SOD-2 occurs following exposure to hypoxia and rapid reoxygenation. This section
aims to investigate how the main canonical IKK complex subunit, IKKβ, affects gene
expression following hypoxia and rapid reoxygenation. Experiments were carried out to
assess the levels of IL-8, cIAP-2 and SOD-2 mRNA present in cells following hypoxia and
rapid reoxygenation with and without inhibition of IKKβ.
Real-time qPCR experiments were carried out as before (Fig. 44) however in these experi-
ments, cells undergoing IKKβ inhibition were treated with 5µM of BMS-345541 alongside
exposure to hypoxia or rapid reoxygenation (dosage selected based on personal communi-
cation with colleagues who frequently use BMS-345541 on U-2 OS cells). BMS-345541 is
an allosteric inhibitor of IKKβ, with a reported 10-fold greater specificity for IKKβ than
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Figure 60. Treatment of U-2 OS cells with the IKKβ Inhibitor BMS-345541 affects Gene
Expression following Hypoxia and Rapid Reoxygenation. U-2 OS cells were exposed to 1%
O2 for 6 hours. Reoxygenated samples were exposed to 1% O2 for 24 hours prior to rapid
reoxygenation. Total RNA was extracted, reverse transcription was performed and cDNA
was analysed (A B = IL-8, C D = cIAP-2, E F = SOD-2) by qPCR using RPL13A as a
reference gene. The ∆ ∆ Ct method of analysis was used, normalising hypoxia samples
to normoxia samples and reoxygenated samples to 24 hour hypoxia samples. Mean values
from 3 independent experiments is presented and statistical analysis was carried out using
one-way ANOVAs using Tukey’s test for multiple comparisons.
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IKKα [363]. It has been shown to inhibit canonical NF-κB pathway activation in previous
publications [364][365], and specificity tests revealed it to have no off-target effects on 15
other key kinases, even at doses of 100µM [363], and it has a predicted half-life of 3.35
days [351].
It should be noted that in some instances the data presented here that was significant
in section 4.7, is not significant here (Fig. 60A). This is most likely due to the number
of repeats; in some cases one of the 3 runs of each experiment appears to be an outlier,
however with only 3 replicates it is difficult to determine with absolute confidence which
one could be classed as an outlier. Closer inspection of the raw data has revealed that
an outlier for one gene is not necessarily an outlier for the other genes; it is therefore not
possible to confidently discard any specific data sets on the basis of a poor sample. Further
repeats should be carried out to ensure that these outliers do not affect interpretation of
the data.
As before, IL-8 expression decreases significantly after 6 hours of hypoxia exposure (p =
0.0163) (Fig. 60A). The results presented here make it unclear whether IKKβ inhibition
has an effect on this as one out of three repeats shows an up-regulation in IL-8 expression
while the others show no change. Again, in 2 out of 3 samples reoxygenation leads to
an increase in IL-8 expression (Fig. 60B). Based on previous experiments we know that
the repeat that does not show increased expression is an outlier (Fig. 46). Inhibition of
IKKβ during reoxygenation leads to a small increase in IL-8 expression however this is
not significant.
Again expression of cIAP-2 decreases following hypoxia, however this is not significant,
most likely due to the low number of repeats (Fig. 60C). Following inhibition of IKKβ
however, the expression of cIAP-2 decreases drastically compared to normoxia (p =
0.0013) and hypoxia untreated samples. This indicates an important role for IKKβ in
the control of cIAP-2 expression in the response to hypoxia. Following reoxygenation
expression of cIAP-2 increases once again; this is not significant in this figure (Fig. 60D).
Interestingly, transcription of cIAP-2 is completely blocked following IKKβ inhibition,
highlighting the role of IKKβ in canonical NF-κB control of gene expression. The data
here indicate that IKKβ is important for cIAP-2 expression under all conditions tested,
even in circumstances where cIAP-2 expression is repressed.
Expression of SOD-2 again decreases following exposure to hypoxia however this is not
significant here (Fig. 60E). Inhibition of IKKβ does not have an effect on SOD-2 expres-
sion following hypoxia. Following reoxygenation SOD-2 expression remains unchanged in
these samples, however earlier work has demonstrated that SOD-2 expression increases
following reoxygenation (Fig. 60F). The data presented here shows that IKKβ inhibition
leads to a slight decrease in SOD-2 expression following reoxygenation. Again, this data is
not significant. Together these findings indicate that IKKβ may play a role in the NF-κB
response to hypoxia and reoxygenation, however the exact nature of this is unclear as yet.
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This ties in with the role of IKKβ as an upstream target in the activation of the canonical
NF-κB pathway, as it controls cIAP-2 expression downstream.
The data presented in this section indicate that inhibition of IKKβ following hypoxia and
reoxygenation can have different effects on the expression of NF-κB target genes. This
highlights the specificity of gene expression in response to stress and demonstrates the
complexity of the cellular response to this stress.
5.6 The Role of the IKK Complex in Cell Proliferation after
Hypoxia and Rapid Reoxygenation
Data presented in chapter 4 showed that both hypoxia and rapid reoxygenation have
significant effects on the proliferation of U-2 OS cells. Exposure to hypoxia caused a
decrease in the proliferation of cells as measured by PrestoBlue, whilst rapid reoxygenation
lead to an increase in proliferation over the first 24 hours followed by decrease following
48 hours. This section aims to determine how inhibition of IKKα and IKKβ affects
proliferation of cells following hypoxia and rapid reoxygenation through the use of small
molecule inhibitors.
Figure 61. Schematic of Hypoxia and Rapid Reoxygenation Time Course for Proliferation
Assays. U-2 OS cells were plated out at 2,500 cells per well in 96-well plates on day zero
and incubated in normoxic conditions for at least 24 hours. Plates were then moved to
and from the anaerobic chamber as the schematic demonstrates over the course of 4 days.
For example the 24 hour reoxygenation plates were moved into 1% O2 on day 2, 48 hours
after plating out, and returned to 21% O2 after 24 hours for a further 24 hours before
reading proliferation by PrestoBlue. Inhibition of proteins in selected wells was carried
out, these were treated either 24 hours or 48 hours prior to harvesting and throughout
the remainder of the experiment. For example a selection of the normoxia only cells were
treated for 24 hours prior to analysis, while another set were treated for 48 hours prior to
analysis.
In this series of experiments the time course carried out was very similar to the one
described in the previous chapter (Fig. 50), however small molecule inhibitors were used
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alongside to inhibit members of the canonical IKK complex. To determine the effect of
IKKβ inhibition on cell proliferation, a subset of plates from each separate time course
were treated with 5µM of the small molecule inhibitor of IKKβ, BMS-345541, prior to
and throughout exposure to hypoxia or rapid reoxygenation.
In separate experiments normoxia only cells were treated with BMS-345541 for 24 or
48 hours to assess the effects of IKKβ inhibition in the absence of other stimuli. This
allows us to interpret the hypoxia and reoxygenation data with the knowledge of how the
inhibitor affects proliferation in otherwise unstimulated cells. We were therefore able to
correct for the inhibition of proliferation following normoxia when examining the role of
the inhibitor in proliferation following hypoxia and reoxygenation.
Figure 62. The Effects BMS-345541 Treatment on Proliferation of U-2 OS Cells. U-2 OS
cells were treated a with 5µM of a small molecular inhibitor to IKKβ, BMS-345541, in
normoxic conditions for 24 or 48 hours to assess the effects of this inhibitor on proliferation
in the absence of other stimuli. Proliferation was analysed using PrestoBlue. Graphs were
plotted using GraphPad prism and two-way ANOVA analyses were carried out using
Tukey’s test to account for multiple comparisons. Data is presented as a percentage of
total proliferation in control plates.
Treatment of normoxia only cells with the IKKβ inhibitor BMS-345541 leads to around
a 50% decrease in proliferation of U-2 OS cells following 24 and 48 hours of treatment
(24h; p = 0.0236, 48h; p = 0.0343) (Fig. 62). This data demonstrates that inhibition of
IKKβ, without any additional stress, leads to a a significant reduction in proliferation,
highlighting the importance of functional IKKβ in normal cell function.
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Figure 63. The Effects of Hypoxia and Rapid Reoxygenation on Proliferation of U-2
OS Cells Following IKKβ Inhibition. U-2 OS cells were treated as described in figure
61, however a subset of cells were treated with 5µM of a small molecular inhibitor to
IKKβ, BMS-345541, prior to final exposure to hypoxia and rapid reoxygenation and for
the remainder of the time course. Proliferation was analysed using PrestoBlue. Graphs
were plotted using GraphPad prism to determine the effect of hypoxia exposure on cells
compared with normoxia only cells, and to compare the effects of reoxygenation on cells
compared with cells exposed to hypoxia for 24 hours. Two-way ANOVA analyses were
carried out using Tukey’s test to account for multiple comparisons.
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As established previously exposure of U-2 OS cells to 1% O2 leads to a decrease in prolif-
eration (Fig. 63). Inhibition of IKKβ in combination with a 24 hour exposure to hypoxic
conditions leads to a 60% decrease in the proliferation of cells. This change in proliferation
after addition of the IKKβ inhibitor is greater in 24 hour hypoxia samples (p = 0.0144).
This indicates that IKKβ is required in the response of cells to hypoxia. Although prolif-
eration after 48 hours of hypoxia in the absence of the inhibitor remains fairly constant,
the addition of the IKKβ inhibitor prevents proliferation (p = 0.0061). Moreover, as no
cells are detected this suggests inhibition of IKKβ signalling during extended hypoxia
triggers cell death due to apoptosis or necrosis. This is an additive effect of hypoxia
exposure and treatment with the IKKβ inhibitor. This result demonstrates that IKKβ
is absolutely critical in the cellular response to hypoxia, particularly following 48 hours
of treatment, and indicates a potential anti-apoptotic role for NF-κB in the response to
hypoxia-induced stress.
Reoxygenation again leads to an initial increase in proliferation of U-2 OS cells compared
with levels seen in 24 hour hypoxia cells, followed by a decrease after 48 hours (Fig. 63).
Treatment with the IKKβ inhibitor, BMS-345541, prevents any increase in proliferation
after 24 hours (p <0.0001) and 48 hours (p <0.0001). This demonstrates that although
inhibition of IKKβ affects proliferation of otherwise untreated cells, the combined effects
of inhibition and reoxygenation have additive effects on proliferation. This clearly demon-
strates that IKKβ is critical for the ability of cells to respond to rapid reoxygenation, and
indicates a potential anti-apoptotic role for the canonical NF-κB pathway in the response
to rapid reoxygenation induced stress.
As described in the first results chapter, rapid reoxygenation leads to an initial boost
in proliferation, however following 48 hours this proliferation decreases and following 2
weeks colony formation is reduced (Fig. 51). The underlying reason for this is unclear,
however could be linked to a sudden restoration of energy as aerobic respiration continues
in the presence of oxygen. As shown in figure 63, IKKβ plays a key role in the response
of U-2 OS cells to rapid reoxygenation 48 hours post-reoxygenation. To investigate how
inhibition affects colony formation and cell survival following 2 weeks of rapid reoxygena-
tion clonogenic assays were carried out looking at the effects of IKKβ inhibition on the
number of colonies formed following rapid reoxygenation.
Colony formation experiments were carried out as before (Fig. 51). In parallel with
the investigations presented earlier, a subset of normoxic and reoxygenation plates were
treated with 10µM of the small molecule inhibitor of IKKβ, TPCA. This inhibitor was
selected over BMS-345541 as it has a higher specificity for IKKβ over IKKα [363][362].
Both sets of plates were treated for a total of 3 hours and 30 minutes, however the first 30
minutes of TPCA treatment was carried out in hypoxia for the reoxygenated plates. Cells
were then seeded onto 10cm plates and analysed after 2 weeks of growth. Data presented
is the percentage of colonies formed compared with total cells seeded (manual counts).
The graph presented in figure 64 contains some of the same data as was presented in
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figure 51, the p-value presented differs slightly as multiple comparisons have been made
during the statistical analysis of this data.
As demonstrated in results chapter 1, reoxygenation leads to a significant decrease in the
ability of cells to form colonies compared to those kept in normoxic conditions (Fig. 51).
Inhibition of IKKβ leads to a decrease in colony formation in normoxic cells that are
otherwise untreated due to the toxicity of the inhibitor used (mean 67% with inhibitor vs.
81% without) (Fig. 64). Following inhibition of IKKβ there is no significant decrease in
colony formation following reoxygenation compared to normoxic cells. This contradicts
data from the proliferation assay (Fig. 63), which indicated that massive cell death occurs
following prolonged IKKβ inhibition. These differences could be due the experimental de-
sign, in the previous experiment cells were exposed to the IKKβ inhibitor for an extended
period of time, while in the colony formation experiment this inhibitor was removed after
3h 30m. Data from the clonogenic data therefore indicates that short-term IKKβ inhi-
bition during reoxygenation has no impact on overall cell survival, while data from the
proliferation assay indicates that long term inhibition of IKKβ during reoxygenation can
have catastrophic consequences for the cell.
Previous work in this section has implicated IKKα in the canonical NF-κB response to
hypoxia and rapid reoxygenation, although there are potential issues with the specificity
of this inhibitor (Fig. 52). The first part of this experiment aimed to establish the effects
of the IKKα inhibitor on proliferation of U-2 OS cells, that are not exposed to any other
stimulus such as hypoxia or rapid reoxygenation (Fig. 66). Here, normoxia only cells
were treated with 3µM of IKKα inhibitor (Strathclyde University) for 24 or 48 hours.
The results show that following treatment for 24 hours there is around a 50% reduction
in proliferating cells (p = 0.0037). After 48 hours of treatment with IKKα inhibitor
proliferation decreases further (p = 0.0030). This data indicates that the IKKα inhibitor
used for these experiments affects the general functionality of the cell regardless of other
stimuli, and a longer treatment has a greater effect on the cells overall health.
One again proliferation of U-2 OS cells decreases following 24 hours of hypoxia and re-
mains stable up to 48 hours (Fig. 66). Following treatment with the IKKα inhibitor,
proliferation of cells decreases further following 24 hours of exposure to hypoxia, with
around a 50% reduction in proliferation of 24 hour hypoxia samples following inhibition
of IKKα (p = 0.0018). This is the same as the decrease observed when normoxic cells
are treated with the inhibitor, indicating that this change is not due to hypoxia. After 48
hours of exposure to hypoxia, inhibition of IKKα leads to a large decrease in proliferation
(p = 0.0050). This decrease is greater than those seen in normoxic cells that are treated
with the IKKα inhibitor and the 48 hour hypoxia treated cells combined. This result
indicates that these combined treatments are additive in their effects, and highlights the
potential importance of IKKα in the cellular response to hypoxia-induced stress.
As shown in previous experiments, proliferation of cells increases following 24 hours of
reoxygenation compared to cells exposed to hypoxia for 24 hours before decreasing again
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Figure 64. The Effects of IKKβ Inhibition During Reoxygenation on Colony Formation
and Cell Survival. U-2 OS cells were exposed to 1% O2 for 24 hours. A subset of plates
were treated with 10 µM of the small molecule inhibitor of IKKβ, TPCA, prior to rapid
reoxygenation or in parallel in normoxia. Following 3 hours of rapid reoxygenation, cells
were trypsinised, counted and re-plated in a range of concentrations over 12 10cm plates.
Normoxia only control plates were plated out in parallel. Plates were left in 21% O2 for 2
weeks to allow for colony formation. Colonies were fixed and stained using crystal violet
before being blinded and counting both computationally and manually. Data presented
is the percentage of colonies formed compared with total cells seeded (manual counts).
Results were plotted using GraphPad Prism and significance was calculated through two-
way ANOVA, using Sidak’s test for multiple comparisons.
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Figure 65. The Effects of IKKα inhibitor Treatment on Proliferation of U-2 OS Cells.
U-2 OS cells were treated with 3µM of IKKα inhibitor in normoxic conditions for 24 or 48
hours to assess the effects of this inhibitor on proliferation in the absence of other stimuli.
Proliferation was analysed using PrestoBlue. Graphs were plotted using GraphPad prism
and two-way anova analyses were carried out using Tukey’s test to account for multiple
comparisons. Proliferation is presented as a percentage of proliferating cells compared to
untreated controls.
after 48 hours (Fig. 66). Treatment with IKKα inhibitor in combination with 24 hours of
reoxygenation leads to a decrease in proliferation (p = 0.0016), however again this change
in proliferation of cells following inhibition of IKKα is around the same as that observed in
IKKα inhibited normoxic cells. This indicates that following 24 hours of reoxygnenation,
the decrease in proliferation is predominantly due to the addition of the inhibitor and not
as a combination of IKKα inhibition and reoxygenation. After 48 hours of reoxygenation
however the proportion of proliferating cells decreases greatly following treatment with
the inhibitor (p = 0.0003). This demonstrates that IKKα plays an important role in the
proliferation of cells after 48 hours of reoxygenation. This change is drastic although does
not show as great a decrease in proliferation as that observed following treatment with
the IKKβ inhibitor, BMS-345541.
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Figure 66. The Effects of Hypoxia and Rapid Reoxygenation on Proliferation of U-2
OS Cells Following IKKα Inhibition. U-2 OS cells were treated as described in figure
61, however a subset of cells were treated with 3µM of a small molecular inhibitor to
IKKα prior to final exposure to hypoxia and rapid reoxygenation and for the remainder
of the time course. Proliferation was analysed using PrestoBlue. Graphs were plotted
using GraphPad prism to determine the effect of hypoxia exposure on cells compared
with normoxia only cells, and to compare the effects of reoxygenation on cells compared
with cells exposed to hypoxia for 24 hours. Two-way anova analyses were carried out
using Tukey’s test to account for multiple comparisons.
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5.7 Brief Summary and Discussion of Chapter 5
This results section aimed to determine the roles of IKKα and IKKβ in the response
to hypoxia and rapid reoxygenation. The data presented in this chapter predominantly
supports a role for IKKβ over IKKα. Inhibition of IKKβ blocks gene expression of the NF-
κB target cIAP-2 across all treatments (Fig. 60), and long term IKKβ inhibition prevents
proliferation following both hypoxia and rapid reoxygenation to a level not observed in
normoxic cells (Fig. 63). In addition to this, inhibition of the upstream kinase of IKKβ,
TAK1, significantly reduces activation of the canonical NF-κB pathway through IκBα
phosphorylation. Based on a thorough literature search, there is no evidence of the
IKKβ inhibitors, TPCA or BMS-345541, ever being used in parallel with hypoxia and
reoxygenation before this project.
Evidence to support the hypothesis that IKKα plays a role in the canonical NF-κB path-
way response to hypoxia and rapid reoxgenation is dependent on the specificity of the
IKKα inhibitor provided by Prof. Simon Mackay. Figure 52 shows that treatment with
this IKKα inhibitor significantly reduces signalling through the canonical NF-κB path-
way, however further experiment demonstrated that this blocking of canonical pathway
signalling was not specific to the response to reoxygenation. Treatment of cells with this
small molecule inhibitor prevented canonical NF-κB pathway activation following etopo-
side or TNF exposure (Fig. 53), which is broadly considered to be primarily mediated
by IKKβ. In a recent publication by Prof. Mackay’s group, inhibitors were tested for
specificity by demonstrating that canonical NF-κB signalling following TNF stimulation
was unaffected after high dosing with the inhibitor [348]. This indicates that the batch
of inhibitor used in this project was having off target effects, potentially targeting IKKβ.
Additional evidence that refutes a role for IKKα in the response to reoxygenation is that
inhibition of its upstream kinase, NIK, has no effect on canonical NF-κB signalling (Fig.
55).
This contradicts previous work that has implicated both IKKα and IKKβ in the response
to hypoxia [147]. Firstly they demonstrated that canonical NF-κB signalling is required
for basal and TNF stimulated HIF1α expression, confirming the link between canonical
NF-κB signalling and HIF1α levels. They then demonstrated that both IKK kinase
subunits are involved in this signalling mechanism through siRNA knockdown of IKKα or
IKKβ, and by exposing IKKα-/-, IKKβ-/- or IKKα/β-/- mouse embryonic fibroblasts to
hypoxia (1% O2) for 2 - 24 hours. The results show no reduction in HIF1α levels following
hypoxia when only one of the kinases is knocked out, however following knockout of both
subunits HIF1α levels are reduced completely [147]. This project has not focussed on
HIF1α expression as a readout and many of the experiments have predominantly focussed
on reoxygenation; this could explain some of the differences observed here. In addition
due to the questions raised regarding the specificity of the IKKα inhibitor used in this
project, one can not draw firm conclusions on what the effects of IKKα inhibition has on
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the response to hypoxia and rapid reoxygenation.
Another study demonstrated that IKKβ plays a critical role in the response to hypoxia
through triggering phosphorylation and degradation of IκBα [343], this degradation was
not observed in data presented in this thesis. In this publication, Cummins et al. demon-
strate that hypoxia leads to an increase in the pool and activity of IKKβ, increasing
the canonical NF-κB pathway’s sensitivity to other stimuli such as TNF. They propose
that hydroxylation and degradation of a fraction of IKKβ occurs during normoxia. In-
hibition of hydroxylation (such as through hypoxia) leads to stabilisation, which leads
to this activation. Cummins et al. used DMOG, a hydroxylase inhibitor, to carry out
the hydroxylation experiments, therefore experiments need to be repeated using hypoxia
rather than DMOG to determine whether this is occurring in hypoxia or reoxygenation.
Although DMOG treatment induces HIF stabilisation, it is not an effective substitute
for hypoxia exposure, as such the observations presented by Cummins et al. could be
artefactual.
One of the more surprising results from this section is the apparent translocation of the
IKK complex subunits into the nucleus following hypoxia. This is reversed following
rapid reoxygenation demonstrating again the differences between the two stimuli. Fol-
lowing quantification of relative band density across multiple independent blots, it was
apparent that the statistical significance of this movement was variable between exper-
iments as observed across figures 56, 58 and 59. This is most likely due to variability
in signal strength between experiments; in some instances very low signal is observed,
making it difficult to capture any quantifiable changes in relative band density. This lack
of reproducibility highlights the need to carry out additional experiments using a differ-
ence technique to determine the cellular location of proteins of interest following hypoxia
and rapid reoxygenation, for example through the use of immunofluorescence microscopy,
which was utilised in some of the key localisation experiments.
Immunofluorescence microscopy was used to validate the findings of the nuclear-cytoplasmic
fractionation experiments, unfortunately due to antibody availability this was only carried
out on IKKβ and NEMO. In the future this experiment could be repeated with IKKα as
a target protein. This microscopy data confirms the movement of NEMO in and out of
the nucleus but shows the opposite pattern of movement of IKKβ. In this instance the
use of a second technique only raised further questions regarding the effects of hypoxia
and rapid reoxygenation on nuclear translocation of members of the IKK complex.
There are many possible reasons for the differences in results between the two techniques,
particularly since NEMO showed consistent results across both techniques while IKKβ
showed opposing results. On such reason could be due to the antibodies used. The IKKβ
antibody used for the western blot was not suitable for use in microscopy and vice versa,
therefore the differences in epitope binding could be affecting the ability of the antibody
to bind to the protein. In contrast, the NEMO antibody was suitable for use across both
techniques so was used for both methods.
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Another caveat is the fact that both of these techniques have to have a significant amount
of sample processing carried out in the anaerobic chamber. It is possible that the lower
oxygen or higher temperature of harvesting samples in this environment, for both cell
fractionation and cell fixing, could affect the data. Indeed the global brightness of the
slides prepared in hypoxia was diminished compared with the slides prepared in normoxia.
It was for this reason that data was analysed automatically and quantitatively, using a
method designed to eradicate any effects of this variation in sample brightness.
The reason for this potential movement of IKK complex members is unknown, however
the pattern of movement of NEMO is consistent with Miyamoto’s papers describing the
serine 85-dependent movement of NEMO into the nucleus following DNA damage where
it interacts with ATM [358][366]. A series of publications have characterised this move-
ment, with the current model describing sumoylation and ubiquitination events on NEMO
that coordinate its sub-cellular localisation [367][368]. The cross-talk between the DNA
damage response pathway and the canonical NF-κB pathway is coordinated by a cyto-
plasmic form of ATM, which is exported from the nucleus in a calcium-dependent manner
in response to genotoxic stress [339]. Once in the cytoplasm it coordinates the activation
of NEMO through phosphorylation on serine 85, which leads to its ubiquitination and
activation. The nuclear localisation of NEMO observed in this study following hypoxia
may indicate a role for ATM in the cellular response to hypoxic stress.
It is notable in this regard that TAK1 has been implicated in the activation of NEMO
by ATM [127][369], and here our fractionation studies link TAK1 with a further IKK
complex member, IKKα (Fig. 59). Although IKKα was not implicated in the ATM-
dependent activation of NEMO in response to genotoxic stress, IKKα has previously
been demonstrated as having a nuclear role as it phosphorylates histone H3 in response
to cytokines [359]. It is possible that hypoxia could be triggering a similar response in
these proteins.
The effects of IKKβ inhibition on gene transcription was also investigated in this section.
Due to lack of reproducibility very little statistically significant data was obtained in these
experiments, therefore further replicates are required before any meaningful conclusions
can be formulated. In addition, alternative approaches could be employed to detect
changes in gene expression such as using luciferase reporter assays. One notable result was
obtained however, treatment with the small molecule inhibitor BMS-345541 drastically
reduced levels of cIAP-2 mRNA following both hypoxia and rapid reoxygenation. This
highlights the differences in the control of expression of different genes in response to a
given stimuli as not all genes have behaved the same way. It should be noted however that
the effects of the inhibitor in the absence of any other stimuli was not tested, therefore it
is possible that this result is due to exposure to BMS-345541 alone.
Also covered in this section is the role of IKKα and IKKβ in cell proliferation and survival
following hypoxia and rapid reoxygenation. The results presented here show that IKKβ
is involved in the response to hypoxia; proliferation of cells decreases following hypoxia.
146
Inhibition of IKKα and IKKβ leads to a further decrease in proliferation following hypoxia,
however due to the questions raised regarding the specificity of the IKKα inhibitor, we can
only confidently say that IKKβ is involved in the continued proliferation of cells following
hypoxia. After reoxygenation for 24 hours an increase in proliferation is seen compared
with hypoxia only treated cells. IKKβ inhibition does not seem to affect proliferation
at this time point, however inhibition alongside a 48 hour reoxygenation exposure leads
to a significant decrease in proliferation highlighting a delayed and anti-apoptotic role
for IKKβ following reoxygenation. Interestingly at longer time points of 2 weeks, colony
formation and survival following reoxygenation is not significantly affected by inhibition
of IKKβ. This could highlight the potential differences between the acute and chronic
effects of reoxygenation on the cell or indeed the different consequences depending on the
length of time that IKKβ is inhibited. It is likely however that the shorter IKKβ inhibitor
exposure utilised in the colony forming assay compared with the proliferation assay could
explain these differences in proliferation and survival. Again, confidence in these findings
is entirely dependent on the specificity of the inhibitors used, as such experiments should
be repeated using alternative means of protein inhibition.
Many of the experiments carried out in this section used small molecule inhibitors to
selectively inhibit proteins of interest. Some benefits of using these over other methods of
inhibition is that it is one of the simplest and cheapest methods of inhibiting a protein.
In addition, many of the small molecule inhibitors available are being tested for, or are
currently in use in patients, as treatments for conditions such as cancer [370]. Specificity
of these kinases inhibitors can be an issue though, as off target effects on other kinases
can be common. Indeed concerns have already been raised in this thesis regarding the
specificity and potential off target effects of the IKKα inhibitor used here (Fig. 52) [348].
The inhibitors used in this thesis were checked for off target effects using the Dundee
Kinase Screen database [371], as well as the information provided in the data sheets when
inhibitors were purchased. Another potential problem associated with small molecule
inhibitors is the half-lives, however the Opera database confirms that the half-lives of
inhibitors used here were far longer than the times that they were used for treatment, the
shortest being 3.14 days [351]. To increase confidence in the efficacy of these inhibitors,
internal validation experiments could be performed in the future, for example dose re-
sponse treatments could be performed measuring the effects on the target protein and
other closely related proteins.
In spite of these precautions that were taken when selecting these small molecule in-
hibitors, it is necessary to repeat the experiments presented here using an alternative
technique for protein inhibition. siRNA knockdown could be used to temporarily inhibit
proteins of interest, although off target effects are possible, it is easy to test that the pro-
tein has been knocked down through western blotting for the target protein. Due to time
constraints it was not possible to carry out siRNA treatments as part of this particular
project, therefore future work should focus on this approach. For longer experiments,
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alternative methods for knocking down a protein should be utilised such as shRNA or
CRISPR as these produce more permanent knockdowns. These are far more time con-
suming and technically challenging however, and do not guarantee effective knockdown or
deletion [372], and in the case of shRNA proteins can be re-expressed over weeks of pas-
sage [373]. As discussed earlier, previous studies have used mouse embryonic fibroblasts
that are null for IKKα, IKKβ or both [147]. These could be utilised in future experiments
to further investigate the role of IKKα and IKKβ, unfortunately these cell lines were not
available to use during this project.
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Chapter 6: The Role of ATR/ATM in NF-κB Activa-
tion after Hypoxia and Rapid Reoxygenation
Data presented so far has demonstrated that hypoxia and reoxygenation lead to activation
of the canonical NF-κB pathway and that IKKβ is required for this activation. The
upstream pathways responsible for this activation of the canonical NF-κB pathway are
currently unknown. This final results chapter therefore aimed to determine the upstream
kinases responsible for detecting and activating the signalling pathways discussed.
Previous work on hypoxia and reoxygenation has implicated the PIKK family members
ATR and ATM in the response to hypoxia and reoxygenation respectively, although not
in the context of NF-κB signalling [374]. The link between ATM and NF-κB pathway
has however been investigated in response to other stresses, previous studies have also
demonstrated that ATM can be activated in response to oxidative stress, but not geno-
toxic stress, in primary human fibroblasts [225]. While unpublished work in the Kenneth
laboratory has implicated ATM in the canonical NF-κB response to hydrogen peroxide
treatment. ATM and ATR could therefore be involved in the canonical NF-κB response
to hypoxia and rapid reoxygenation.
As discussed in the introduction, ATM and ATR are critical responders to genotoxic and
replication stresses respectively, and have key roles in the control of cell cycle progression.
As such, the first part of this chapter aimed to determine whether double strand breaks
or changes in cell cycle dynamics occur during hypoxia and reoxygenation. Indeed, both
hypoxia and reoxygenation have been linked to the DNA damage response and cell cycle
arrest previously [270][271]. These were investigated through flow cytometry analysis of
cells probed for γH2AX and BrDU respectively.
Once the effects of hypoxia and rapid reoxygenation on DNA damage and cell cycle
progression had been investigated, the role of ATM and ATR in the response to hypoxia
and rapid reoxygenation was analysed. This involved a series of experiments using small
molecule inhibitors targeted to proteins of interest followed by analysis of activation of
their downstream targets as well as the canonical NF-κB pathway. These experiments
used western blot analysis on whole protein extracts as well as nuclear and cytoplasmic
extracts to determine the location of proteins of interest in the cell.
After establishing proteins that work upstream of the canonical NF-κB pathway in the
response to hypoxia and rapid reoxygenation, the third and final aim for this chapter
was to determine how ATM and ATR inhibition affects downstream cellular processes
such as the regulation of gene transcription and cell proliferation. Again, small molecule
inhibitors to were used to target ATM and ATR and cells were analysed for changes in
expression of IL-8, cIAP-2 and SOD-2 through real-time qPCR. The effects of ATM and
ATR inhibition on proliferation following hypoxia and reoxygenation was determined by
PrestoBlue assays.
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6.1 DNA Damage Analysis after Hypoxia and Rapid Reoxy-
genation
As discussed in section 1.4, oxidative stress is characterised by an imbalance of ROS, which
are able to cause damage to proteins, lipids and DNA [235][236][237]. Data in the previous
section (Fig. 56 and 57) has shown patterns of NF-κB activation following reoxygenation
that are similar to those seen following genotoxic stress [117][358], particularly regarding
the nuclear and cytoplasmic movement of NEMO [367][368] and the rapid activation of
NF-κB through the canonical pathway in the absence of IκBα degradation [164]. It
is widely known that DNA damage can lead to the activation of the canonical NF-κB
pathway [92][93][94][42]. Determining whether DNA damage occurs following hypoxia
and rapid reoxygenation was therefore critical for understanding the NF-κB response to
hypoxia and rapid reoxygenation-induced oxidative stress.
To determine the effects of hypoxia and rapid reoxygenation on DNA damage, γH2AX
levels were detected using flow cytometry. U-2 OS cells were exposed to hypoxia and
reoxygenation for the times indicated (Fig. 67). Cells were fixed and stained for γH2AX
to assess the presence of DNA double strand breaks. A negative control of IgG stain was
carried out in parallel as well as an etoposide positive control (data not shown). Levels of
γH2AX are similar between the etoposide controls and the 2 and 6 hour hypoxia samples.
Levels of γH2AX signal was measured using flow cytometry and analysed using GraphPad
Prism.
A significant increase in the percentage of cells that stain positive for γH2AX is observed
following 6 hours of exposure to hypoxia (Fig. 67). Interestingly, following 24 hours of
hypoxia the percentage of cells positive for γH2AX staining is the same as in normoxia
only cells. This result indicates that DNA damage occurs in the form of double strand
breaks following hypoxia, however cells are able to repair this damage while still in hypoxic
conditions.
In contrast to the effects seen following exposure to hypoxia, rapid reoxygenation has no
effect on the percentage of cells staining positive for γH2AX (Fig. 67). This indicates
that no further DNA double strand breaks occur following reoxygenation, however it does
not rule out the presence of other forms of DNA damage such as single strand breaks.
The results presented in this section indicate a potential role for DNA damage signalling
in the cellular response to hypoxia. The increase in the proportion of cells staining positive
for γH2AX indicates that double strand DNA breaks are occurring. This could implicate
the PIKK family of proteins in this response, particularly ATM. However other family
members such as ATR and DNA-PK could be implicated as they are also known to
phosphorylate H2AX at the site analysed here in response to replication stress or double
strand breaks respectively [195][271]. Reoxygenation does not seem to cause any increase
in double strand breaks however this does not rule out other forms of DNA damage.
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Figure 67. The Effects of Hypoxia and Rapid Reoxygenation on DNA Damage in U-2 OS
Cells. U-2 OS cells were exposed to 1% O2 for 2 hours, 6 hours or 24 hours. Reoxygenation
was carried out for 2 hours or 6 hours following 24 hours of hypoxia exposure. Cells
were harvested, fixed and stained for γH2AX and data was plotted and analysed using
GraphPad Prism. Negative IgG stain controls and a positive etoposide treated controls
were carried out in parallel (data not shown). Data was analysed using one way anova
accounting for multiple comparisons using Tukey’s test.
6.2 The Effects of Hypoxia and Rapid Reoxygenation on Cell
Cycle Dynamics
The DNA damage sensing kinases ATM, ATR and DNA-PK play critical roles in the cell
cycle, signalling to downstream targets to prevent progression through the cycle while
DNA is repaired [202][203][204][211]. As such cell cycle dynamics are an indicator of
overall cell health and gives insight into the nature of cell damage. In this section the
effect of hypoxia and rapid reoxygenation on the cell cycle of U-2 OS cells was investigated.
U-2 OS cells were exposed to hypoxia or reoxygenated for the times indicated (Fig. 68).
Cells were trypsinised, fixed and stained for BrDU to assess progression through the cell
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cycle using flow cytometry. The percentage of cells in each phase of the cell cycle was
determined and mean results from 4 independent experiments were plotted (Fig. 68).
No significant changes in cell cycle dynamics was observed during hypoxia, however small
trends can be seen across all phases of the cell cycle (Fig. 68). Following rapid reoxy-
genation the percentage of cells in G1 phase significantly decreased towards levels seen in
untreated/normoxia cells (Fig. 68), effectively reversing the effects observed following 24
hours of hypoxia exposure (p = 0.0109). These data suggest that reoxygenation of the
cells has reversed a potential G1/S phase checkpoint block that occurred during hypoxia
in a small proportion of cells. It is clear from the results presented in figure 68 that
hypoxia and rapid reoxygenation have some effects on cell cycle dynamics, however these
are marginal, and in the case of most of the data here, insignificant.
Another method for analysing cell cycle dynamics, proliferation and cell division levels is
though determining the mitotic index of populations of cells. To do this cells were exposed
to hypoxia and reoxygenation for the times (Fig. 69). Cells were fixed and stained with
DAPI to visualise chromatin in the cell under fluorescence microscopy. Multiple images
were taken across different slides and total cell number and mitotic index was determined
using ImageJ. Mitotic index is the percentage of cells undergoing mitosis per image.
The results of the mitotic index analysis show that there are some small changes in the
mean proportion of cells undergoing mitosis during hypoxia and rapid reoxygenation (Fig.
69). Following hypoxia, the percentage of cells undergoing mitosis increases up to 24 hours
of hypoxia however this data is not significant. Following reoxygenation the levels of cells
undergoing mitosis decrease significantly (p = 0.0176). This suggests that a G2/M phase
block could be occurring during reoxygenation as fewer cells enter mitosis.
Changes in cell cycle dynamics following reoxygenation could be due to a number of
factors. A decrease in G1 phase cells could indicate that more cells are entering S-
phase, in the context of reoxygenation this could be due to the sudden increase in aerobic
respiration allowing cells to produce components required for S-phase.
6.3 A Role for ATM in the Canonical NF-κB Pathway Response
to Hypoxia and Rapid Reoxygenation
Work presented earlier in this section has demonstrated that hypoxia leads to a significant
increase in γH2AX levels, indicating that hypoxia causes double strand DNA breaks,
implicating ATM in the cellular response to hypoxia [375]. Other studies have shown
that ATM activation in response to genotoxic stress leads to the repression of NF-κB
target genes [374]. This is similar to what is observed in the response to hypoxia in
experiments presented in this project; 6 hours of hypoxia exposure leads to the repression
of transcription of IL-8, cIAP-2 and SOD-2. In addition to these findings, unpublished
work in the Kenneth laboratory has implicated ATM in the canonical NF-κB response to
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Figure 68. The Effects of Hypoxia and Rapid Reoxygenation on The Cell Cycle. U-2 OS
cells were exposed to 1% O2 for the times indicated. Reoxygenated samples were exposed
to 1% O2 for 24 hours before reoxygenation using spent media for 3 hours or 6 hours. Cells
were trypsinised, fixed and stained for BrDU before analysis by flow cytometry. Results
show that hypoxia and rapid reoxygenation have effects on cell cycle progression. Data
was analysed using one-way ANOVA accounting for multiple comparisons using Tukey’s
test.
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Figure 69. The Effects of Hypoxia and Rapid Reoxygenation on Mitotic Index. U-2 OS
cells were exposed to 1% O2 for the times indicated. Reoxygenated samples were exposed
to 1% O2 for 24 hours before reoxygenation using spent media for 3 hours or 6 hours. Cells
were fixed and stained with DAPI before analysis using immunofluorescence microscopy.
10x zoom images were taken across 3 wells per treatment. One-way ANOVA statistical
tests were performed using Tukey’s test for multiple comparisons (n = 3).
hydrogen peroxide treatment. It is therefore plausible that ATM is involved in the NF-κB
response to hypoxia and rapid reoxygenation.
Figure 27 (section 4.1) demonstrated that hydrogen peroxide treatment leads to canoni-
cal NF-κB activation, this experiment was also carried out in the presence of the ATM
inhibitor, KU-55399 [376] (Fig. 70). KU-55933 is a selective and competitive ATM in-
hibitor, it has over 160-fold greater specificity to ATM than its nearest off target kinase,
DNA-PK [377] and has been used successfully in multiple publications [378][379]. KU-
55933 has a predicted half life of 4.41 days [351], it is therefore a suitable inhibitor for use
in this project. Cells were treated with 20µM of hydrogen peroxide for the times indicated
with or without a 30 minute pretreatment with 5µM of KU-55399. This dose was again
selected based on personal communication with colleagues who have used this inhibitor
on this cell line previously. Whole cell lysates were extracted and analysed as described
in figure 27.
Data presented in figure 70 demonstrates that the activation of the canonical NF-κB
pathway is unchanged following inhibition of ATM using the small molecule inhibitor
KU-55399 (Fig. 70). This result is surprising as unpublished data (Kenneth lab) has
implicated ATM as the upstream kinase responsible for the activation of the NF-κB
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Figure 70. Hydrogen Peroxide Treatment leads to Canonical NF-κB Activation in U-
2 OS Cells Independently of ATM. Cells were treated with 20µM of H2O2 for between
30 minutes and 7 hours, with or without pretreatment with the ATM inhibitor KU-
55399. Whole cell lysates were extracted using 8M urea lysis buffer and western blots were
performed looking at phosphorylation events associated with canonical NF-κB activation.
A - Representative blot across 3 independent experiments. B-C - Mean relative density,
analysed by one-way ANOVA using Sidak’s test for multiple comparisons.
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pathway in response to hydrogen peroxide in HEK293 cells. The small molecule inhibitor
was again tested on etoposide treated cells and was shown to be working as expected
(data not shown), therefore the results presented here demonstrate clearly that ATM is
not involved in the canonical NF-κB pathway response to hydrogen peroxide treatment
in U-2 OS cells. It was therefore important to determine whether ATM is activated in
response to hydrogen peroxide treatment in this cell line. To test for this, extracts used
in figure 70 were re-run and probed for markers of ATM and ATR activation.
A significant increase in Kap1, ATR and Chk1 is observed following hydrogen peroxide
treatment (Fig. 71). The increase in Kap1 and Chk2 phosphorylation is indicative of
ATM activation in response to double strand breaks, where ATM is phosphorylated and
in turn phosphorylates Kap1 and Chk2. The increase in phosphorylation of ATR and its
downstream target Chk1 suggests that the DNA damage that is occurring that cannot
be solely resolved by ATM activation alone, possibly due to the presence of other forms
of DNA damage such as single strand breaks. Previous studies have shown that ATR is
responsible for phosphorylation of H2AX in the response to oxidative stress induced by
hydrogen peroxide treatment [193]. This could be one of the cell signalling mechanisms
that is occurring here. These data indicate that both genotoxic and oxidative stress is
occurring following treatment with hydrogen peroxide, and both ATR and ATM appear
to be activated in this response.
Focussing next on the effect of inhibition of ATM; KU-55399 treatment has no significant
effect on Kap1, ATR or Chk1 activation following hydrogen peroxide treatment (Fig. 71).
However Chk2 phosphorylation is significantly reduced following this inhibition of ATM,
thus indicating that the inhibitor is effective. As Kap1 is a downstream target of ATM it
was expected that inhibition of ATM would also prevent phosphorylation at this site. It
is possible however that phosphorylation of Kap1 in this context is dependent on another
kinase, indeed previous studies have suggested that ATR and DNA-PK are also able to
phosphorylate Kap1 at this site [380]. Chk2 is responsible for the coordination of cell
cycle arrest in response to genotoxic stress sensed by ATM; ATM therefore appears to
control cell cycle arrest in response to hydrogen peroxide treatment.
Experiments that have focussed on the effects of hydrogen peroxide treatment on NF-κB
and PIKK signalling have demonstrated that ATM coordinates downstream signalling
to Chk2 (Fig. 71). To determine whether ATM is implicated in the cellular response
to hypoxia and rapid reoxygenation, U-2 OS cells were exposed to hypoxia and rapid
reoxygenation for the times indicated (Fig. 72). Total protein lysates were extracted and
analysed as before (Fig. 71), probing for phosphorylation events associated with ATM
activation.
Following exposure to hypoxia no significant changes in phosphorylation are observed
across all proteins analysed (Fig. 72), indicating that ATM is not activated in the response
to hypoxia. Following reoxygenation an increase in phosphorylation of Chk2 and ATM
occurs, however quantification of these blots shows that the only significant increase that
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Figure 71. Hydrogen Peroxide Treatment leads to the Activation of PIKK Family Mem-
bers in U-2 OS Cells. Cells were treated with 20µM of H2O2 for between 30 minutes and 3
hours. Whole cell lysates were extracted using 8M urea lysis buffer and western blots were
performed looking at phosphorylation events associated with DNA damage responses. A
- Representative blot across 3 independent experiments. B-E - Mean relative density,
analysed by one-way ANOVA using Sidak’s test for multiple comparisons.
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Figure 72. Rapid Reoxygenation leads to ATM Phosphorylation in U-2 OS Cells. Cells
were exposed to hypoxia (1% O2) for between 30 minutes and 24 hours, or reoxygenated
(21% O2) after 24 hours in hypoxia for between 30 minutes and 7 hours. Western blots
were carried out probing for phsophorylation of ATM and its downstream targets Kap1
and Chk2. A 30 minute 25µM etoposide treatment was run as well as a positive control. A
- Representative blot of 3 independent experiments. B-D - Relative band density (n = 3)
presented as mean, statistical analyses were carried out using one-way ANOVA (Sidak’s
test).
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occurs concerns ATM phosphorylation. These data implicates ATM in the response of
cells to reoxygenation but not hypoxia.
In contrast to the previous blot that showed the response of these proteins to hydrogen
peroxide treatment (Fig. 71), no genotoxic stress is induced in the response to hypoxia
and reoxygenation as measured by phosphorylation of Kap1. Here we observe activation
of ATM in the absence of genotoxic stress, indicating that oxidative stress alone is causing
this response [225]. Together with the γH2AX data (Fig. 67) this indicates that DNA
damage does not occur following reoxygenation, and suggests that the activation of H2AX
during hypoxia as shown in figure 67 is a result of ATR responding to single strand breaks
as described previously [193].
To determine whether ATM acts as an upstream kinase in the NF-κB response to rapid
reoxygenation, experiments were carried out using the small molecule inhibitor of ATM;
KU-55933 [376] (Fig. 73). This is a direct repeat of the experiment presented earlier (Fig.
52), albeit using a different inhibitor that targets ATM rather than IKKα.
Following rapid reoxygenation phosphorylation of all protein markers of canonical NF-
κB pathway activation occurs, however in this set of experiments this is only significant
with regard to IκBα phosphorylation (Fig. 73). Treatment with the small molecule
inhibitor of ATM, KU-55933, has no significant effect on the levels of phosphorylation of
the proteins analysed here. This demonstrates that activation of the canonical NF-κB
pathway following reoxygenation is not dependent on ATM based on the assumption that
this inhibitor is working as anticipated.
Earlier studies have implicated ATM in the response to reoxygenation [226], therefore
the results observed in figure 73 were unexpected. Of course, one explanation for this
discrepancy is that the data presented in this thesis was carried out using a modified
reoxygenation protocol. Regardless, to confirm that the results presented here are not
due to an ineffective inhibitor, experiments were designed to confirm that KU-55933 was
functioning as expected. It is well established that ATM is involved in the response to
etoposide-induced genotoxic stress through DNA damage response signalling and through
the canonical NF-κB pathway. An etoposide treatment time course was therefore carried
out with and without inhibition of ATM using KU-55933. Western blots were carried out
on whole cell lysates, probing for markers of canonical NF-κB activation or the ATM-
controlled DNA damage response.
The results of this experiment shows that etoposide treatment leads to significant phos-
phorylation of all members of the canonical NF-κB members analysed here (Fig. 74),
demonstrating clearly that this pathway is activated in response to etoposide. Inhibition
of ATM using KU-55933 significantly attenuates this activation in the case of IKKα/β
and RelA phosphorylation. An insignificant decrease in IκBα phosphorylation is also ob-
served. Treatment with the ATM inhibitor blocks signalling through the canonical NF-κB
pathway in response to etoposide treatment.
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Figure 73. ATM Inhibition does not affect Canonical NF-κB Activation following Rapid
Reoxygenation in U-2 OS Cells. U-2 OS cells were exposed to 1% O2 for 24 hours prior to
rapid reoxygenation for the times indicated, with or without treatment with 5µM of the
inhibitor of ATM, KU-55933. Whole cell extracts were harvested using urea lysis buffer
with added protease inhibitors and western blots were performed probing for proteins and
phosphorylation events associated with canonical NF-κB activation. A - Representative
blot of 3 independent experiments. B-D - Relative band density (n = 3) presented as
mean, statistical analyses were carried out using one-way ANOVA (Sidak’s test).
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Figure 74. ATM Inhibition blocks Canonical NF-κB Activation and the DNA Damage
Response following Etoposide Treatment in U-2 OS Cells. U-2 OS cells were treated with
25µM etoposide for the times indicated, with or without treatment with 5µM KU-55933.
Whole cell extracts were harvested using urea lysis buffer with added protease inhibitors
and western blots were performed probing for phosphorylation events associated with
canonical NF-κB activation (A) or ATM activation (B). A-B - Representative blot of
3 independent experiments. C-H - Relative band density (n = 3) presented as mean,
statistical analyses were carried out using one-way ANOVA (Sidak’s test).
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A significant increase in phosphorylation of all markers of ATM activation also occurs
following treatment with etoposide (Fig. 74), demonstrating that etoposide treatment is
causing genotoxic stress as expected. In addition to this, inhibition of ATM using KU-
55933 significantly blocks this activation of ATM and its downstream targets. Together
the data presented in figure 74 demonstrate that the ATM inhibitor is functioning correctly
as it blocks signalling through these two well-established signalling pathways.
6.4 A Role for ATR in the Canonical NF-κB Pathway Response
to Hypoxia and Rapid Reoxygenation
Another PIKK family member, ATR, has also been implicated in the response to hypoxia
and reoxygenation [226][381]. These studies demonstrated that ATR is able to phospho-
rylate H2AX in the response to hypoxia-induced DNA damage [226], while others have
demonstrated that this process can occur following hydrogen peroxide treatment in the
absence of double-strand breaks [193]. Data presented in the previous section has shown
that ATR is phosphorylated in response to hydrogen peroxide treatment. The results of
the γH2AX stain indicate that no double strand breaks occur following reoxygenation,
however ATR responds to single strand breaks and is able to phosphorylate H2AX in
response to these [193].
This section therefore aimed to determine whether ATR could have a role in the NF-
κB response to hypoxia and rapid reoxygenation. The following experiment was carried
out as described earlier (Fig. 39), however blots were probed for phosphorylation events
associated with ATR activation; the auto-phosphorylation sites on both ATR and its
downstream kinase Chk1.
No significant increase in activation is observed following hypoxia, however significant
auto-phosphorylation of both ATR and Chk1 occurs following reoxygenation (Fig. 75).
This demonstrates that ATR is activated in the response to reoxygenation, it then most
likely phosphorylates and activates Chk1, potentially to control progression through the
cell cycle. Of course the increase in Chk1 activation could be due to phosphorylation
from a second upstream kinase. The phosphorylation site analysed here is an auto-
phosphorylation site that Chk1 auto-phosphorylates following a seperate phosphorylation
from an upstream kinase at independent sites. Chk1 is phosphorylated by the active ATR
on serines 317 and 345 prior to coordinating its autophosphorylation of serine 298 [382].
The results presented in figure 75 implicate ATR as an important protein in the cellu-
lar response to rapid reoxygenation-induced oxidative stress. To determine whether this
activation of ATR is linked to the activation of the canonical NF-κB pathway experi-
ments were carried out using the widely-used small molecular inhibitor of ATR, VE-821
[383][384]. VE-821 is a potent ATP-competitive inhibitor of ATR and has a half life of
3.17 days [351]. According to the data sheet provided, it has minimal off-target effects on
other closely related PIKKs and against other kinases tested [385].
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Figure 75. ATR and Chk1 are Activated following Rapid Reoxygenation in U-2 OS Cells.
U-2 OS cells were exposed to 1% O2 for the times indicated. Reoxygenated samples were
exposed to hypoxia for 24 hours prior to rapid reoxygenation. Cells were lysed using urea
lysis buffer with added protease inhibitors and western blots were performed probing for
activation of ATR and Chk1. 1 hour of etoposide treatment was used as a positive control.
A - Representative blot of 3 independent experiments. B-C - Relative band density (n =
3) presented as mean, statistical analyses were carried out using one-way ANOVA (Sidak’s
test).
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This is a direct repeat of the experiments presented earlier (Fig. 52 and 73), however
cells were targeted for ATR inhibition using 10µM of the competitive inhibitor VE-821
[386]. Timings and doses were again determined through personal communication with
colleagues that commonly use this inhibitor on U-2 OS cells.
As determined previously, rapid reoxygenation leads to the activation of the canonical NF-
κB pathway as measured by phosphorylation of IκBα and RelA; in this set of experiments
this is only statistically significant in the case of IκBα (Fig. 76). Treatment with the
ATR inhibitor reduces this activation across all time points measured for both proteins,
however relative band density analysis has revealed that this difference is significant with
regard to IκBα but not RelA. As perhaps the most reliable read-out of canonical NF-
κB activation presented in this thesis, this significant decrease in phospho-IκBα levels
suggests that ATR is involved in the canonical NF-κB response to reoxygenation.
Since ATR has been shown to have a role upstream of the canonical NF-κB pathway in
response to reoxygenation the role of its downstream target Chk1 was investigated. Data
presented in this thesis has already demonstrated that Chk1 is activated in the response
to reoxygenation (Fig. 75), however whether this has a direct role in the activation of the
canonical NF-κB pathway is unknown. To investigate the role of Chk1 in the response
to rapid reoxygenation the previous experiments (Fig. 52, 73 and 76) were repeated for
the 15 minutes and 1 hour time points using a Chk1 inhibitor; CCT245737 [387]. This
inhibitor has over 1,000-fold selectivity over Chk2 and CDK1 [388], the predicted half life
of this inhibitor is 2.86 hours [387], although shorter than the other inhibitors used, this
is still longer than the time points used in this experiment.
Cells targeted for Chk1 inhibition were pretreated with 5µM of the ATP-competitive Chk1
inhibitor for 30 minutes prior to rapid reoxygenation (dosing and timings determined by
personal communication). Since the upstream kinases, ATR and ATM, have been impli-
cated in this response, they were targeted with small molecule inhibitors (10µM of VE-821
and 5µM KU-55399 respectively), allowing for direct comparisons of effects. Western blots
were probed for markers of PIKK pathway activation and markers of canonical NF-κB
pathway activation.
Although earlier figures showed a significant increase in ATM, ATR and Chk1 phospho-
rylation following reoxygenation (Fig. 72 and 75), only Chk1 phosphorylation shows a
significant increase in phosphorylation in figure 77. These discrepancies are most likely
due to variability in the quality of the western blots, either due to problems associated
with the antibodies or due to technical issues.
The effects of inhibition of either Chk1, ATR or ATM are predominantly insignificant re-
garding the activation of the PIKK pathway members. The exception to this is observed
in figure 77E, where treatment with the Chk1 inhibitor significantly reduces autophos-
phorylation and activation of Chk1.
As established previously, activation of the canonical NF-κB pathway occurs following
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Figure 76. The Effect of ATR Inhibition on Canonical NF-κB Activation following Rapid
Reoxygenation in U-2 OS Cells. U-2 OS cells were exposed to 1% O2 for 24 hours prior
to rapid reoxygenation for the times indicated, with or without treatment with 10µM of
the small molecule inhibitor of ATR, VE-821. Whole cell extracts were harvested using
urea lysis buffer with added protease inhibitors and western blots were performed probing
for proteins and phosphorylation events associated with canonical NF-κB activation. A -
Representative blot of 3 independent experiments. B-C - Mean relative band density (n
= 3), statistical analyses were carried out using one-way ANOVA (Sidak’s test).
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Figure 77. The Effects of Inhibition of Chk1, ATR and ATM on PIKK Signalling and
NF-κB Activation following Rapid Reoxygenation in U-2 OS Cells. U-2 OS cells were
exposed to hypoxia for 24 hours prior to rapid reoxygenation, with or without treatment
with inhibitors of Chk1 (5µM), ATR (10µM) or ATM (5µM). Whole cell extracts were
harvested using urea lysis buffer with added protease inhibitors and western blots were
performed probing for phosphorylation events associated with PIKK or canonical NF-
κB activation. A-B - Representative blot of 3 independent experiments. C-H - Relative
density (n = 3), statistical analyses were carried out using one-way ANOVA (Sidak’s test).
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reoxygenation, as observed by a significant increase in IκBα phosphorylation (Fig. 77G).
No significant change in IKKα/β or RelA phosphorylation is observed, in spite of the
increase in the mean relative density of the latter. As shown previously, treatment with the
ATM inhibitor has no effect on canonical NF-κB signalling, while treatment with the ATR
inhibitor causes a significant decrease in activation as measured by IκBα phosphorylation
(Fig. 77G). This confirms earlier findings that ATR, and not ATM, acts upstream of the
canonical NF-κB pathway in response to reoxygenation.
Interestingly, treatment with the Chk1 inhibitor leads to a significant increase in IκBα
phosphorylation following reoxygenation (Fig. 77G). This is indicative of a feedback loop
where the cell tries to compensate for the loss of active Chk1. Perhaps in this case a
cell cycle response fails, triggering further activation of ATR and a stronger canonical
NF-κB pathway response. Further investigations should be carried out to investigate this
hypothesis.
6.5 Localisation of ATM and ATR following Hypoxia and Re-
oxygenation
To assess the cellular location of ATR and ATM following hypoxia and rapid reoxygena-
tion, the experiment presented in figure 56 was repeated. This time however membranes
were probed for total ATR and total ATM. The data presented in figure 78 shows no
significant changes in cellular localisation of ATR or ATM, or phosphorylation of ATR
based on sub-cellular location.
Although not significant, an increase in cytoplasmic ATR and ATM is observed reoxy-
genation. Further experiments should be carried out using alternative techniques to de-
termine whether this is truly occurring. As discussed earlier this method of determining
sub-cellular location of proteins of interest has a high degree of variability between re-
peats, and therefore future work should be carried out to supplement these experiments.
6.6 NF-κB Controlled Gene Transcription After Hypoxia and
Rapid Reoxygenation is Affected by Inhibition of Upstream
Components
The previous section has explored the roles of ATM and ATR as upstream kinases in the
NF-κB response to rapid reoxygenation, highlighting ATR as the main kinase responsible
for the transduction of signal downstream through the canonical NF-κB pathway. The
effects of ATM or ATR inhibition on gene transcription following hypoxia or reoxygenation
is currently unknown. However, data presented in sections 6.3 and 6.4 suggest that ATM
inhibition will have no effect, while ATR inhibition will.
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Figure 78. The Effects of Hypoxia and Rapid Reoxygenation on Sub-cellular Location of
ATR and ATM. U-2 OS cells were exposed to 1% O2 for the indicated times. Reoxygenated
samples were exposed to 1% O2 for 24 hours prior to rapid reoxygenation. Nuclear and
cytoplasmic proteins were extracted and analysed by western blot probing for ATR and
ATM. A - Representative blot of 3 independent experiments. B-D - Relative density (n
= 3), statistical analyses were carried out using one-way ANOVA (Sidak’s test).
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Figure 79. Treatment of U-2 OS cells with the ATM Inhibitor KU-55399 Does Not Affect
Gene Expression following Hypoxia and Rapid Reoxygenation. U-2 OS cells were exposed
to 1% O2 for 6 hours. Reoxygenated samples were exposed to 1% O2 for 24 hours prior to
rapid reoxygenation. Total RNA was extracted, reverse transcription was performed and
cDNA was analysed (A B = IL-8, C D = cIAP-2, E F = SOD-2) by qPCR using RPL13A
as a reference gene. The ∆ ∆ Ct method of analysis was used, normalising hypoxia
samples to normoxia samples and reoxygenated samples to 24 hour hypoxia samples.
Statistical analysis was carried out using one-way ANOVA (Tukey’s test).
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Figure 80. Treatment of U-2 OS cells with the ATR Inhibitor VE-821 affects Gene Ex-
pression following Hypoxia and Rapid Reoxygenation. U-2 OS cells were exposed to 1%
O2 for 6 hours. Reoxygenated samples were exposed to 1% O2 for 24 hours prior to
rapid reoxygenation. Total RNA was extracted, reverse transcription was performed and
cDNA was analysed by qPCR using RPL13A as a reference gene. The ∆ ∆ Ct method of
analysis was used, normalising hypoxia samples to normoxia samples and reoxygenated
samples to 24 hour hypoxia samples. Statistical analysis was carried out using one-way
ANOVA using Tukey’s test for multiple comparisons.
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The following experiments aimed to determine whether treatment of cells with small
molecule inhibitors of ATM or ATR affects transcription of NF-κB target genes, IL-8,
c-IAP-2 or SOD-2, following both hypoxia and rapid reoxygenation. Experiments were
carried out as described earlier (Fig. 60), using 5µM of KU-55399 to inhibit ATM.
As seen previously, expression of IL-8 and cIAP-2 significantly decreases following expo-
sure to hypoxia for 6 hours (p <0.0001) and increases following reoxygenation (Fig. 79).
Changes in SOD-2 expression are also observed as before but the 3 experiments presented
here do not give significant results. As expected, inhibition of ATM using KU-55399 has
no significant effect on the expression of any of these genes. Indicating that ATM is not
directly involved in the activation of the canonical NF-κB pathway following hypoxia and
rapid reoxygenation.
To assess the role of ATR in the response to hypoxia and reoxygenation cells were pre-
treated with 10µM of VE-821 as described in previous experiments (Fig. 76). In this set
of experiments, expression of IL-8, cIAP-2 and SOD-2 decreases following hypoxia and in-
creases following reoxygenation (Fig. 80) as observed in experiments presented in section
4.7. In this set of experiments however, the only significant changes in gene expression
concern IL-8 following hypoxia. Indeed, inhibition of ATR has no significant effect on the
expression of any of these target genes, however during hypoxia time points it appears to
consistently prevent repression of these genes. Further repeats of the experiment would
increase the experimental power and perhaps increase confidence in the data set.
The results presented in this section have demonstrated that ATR could play a role in the
control of NF-κB gene expression following exposure to hypoxia, however further repeats
should be carried out before any firm conclusions can be made. As expected, inhibition of
ATM has no effect on the expression of IL-8, cIAP-2 and SOD-2. This is concordant with
previous work that indicates that although is is activated in response to reoxygenation,
it does not appear to play a role in the activation of the canonical NF-κB pathway.
6.7 The Role for ATM and ATR in Cell Proliferation after Hy-
poxia and Rapid Reoxygenation
Data presented in chapters 1 and 2 demonstrated that both hypoxia and rapid reoxygena-
tion lead to significant changes in proliferation of U-2 OS cells, and that both IKKα and
IKKβ are involved in this response. Exposure to hypoxia leads to a decrease in prolifer-
ation, while reoxygenation leads to an increase in proliferation after 24 hours but levels
decrease again following 48 hours. Inhibition of IKKα or IKKβ has shown to decrease
proliferation further following hypoxia and following 48 hours of reoxygenation.
This section aimed to further analyse the changes in proliferation following hypoxia and
reoxygenation through inhibition of other proteins investigated in this project; ATM and
ATR. As demonstrated earlier in this thesis, these upstream kinases have been implicated
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Figure 81. Schematic of Hypoxia and Rapid Reoxygenation Time Course for Proliferation
Assays. U-2 OS cells were plated out at 2,500 cells per well in 96-well plates on day zero
and incubated in normoxic conditions for at least 24 hours. Plates were then moved to
and from the anaerobic chamber as the schematic demonstrates over the course of 4 days.
For example the 24 hour reoxygenation plates were moved into 1% O2 on day 2, 48 hours
after plating out, and returned to 21% O2 after 24 hours for a further 24 hours before
reading proliferation by PrestoBlue. Inhibition of proteins in selected wells was carried
out, these were treated either 24 hours or 48 hours prior to harvesting and throughout
the remainder of the experiment. For example a selection of the normoxia only cells were
treated for 24 hours prior to analysis, while another set were treated for 48 hours prior to
analysis.
in the response to hypoxia and rapid reoxygenation, but only the latter appears to be
involved in the canonical NF-κB pathway response to these stresses.
The time courses carried out in this section followed the same treatment times and expo-
sure to changes in gas levels as described in chapter 5, except this time cells were treated
with ATM or ATR inhibitors (Fig. 81). As before, to determine the effects of these in-
hibitors on otherwise untreated cells, normoxia only cells were dosed with inhibitors for 24
or 48 hours. Treatment of normoxia only cells with 5µM of the ATM inhibitor KU-55399
alone does not affect proliferation of U-2 OS cells to a significant level (Fig. 82).
As observed in previous experiments, hypoxia exposure leads to a decrease in proliferation
of U-2 OS cells (Fig. 83). Treatment of cells with the ATM inhibitor KU-55399 caused
a significant decrease in proliferation following 24 hours hypoxia. Since no significant
effect is observed in inhibitor only treated cells (Fig. 82) we can conclude that this is
due to the additive effects of hypoxia exposure and the presence of the inhibitor. No
significant difference in proliferation is observed following ATM inhibition following 48
hours of hypoxia exposure. This indicates that ATM could be involved in the response to
hypoxia in the first 24 hours of exposure.
Previous experiments presented here have shown that rapid reoxygenation has a signifi-
cant effect on proliferation (Fig. 83). The data presented in figure 83 however show no
significant changes in proliferation following reoxygenation. In addition, ATM inhibition
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Figure 82. The Effects of KU-55933 Treatment on Proliferation of U-2 OS Cells. U-2 OS
cells were treated with 5µM of a small molecular inhibitor to ATM, KU-55933, in normoxic
conditions for 24 or 48 hours to assess the effects of this inhibitor on proliferation in the
absence of other stimuli. Proliferation was analysed using PrestoBlue. Graphs were
plotted using GraphPad prism and two-way ANOVA analyses were carried out using
Tukey’s test to account for multiple comparisons.
has no significant effect on proliferation following reoxygenation (Fig. 83). Overall the
data presented in figure 83 indicate a role for ATM in the control of proliferation in the
first 24 hours of hypoxia exposure but not during reoxygenation.
Since ATR has been shown to be involved upstream of the canonical NF-κB in response
to reoxygenation (Fig. 76), its role in control of proliferation was analysed in the same
manner. Previous work has shown that ATR’s downstream target Chk1 is activated in
the response to rapid reoxygenation, presumably to control cell cycle progression.
Again, initial experiments aimed to determine the effects of the inhibitor of ATR, VE-
821, on proliferation of cells in the absence of other stimuli. Here, normoxia only cells
were treated with 10µM of the ATR inhibitor VE-821 for 24 or 48 hours (Fig. 84). A
significant reduction in proliferation is observed following 24 hours (25%) and 48 hours
(50%) of VE-821 treatment. These results demonstrate that even in the absence of other
stimuli, dosing of cells with the ATR inhibitor leads to a reduction in proliferation. It is
important to note that this effect of ATR inhibition in the absence of other stimuli could
be having an effect on proliferation due to mild oxidative and replicative stress induced
as the cells grow at 21% O2. This level of oxygen is far higher than levels observed in vivo
therefore cells are more likely to obtain oxidative damage even in the absence of other
stimuli.
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Figure 83. The Effects of Hypoxia and Rapid Reoxygenation on Proliferation of U-2
OS Cells Following ATM Inhibition. U-2 OS cells were treated as described in figure
61, however a subset of cells were treated with 5µM of a small molecular inhibitor to
ATM, KU-55399, prior to final exposure to hypoxia and rapid reoxygenation and for the
remainder of the time course. Proliferation was analysed using PrestoBlue after 1 hour.
Graphs were plotted using GraphPad prism to determine the effect of hypoxia exposure
on cells compared with normoxia only cells, and to compare the effects of reoxygenation
on cells compared with cells exposed to hypoxia for 24 hours. Two-way ANOVA analyses
were carried out using Tukey’s test to account for multiple comparisons.
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Figure 84. The Effects of VE-821 Treatment on Proliferation of U-2 OS Cells. U-2 OS
cells were treated with 10µM of a small molecular inhibitor to ATR, VE-821, in normoxic
conditions for 24 or 48 hours to assess the effects of this inhibitor on proliferation in
the absence of other stimuli. Proliferation was analysed using PrestoBlue. Graphs were
plotted using GraphPad prism and two-way ANOVA analyses were carried out using
Tukey’s test to account for multiple comparisons.
As seen before, following exposure to hypoxia proliferation of cells decreases (Fig. 85).
Treatment with the small molecule inhibitor of ATR, VE-821, leads to a significant de-
crease in this proliferation. This could predominantly be due to the fact that inhibitor
treatment in the absence of other stimuli leads to a decrease in proliferation, however the
effect is larger in hypoxic conditions. This indicates that ATR plays a role in the control
of proliferation of cells following hypoxia exposure.
Reoxygenation does not have as profound an effect as observed in other experiments (Fig.
50), however it is still possible to determine the effects of ATR inhibition on proliferation
in these samples. Although data presented in figure 85 shows that treatment with VE-821
significantly decreases proliferation following reoxygenation, this decrease in proliferation
following treatment is very similar to that observed when normoxia only cells are treated
with the inhibitor. It is therefore impossible to say with confidence that ATR plays a role
in proliferation of cells following reoxygenation.
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Figure 85. The Effects of Hypoxia and Rapid Reoxygenation on Proliferation of U-2
OS Cells Following ATR Inhibition. U-2 OS cells were treated as described in figure
61, however a subset of cells were treated with 10µM of a small molecular inhibitor to
ATR, VE-821, prior to final exposure to hypoxia and rapid reoxygenation and for the
remainder of the time course. Proliferation was analysed using PrestoBlue after 1 hour.
Graphs were plotted using GraphPad prism to determine the effect of hypoxia exposure
on cells compared with normoxia only cells, and to compare the effects of reoxygenation
on cells compared with cells exposed to hypoxia for 24 hours. Two-way ANOVA analyses
were carried out using Tukey’s test to account for multiple comparisons.
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6.8 Summary and Brief Discussion of Chapter 6
The results presented in this chapter demonstrate that both ATM and ATR are activated
in the response to reoxygenation-induced stress, however this data only highlights a role
for ATR in the canonical NF-κB response to this stress. The exact mechanism behind
this activation and the complex upstream signalling pathway that links ATR activation
to IKKβ activation remains unclear. Future research could aim to establish the precise
kinetics behind this response.
The data presented in the first part of this chapter indicates that double strand breaks
occur after exposure to hypoxia based on increased γH2AX levels. This damage appears
to be repaired during hypoxia and is not present in reoxygenated samples. This im-
plicates ATM in the response to hypoxia as ATM is one of the main sensors of double
strand DNA breaks and coordinates the repair of this damage, usually through homo-
logus recombination [159]. However studies have also shown that ATR [193] is able to
phosphorylate H2AX at this serine 139 in response to single strand breaks, indicating
that replication stress could be the reason for H2AX phosphorylation after hypoxia. This
also could explain how the cell is able to overcome this damage so rapidly and within a
hypoxic environment. The data presented here contradict previous findings that suggest
that reoxygenation, not hypoxia leads to DNA damage [389][270], however 0.01-0.02% O2
was used in their studies. This data is however concurrent with the findings of Pires et al.,
who suggest that replication stress and stalled replication forks during hypoxia is caused
by depletion in nucleotide levels [271].
The technique used here to detect γH2AX only indicates the proportion of cells that stain
positive for γH2AX, it does not show the number of foci therefore we cannot determine
the quantity of double strand breaks that have occurred (Fig. 67) [390]. To analyse this
immunofluorescence microscopy could be carried out, however due to the low fluorescence
signal that results from fixing cells in hypoxia would have made quantification and re-
producibility difficult. Foci were markedly less visible in hypoxia samples therefore the
results would not be valid as any foci present would be harder to detect both manually
and automatically. This observation of a decreased signal from hypoxia-fixed samples
could be due to low oxygen levels affecting how formaldehyde works as a fixative.
The data generated in this chapter indicate that hypoxia and reoxygenation do not sig-
nificantly affect cell cycle progression with the exception of reoxygenation, which leads
to a decrease in G1-phase cells as well as a decrease in mitotic cells. This indicates that
some minor shifts in cell cycle dynamics occurs, indeed the overall trend of the data in-
dicates that a G1-S arrest is reversed following reoxygenation in a small population of
cells. Proliferation assays revealed that inhibition of ATR leads to a small decrease in
proliferation following hypoxia and reoxygenation (Fig. 85), although some of this effect
is due to the inhibitor alone (Fig. 84). Following on from this, ATR inhibition prevented
the decrease in SOD2 expression seen following hypoxia (Fig, 80). Although speculative
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at this stage, together this data implicates ATR in the control of cell proliferation and
metabolism following exposure to hypoxia.
This section has highlighted the difference in the kinetics of NF-κB pathway activation
in response to hydrogen peroxide, reoxygenation and etoposide treatments. Phosphoryla-
tion of ATM is observed across all treatments, however phosphorylation of Kap1 reveals
that DNA damage only occurs following hydrogen peroxide and etoposide treatments.
Following inhibition of ATM, Kap1 phosphorylation is only blocked in the context of
etoposide treatment. This perhaps highlights alternate roles for ATM across these three
stimuli. Activated ATM only transduces signal through the canonical NF-κB pathway
following etoposide treatment, indicating that although genotoxic stress occurs following
both hydrogen peroxide and etoposide treatment, the former activates NF-κB through a
different mechanism. This mechanism was not established as part of this project, however
one hypothesis is that it follows a similar activation pathway to that of reoxygenation. In
this context the activation of the canonical NF-κB pathway is dependent on ATR.
Again, the validity of these experiments that aimed to investigate the role of ATM and
ATR in NF-κB activation following hypoxia and reoxygenation relies solely on the effec-
tiveness of the small molecule inhibitors used to target proteins of interest. Although
every effort has been made to ensure that these kinase inhibitors were specific to the
target, had been used in previous publications and had an appropriate half life, further
experiments should be carried out using different mechanisms of knockdown. As discussed
in section 5.7, siRNA, shRNA or CRISPR could be utilised in the future. Unfortunately
due to time restrictions this could not be carried out as part of the project presented here.
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Discussion
The main aim of this project was to determine the molecular mechanism of NF-κB path-
way activation following hypoxia and rapid reoxygenation. Although previous studies
have aimed to establish the kinetics of activation in the response to hypoxia, the findings
have been conflicting due to variations in hypoxic protocol and the cell lines used. Studies
on the effects of reoxygenation on NF-κB activation have been minimal, with very little
known about the mechanism behind this response. As discussed in chapter 4, all of the
major findings in this report were carried out using an improved method of inducing rapid
oxygen changes in cells. As such, the majority of data presented here is novel, as previous
reports on hypoxia and reoxygenation have utilised a method of gas exchange that can
stimulate NF-κB activation independently of other stresses. Indeed, this could explain
some of the different results observed in this thesis compared to previous publications.
Data in this thesis has demonstrated that the mechanism of NF-κB activation following
hypoxia is very similar to that following reoxygenation. Signal is transduced through the
IKK complex to IκBα, which is then phosphorylated on serines 32 and 36. Activation of
NF-κB occurs, as RelA translocates into the nucleus to control gene expression. The main
observable difference between these two pathways is that although IKKβ is phosphorylated
in response to both stimuli, IKKα phosphorylation is also observed during hypoxia. The
importance of this difference is currently unknown as experiments that focussed on the
role of IKKα relied on a potentially non-xpecific IKKα inhibitor [348]. Previous work
has implicated phosphorylation of tyrosine 42 in the response to hypoxia, this particular
post-translational modification has been associated with the activation of NF-κB in the
absence of IκBα degradation [125]. The lack of IκBα degradation has also been linked
to sumoylation of critical residues that are normally ubiquitinated to target IκBα for
proteasomal degradation [118]. In this project degradation of IκBα was not observed
following hypoxia and reoxygenation, indicating that this mechanism could be activated
here. Further work should aim to determine whether this is the case.
A large part of this project utilised small molecule inhibitors to inhibit activation of
proteins of interest. A major proportion of the data presented in this thesis is therefore
reliant on the effectiveness and specificity of these inhibitors. As such every effort was
made to determine that they would not have off target effects, had an appropriate half-life
for the experiments being carried out and had been used in peer-reviewed publications
where possible. The use of the IKKα inhibitor in particular highlighted some of the
problems with using these as a method of inhibition. Even though IKKα has not been
previously associated with the response to TNF or etoposide, treatment with this inhibitor
completely blocked signalling through the canonical NF-κB pathway. More alarmingly, in
a recent publication these inhibitors were tested using the exact same protocol presented
in this thesis and showed that treatment with the inhibitor had no effect on canonical
NF-κB signalling. As such, it is very probable that the IKKα inhibitor used in this thesis
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was not behaving as expected, and was having off-target effects, perhaps to IKKβ. Due
to this finding it is impossible to draw any firm conclusions on the role of IKKα in the
response to reoxygenation.
To reduce any concerns regarding the effectiveness of the inhibitors, additional work
should be carried out using alternative methods for either knocking down or inhibiting a
protein of interest. Preliminary tests using siRNA targeted to IKKα, IKKβ, ATR and
ATM were carried out during this project (data not shown), all of which showed effective
total protein knockdown. Unfortunately due to time restrictions further experimentation
was not possible. Future work should focus on repeating any inhibitor experiments using
siRNA to confirm findings; the resulting increased confidence in the data would improve
the chances of publication of this data in a peer-reviewed journal. Additional methods
for carrying out genetic knockdowns could include shRNA and CRISPR, these methods
are more time consuming and as such were not carried out as part of this project.
Some of the experiments presented in this thesis studied the cellular translocation of pro-
teins of interest following hypoxia and reoxygenation. Results obtained through western
blotting of cytoplasmic and nuclear extracts indicated that IKKα, IKKβ, NEMO, ATR
and ATM translocate into the nucleus following hypoxia, and return to the cytoplasm
following reoxygenation. Unfortunately, although several repeats of each experiment was
carried out, it was impossible to obtain consistently significant findings between experi-
ments perhaps indicating that this is not a real observation. The only protein that showed
consistent translocation in this manner was IKKα, perhaps indicating alternative roles of
this protein in the response to hypoxia and reoxygenation. Indeed nuclear IKKα has been
observed previously in response to proinflammatory cytokines, pathogens, and growth fac-
tors, here it is able to bind to DNA and coordinate NF-κB target gene expression [391].
This nuclear role of IKKα should be investigated further to gain more insight into the
kinetics of canonical NF-κB signalling in response to oxidative stress. Confirmation of
chromatin binding could be carried out using Ch-IP and protein-protein interactions could
be investigated out by co-IP. Although an interesting observation as it stands, carrying
out these additional experiments would increase the confidence in the data set and would
contribute to a publishable mechanism of the IKKα response to hypoxia.
The trends observed in the western blots studying the translocation of other proteins of
interest were not consistently statistically significant. This was most likely due to the
technique used to determine cellular location of proteins of interest. Immunofluorescence
microscopy was utilised alongside nuclear and cytoplasmic fractionation experiments prob-
ing for IKKβ and NEMO. As discussed in chapter 5, in the case of NEMO translocation
results were consistent across both techniques indicating a nuclear role for NEMO in re-
sponse to hypoxia. In contrast, studies on IKKβ translocation showed opposite results,
most likely due to the use of a different antibody. We cannot therefore make any con-
clusions regarding the movement of IKKβ following hypoxia and reoxygenation. The
movement of NEMO however is consistent with reports of a nuclear activation of NF-κB
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following genotoxic stress where it dimerises with ATM, is exported from the nucleus and
activates the canonical NF-κB pathway [358]. Indeed, based on western blot analysis,
ATM and ATR follow the same pattern of movement as the IKK complexes, indicating
that this could be the case here. Although as discussed above, this movement needs to
be confirmed by an alternative method such as immunofluorescence microscopy, and fur-
ther research should be carried out using techniques such as co-IPs to determine whether
protein-protein interactions are at play here. Although this data is not of publishable
standard as it stands, it does provide some interesting preliminary data that could be
used to direct a further project focussing on the kinetics of NF-κB pathway activation
following exposure to hypoxia and reoxygenation.
As discussed on section 1.4, many of the genes analysed in this report had previously been
studied in hypoxia, while only 2 genes had been studied in the context of reoxygenation.
Due to differences in the hypoxia protocol and cell lines used, many previous publica-
tions had opposing findings regarding the direction of change in gene expression. Since
an alternative method of hypoxia induction was used in this thesis, again there are some
contradictory findings from those previously published in the literature. Previous work
has shown that IL-8 and cIAP-2 gene expression increases following hypoxia, while data
presented here shows a significant decrease. In addition, SOD-2 expression decreased sig-
nificantly following hypoxia. Data identifying changes in NF-κB target genes in response
to reoxygenation was scarce, results presented in this thesis shows the effects of reoxy-
genation on 7 genes of interest. An increase in expression was observed in IL-8, cIAP-2
and SOD-2, indicating that the effects of hypoxia exposure are reversed following reoxy-
genation. The change in expression of SOD-2 in particular could suggest that this is due
to changes in metabolic activity of the cell as rates of aerobic respiration changes due to
oxygen fluctuations. Further work could focus on other genes of interest and the effects of
protein inhibition on gene expression should be re-evaluated using siRNA knockdown and
with a larger number of experimental replicates. In addition, the potential role of active
repression following hypoxia should be investigated as it would add to previous literature
that has shown this unusual effect of NF-κB signalling. As discussed in section 4 this
could be investigated using rescue experiments as described previously [119], alongside
Ch-IP experiments.
In chapter 4 several experiments were carried out with the aim of determining the exact
ROS produced following exposure to hypoxia and reoxygenation. Previous work had failed
to elucidate the exact species of ROS responsible for the effects observed in cells following
these stimuli. This is due to variations in the method of reading ROS, the time points
studied and the cell or tissue type used. The results presented in this thesis failed to find
an answer due to a number of factors; the time point used, the effects of hypoxia on the
dye and the lack of detail on the exact probes used in the kit. PRDX-3 western blots
did not help in this case due to the protein extraction method used, however analysing
oxidation of proteins in future experiments is probably the best approach to show the
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effects of ROS on cell signalling. Further work should therefore aim to characterise the
oxidation state of PRDX-3 and members of the canonical NF-κB signalling pathway
[240][241][239][256]. This could be carried out through western blot analysis on extracts
that have been harvested under acid lysis conditions to prevent artefactual oxidation
events during sample preparation.
In addition to characterising the effects of hypoxia and reoxygenation on gene expression
and canonical NF-κB signalling, one of the aims of this project was to determine the
effects of hypoxia and reoxygenation on cellular functions such as proliferation, cell cycle
dynamics and DNA damage. Although previous work has focussed on some of these
key cellular processes, the protocols followed differed and did not account for the effects
of fresh media on the cell. The effects of hypoxia and reoxygenation were the same as
reported in earlier publications, with a decrease and increase in proliferation observed
respectively [272][273][274].
Again, treatment with the small molecule inhibitors should be repeated using an alter-
native method of knockdown before any firm conclusions can be made, however IKKβ
inhibition appears to affect proliferation following both hypoxia and reoxygenation. Fu-
ture work should aim to confirm this as well as explore some of the effects of inhibition of
other proteins of interest. Although some longer clonogenicity experiments were carried
out, the roles of proteins of interest in this response is currently unknown due to the
short length of time that the cells were exposed to the inhibitor for. The used of shRNA
knockdown would be a far better approach to tackling this question as proteins would be
knocked down long term, throughout the course of the whole experiment.
The effects of hypoxia and reoxygenation on cell cycle progression indicated that some
small changes in cell cycle progression occurs as oxygen levels are changed. This was
only significant with regard to a decrease in G1-phase cells following reoxygenation. This
result indicates that in a small, not significant, population of cells hypoxia prevents pro-
gression into S-phase; this is reversed following reoxygenation. The exact reason for these
changes can only be speculated at this point, but could explain the decrease in prolifer-
ation observed following hypoxia. Perhaps the lack of oxygen blocks production of key
components required for S-phase such as nucleotides due to a decrease in metabolic ac-
tivity. The effect of hypoxia and reoxygenation on DNA damage indicates that this could
be the case.
A previous study has indicated that DNA damage only occurs following reoxygenation
[270], however data presented here is more concurrent with the findings of Pires et al,
who observe replication stress during hypoxia [271]. DNA damage analysis showed that
exposure to hypoxia leads to an increase in γH2AX levels, this returns to normal after 24
hours of hypoxia and does not re-occur following reoxygenation. Initially this implicated
ATM in the response to hypoxia as it phosphorylates H2AX in the response to double
strand breaks, however other PIKK family members, ATR and DNA-PK have been shown
to phosphorylate H2AX at this residue [193][194][195]. Additional experiments could be
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carried out to further characterise this effect, for example through the use of alternative
methods of DNA damage detection such as though COMET assays or through DNA
fibre assays. Pires et al. suggest that stalled replication forks could be causing this
H2AX phosphorylation, implicating ATR in this response, this hypothesis could be tested
through inhibition of ATR using siRNA knockdown [271]. If ATR is the kinase responsible
for this effect then changes in γH2AX levels would be affected by its inhibition.
Indeed, ATR was identified as a potential upstream kinase responsible for activation of
the canonical NF-κB pathway in response to reoxygenation in this project. Western
blot analysis showed that although both ATM and ATR are activated in the response
to reoxygenation, only inhibition of ATR affects signalling downstream to the canonical
NF-κB pathway. These inhibition experiments were again only carried out though the
use of small molecule inhibitors, as such they must be repeated to increase the quality of
the data set to a publishable standard.
Notwithstanding the issues raised above, this study has determined the basic mechanism
behind NF-κB activation following hypoxia and reoxygenation. This involves IKKβ (and
IKKα during hypoxia), serine 32/36 phosphorylation of IκBα and activation of NF-κB in
the absence of IκBα degradation. While carrying out this aim certain further experiments
of interest have been highlighted, such as investigating the potential role of tyrosine 42
phosphorylation and sumoylation of IκBα, or the oxidation of proteins in the canonical
NF-κB pathway. A potential upstream activator of the canonical NF-κB pathway in
response to reoxygenation was also identified in the form of ATR. This is a novel finding
and would be a publishable observation following further analysis. Future experiments
should aim to confirm the results shown here, further characterise the kinetics of ATR
activation and its interactions with other proteins downstream to activate NF-κB. This
should be carried out using an alternative mechanism of ATR inhibition, through further
investigations into other proteins such as TAK1 and the TAK1-binding protein (TAB)
proteins and a series of co-IP and cellular localisation experiments. This data would build
on some of the other findings of this project that focussed on the effects of hypoxia and
reoxygenation on other cellular processes such as cell cycle progression, proliferation and
DNA damage. Indeed, since ATR has been implicated in all of these responses previously
or in this report, further investigations into the role of ATR in these cellular processes
following hypoxia and reoxygenation would create an interesting and novel picture of
the NF-κB response to these stimuli. Future projects should therefore build on the work
presented here to answer the remaining questions that have been highlighted, together this
would produce interesting and publishable data on the response of the NF-κB pathway
to hypoxia and reoxygenation.
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